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Aortic stenosis is not only characterized by progressive valve narrowing but also by 
the hypertrophic response of the left ventricle that ensues. In this most common 
valvular condition novel imaging approaches (cardiovascular magnetic resonance 
[CMR] and positron emission tomography [PET]) have shown promise in the 
assessment of disease progression and risk stratification. The central aim of this 
thesis was to investigate the potential of CMR imaging to refine risk prediction and to 
improve the imaging protocol of 18F-sodium fluoride PET for aortic stenosis. 
Methods and Results 
Asymmetric wall thickening in aortic stenosis 
In a prospective observational cohort study, 166 patients with aortic stenosis (age 69, 
69% males, mean aortic valve area 1.0±0.4cm2) and 37 age and sex-matched 
healthy volunteers underwent phenotypic characterisation with comprehensive 
clinical, imaging and biomarker evaluation. Asymmetric wall thickening on both 
echocardiography and cardiovascular magnetic resonance was defined as regional 
wall thickening ≥13 mm and >1.5-fold the thickness of the opposing myocardial 
segment. 
Asymmetric wall thickening was observed in 26% (n=43) of patients with aortic 
stenosis using magnetic resonance and 17% (n=29) using echocardiography. Despite 
similar demographics, co-morbidities, valve narrowing, myocardial hypertrophy and 
fibrosis, patients with asymmetric wall thickening had increased cardiac troponin I and 
brain natriuretic peptide concentrations (both p<0.001). Over 28 [22, 33] months of 
follow-up, asymmetric wall thickening was an independent predictor of aortic valve 
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replacement or death whether detected by magnetic resonance (HR=2.15; 95 CI 1.29 
to 3.59; p=0.003) or echocardiography (HR=1.79; 95 CI 1.08 to 3.69; p=0.021).  
Animal model of pressure overload 
We performed serial Cardiac Magnetic Resonance (CMR) imaging every 2-week in 
31 mice subjected to pressure overload (continuous angiotensin II infusion) for 6 
weeks and investigated reverse remodelling by repeating CMR 1 month following 
normalization of afterload (n=9). Cine CMR was used to measure left ventricular 
volumes, mass, and systolic function whilst myocardial fibrosis was assessed using 
indexed ECV (iECV) calculated from T1-relaxation times acquired with a small animal 
modified look-locker inversion recovery sequence. 
During the initial phase of increased pressure afterload indices of left ventricular 
hypertrophy (0.091 [0.083, 0.105] vs 0.123 [0.111, 0.138] g) and myocardial fibrosis 
(iECV: 0.022 [0.019, 0.024] vs 0.022 [0.019, 0.024] mL) increased in line with blood 
pressure measurements (65.1±12.0 vs 84.7±9.2 mmHg) whilst left ventricular ejection 
fraction (LVEF, 59.3 [57.6, 59.9] vs 46.9 [38.5, 49.6] %) deteriorated significantly (all 
p≤0.01 compared to baseline). 
During the reverse remodelling phase blood pressure normalized (68.8±5.4 vs 
65.1±12.0 mmHg, p=0.42 compared to baseline). Whilst LV mass (0.108 [0.098, 
0.116] vs 0.091 [0.083, 0.105] g) and iECV (0.034 [0.032, 0.036] vs 0.022 [0.019, 
0.024] mL) improved both remained elevated compared to baseline (p<0.05). 
Similarly, the LVEF remained impaired 51.1 [42.9, 52.8] vs 59.3 [57.6, 59.9] %, 
p=0.03. There was a strong association between LVEF and iECV values during 





Gender differences in aortic stenosis 
Two hundred forty-nine patients (66±13 years, 30% women) with at least mild AS 
were recruited from two prospective observational cohort studies and underwent 
comprehensive Doppler echocardiography and CMR exams. On CMR, T1 mapping 
was used to quantify extracellular volume (ECV) fraction as a marker of diffuse 
fibrosis, and late gadolinium enhancement (LGE) was used to assess focal fibrosis. 
There was no difference in age between women and men (66±15 vs 66±12 years, 
p=0.78). However, women presented a better cardiovascular risk profile than men 
with less hypertension, dyslipidemia, diabetes, and coronary artery disease (all 
p≤0.10). As expected, LV mass index measured by CMR was smaller in women than 
in men (p<0.0001). Despite fewer comorbidities, women presented larger ECV 
fraction [29.0 (27.4-30.6) vs. 26.8 (25.1-28.7) %, p<0.0001] and similar LGE [4.5 (2.3-
7.0) vs. 2.8 (0.6-6.8) %, p=0.20] than men. In multivariable analysis, female sex 
remained an independent determinant of higher ECV fraction and LGE (both p≤0.05). 
Prior CT angiography for PET 
Forty-five patients (age 67.1±6.9 years, 76% males) underwent CTA (CTA1) and 
combined 18F-NaF PET/CTA (CTA2) imaging within 14 [10,21] days. We fused CTA1 
from visit one with 18F-NaF PET from the second visit (PET) and compared visual 
pattern of activity, maximal standard uptake values (SUVmax) and target to 
background (TBR) measurements on (PET/CTA1) fused versus hybrid (PET/CTA2) 
data. 
On PET/CTA2, 226 coronary plaques were identified. Fifty-eight coronary segments 
from 28 (62%) patients had high 18F-NaF uptake (TBR>1.25), whilst 168 segments 
had lesions with 18F-NaF TBR ≤1.25. Uptake in all lesions was categorized identically 
on co-registered PET/CTA1. There was no significant difference in 18F-NaF uptake 
values between PET/CTA1 and PET/CTA2 (SUVmax: 1.16±0.40 vs. 1.15±0.39, 
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p=0.53; TBR:1.10±0.45 vs. 1.09±0.46, p=0.55). The intraclass correlation coefficient 
for SUVmax and TBR was 0.987 (95%CI 0.983 to 0.991) and 0.986 (95%CI 0.981 to 
0.992). There was no fixed or proportional bias between PET/CTA1 and PET/CTA2 
for SUVmax and TBR. Cardiac motion correction of PET scans improved 
reproducibility with tighter 95% limits of agreement (±0.14 for SUVmax and ±0.15 for 
TBR vs. ±0.20 and ±0.20 on diastolic imaging; p<0.001). 
Delayed PET imaging 
Twenty patients (67±7years old, 55% male) with stable coronary artery disease 
underwent coronary CT angiography and PET/CT both 1 h and 3 h after the injection 
of 266.2±13.3 MBq of 18F-NaF. We compared the visual pattern of coronary uptake, 
maximal background (blood pool) activity, noise, standard uptake values (SUVmax), 
corrected SUV (cSUVmax) and target to background (TBR) measurements in lesions 
defined by CTA on 1h vs 3h post injection 18F-NaF PET. 
On 1h PET 26 CTA lesions with 18F-NaF PET uptake were identified in 12 (60%) 
patients.  On 3h PET we detected 18F-NaF PET uptake in 7 lesions which were not 
identified on the 1h PET. The median cSUVmax and TBR values of these lesions 
were 0.48 [interquartile range (IQR) 0.44-0.51] and 1.45 [IQR, 1.39-1.52] compared 
to -0.01 [IQR, -0.03-0.001] and 0.95 [IQR, 0.90-0.98] on 1h PET, both p<0.001. 
Across the entire cohort 3h PET SUVmax values were similar to 1h PET 
measurements 1.63 [IQR, 1.37-1.98] vs. 1.55 [IQR, 1.43-1.89], p=0.30 and the 
background activity was lower 0.71 [IQR, 0.65-0.81] vs. 1.24 [IQR, 1.05-1.31], 
p<0.001. On 3h PET, the TBR values, cSUVmax and the noise were significantly 
higher (2.30 [IQR, 1.70-2.68] vs 1.28 [IQR, 0.98-1.56], p<0.001; 0.38 [IQR, 0.27-0.70] 
vs 0.90 [IQR, 0.64-1.17], p<0.001 and 0.10 [IQR, 0.09-0.12] vs. 0.07 [IQR, 0.06-0.09], 
p=0.02). The median cSUVmax and TBR values increased by 92% (range: 33-225%) 




In aortic stenosis, asymmetric wall thickening is associated with adverse prognosis, 
in this condition there are significant differences in the fibrosis burden between male 
and female patients and the adverse remodeling of the ventricle can be reproduced 
in a simple animal model of pressure overload. For 18F-NaF PET utilizing a CT 
angiography acquired before the PET acquisition enables adequate uptake 
quantification and delayed emission scanning facilitates image analysis.    
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Lay Summary  
Aortic stenosis is the most common heart valve condition in the western world. In this 
disease the aortic valve (which allows blood to exit the heart and stops blood flowing 
back into the heart after a contraction) through a process involving inflammation and 
progressive calcium formation, becomes narrowed. The progressive narrowing of the 
aortic valve leads to an increased strain on the heart muscle which has to work 
increasingly hard to pump blood through the stenotic valve. Over time the heart 
muscle thickens to maintain performance, but eventually the heart fails, and the valve 
has to be replaced. 
In the past decade novel imaging approaches for diagnosing and monitoring the 
progression of aortic stenosis have emerged. These include cardiovascular magnetic 
resonance imaging which enables in depth characterization of the heart muscle and 
18F-sodium fluoride positron emission tomography (PET) in combination with 
computed tomography which holds promise in predicting the progression of valve 
calcifications. The overall aim of this thesis was to investigate the heart muscle 
response to aortic stenosis using cardiovascular magnetic resonance and improve 
the 18F-sodium fluoride positron emission tomography imaging protocol. 
Asymmetric wall thickening 
In a cohort of 166 patients with aortic stenosis we evaluated the prevalence and 
prognostic significance of asymmetric wall thickening on echocardiography which is 
the most accessible tool for heart imaging and using cardiovascular magnetic 
resonance imaging.  
Asymmetric wall thickening was observed in 26% (n=43) of patients with aortic 
stenosis using magnetic resonance and 17% (n=29) using echocardiography. Despite 
similar demographics, valve narrowing and conventional heart muscle characteristics, 
patients with asymmetric wall thickening had increased markers of heart strain. In 
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longitudinal observation of patients, asymmetric wall thickening was an independent 
predictor of aortic valve replacement or death whether detected by magnetic 
resonance or echocardiography. 
Animal model of the heart muscle changes in aortic stenosis 
We performed serial cardiac magnetic resonance imaging every 2-week in 31 mice 
subjected to a continuous infusion of a drug which raises blood pressure for 6 weeks 
and investigated recovery by repeating imaging 1 month following normalization of 
blood pressure.  
During the initial phase of the experiment measures of heart muscle thickening and 
fibrosis increased in line with blood pressure measurements whilst the heart 
performance deteriorated significantly. During the recovery phase blood pressure 
normalized, but parameters of muscle thickening and fibrosis remained higher than 
at baseline. The changes in fibrosis both in the initial and the recovery phase of the 
experiment predicted the later changes in heart performance.  
Gender differences in aortic stenosis 
Two hundred forty-nine patients with aortic stenosis were recruited from two cohort 
studies and underwent comprehensive echocardiography and cardiovascular 
magnetic resonance exams. There was no difference in age between women and 
men. However, women presented a better cardiovascular risk profile than men with 
less hypertension, dyslipidemia, diabetes, and coronary artery disease. Despite a 
favorable risk profile, women presented with more fibrosis than men. 
 
Prior computed tomography angiography for positron emission tomography 
Forty-five patients underwent computed tomography and combined 18F-sodium 
fluoride PET with computed tomography imaging within 2 weeks. We fused computed 
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tomography from visit one with 18F-sodium fluoride PET from the second visit and 
compared visual pattern and measures of 18F-sodium fluoride activity on the PET 
fused with computed tomography from the first visit versus single visit data. 
We found no significant difference in 18F-sodium fluoride activity values between the 
single visit and prior computed tomography datasets. Using the visit one computed 
tomography the generated fused datasets enabled quantification of 18F-sodium 
fluoride PET. The reproducibility of such results is enhanced by motion correction of 
PET data. The proposed approach may enable a practical method for the selection 
of high-risk patients for 18F-sodium fluoride PET scan based on results from an initial 
CTA scan. 
Delayed PET imaging 
Twenty patients underwent combined PET with computed tomography imaging 1 
hour and 3 hours after injection of 18F-sodium fluoride. We compared the visual 
pattern and measures of 18F-sodium fluoride activity on 1 hour versus 3 hours after 
injection PET imaging. 
Compared to 1-hour imaging on the 3 hours after injection scan we detected more 
areas of increased 18F-sodium fluoride activity. The most commonly used measures 
of 18F-sodium fluoride activity were on average 92% higher on 3 hours after tracer 
injection PET imaging. Likewise, the image quality improved as a result facilitating 
distinguishing increased PET tracer activity.  
 
Conclusions 
In summary in aortic stenosis asymmetric wall thickening is a distinct form of heart 
adaptation which is associated with higher risk of rapid disease progression. In aortic 
stenosis fibrosis as seen on magnetic resonance imaging is different between women 
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and men. The sequence of events which is characteristic for aortic stenosis can be 
reproduced in a small animal model.  For 18F-sodium fluoride PET utilizing a 
computed tomography scan from an imaging session before the PET enables 
accurate evaluation of tracer activity. For this imaging modality prolonging the interval 






18F-NaF 18F-sodium fluoride 
AS  Aortic stenosis 
CMR  Cardiovascular magnetic resonance 
CT  Computed tomography 
CTA  Computed tomography angiography 
ECV  Extracellular volume fraction 
iECV  Indexed extracellular volume fraction 
HR  Hazard ratio 
ICC  Intraclass correlation coefficients 
IQR  Interquartile range 
LGE  Late gadolinium enhancement 
LV  Left ventricle 
PET  Positron emission tomography 
SUV  Standard uptake value 
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Calcific aortic valve stenosis (AS) is the most common form of valve disease and a 
major health care burden (Thaden, Nkomo, & Enriquez-Sarano, 2014). This condition 
is characterized by progressive narrowing of the valve and while the disease 
originates in the valve, the development of symptoms and adverse events in aortic 
stenosis also relates to how the left ventricle adapts to the associated increase in 
afterload (Carabello Blase, 2013). Aortic stenosis triggers a hypertrophic response in 
the myocardium that initially restores wall stress and maintains cardiac performance, 
but eventually leads to decompensation, driving the transition to heart failure, 
symptoms and ultimately death (Dweck, Boon, & Newby, 2012; Hein et al., 2003). 
Interestingly, only a weak association exists between the severity of valve obstruction 
and the magnitude of the hypertrophic response, making it important that both 
processes are considered independently (M. R. Dweck, S. Joshi, et al., 2012). 
1.1 Prevalence 
Aortic stenosis is the most prevalent form of valve disease in developed countries, 
which with an ageing population, is projected to treble by 2050 (Eveborn, Schirmer, 
Heggelund, Lunde, & Rasmussen, 2013; Nkomo et al., 2006). In a recent meta-
analysis which encompassed 7 large population-based studies, it was estimated that 
in the western world over 12% of those age ≥75 years have stenosed aortic valves 
(Osnabrugge et al., 2013). Another recent study showed that the incidence of severe 
AS increases with age and reaches 2–3% in patients over 65 years of age (Brian R. 
Lindman et al., 2016). While in the past this condition was primarily a results of 
rheumatic heart disease, nowadays calcific aortic stenosis occurs in elderly patients 






1.2 Clinical management  
Despite the widespread prevalence of aortic stenosis, we lack medical therapies 
capable of modifying disease progression or halting ventricular decompensation. 
Currently patient management consists of watchful waiting until patients with severe 
stenosis develop evidence of left ventricular decompensation, either in the form of 
symptoms or a reduction in ejection fraction(Baumgartner et al., 2017; Nishimura Rick 
et al., 2017). At this point, mortality rates rise rapidly and aortic valve replacement 
(AVR) is recommended (Ross & Braunwald, 1968). Without aortic valve replacement 
outcome of symptomatic AS subjects is extremely poor, with survival rates as low as 
50% at 2 years and 20% at 5 years (Horstkotte & Loogen, 1988).  
1.3 Natural history of Aortic Stenosis 
Deterioration of the valve leaflets (cusps) was long regarded as a ‘wear and tear’ 
process which over time leads to calcium deposition. More recently this progressive 
degeneration has been carefully studied and as a result it is now widely appreciated 
that aortic stenosis is governed by a series of processes including: inflammation and 
deposition of lipids and calcium (M Otto, Kuusisto, D Reichenbach, Gown, & D 
O'Brien, 1994; Tania A. Pawade, Newby, & Dweck, 2015). The latter originate as 
regions of microcalficiation which co-localize with lipid deposits. These microscopic 
deposits are believed to promote further hydroxyapatite formation creating a positive 
feedback loop wherein calcification and inflammation aggravate one another(Nadra 
et al., 2005; Rajamannan et al., 2002; Weiss Robert, Ohashi, Miller Jordan, Young 
Stephen, & Heistad Donald, 2006). With foci of calcification established within the 
valve it appears that the disease enters a self-perpetuating cycle of injury and 
calcification (Mohler Emile et al., 2001; Rajamannan et al., 2003). It was proposed 
that calcific deposits lead to a mechanical leaflet compliance mismatch resulting in 
mechanical injury which results in further inflammatory response(Tania A. Pawade et 
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al., 2015). Ultimately these processes lead to severe valve narrowing which is 
associated with an 80% 5-year risk of progression to valve replacement, heart failure 
or death (Otto et al., 1997). 
Since AVR is the only available therapy for AS, appropriate timing of the intervention 
is crucial. In every day clinical practice, it is either symptoms or a decrease in LV 
ejection fraction that triggers intervention (Baumgartner et al., 2017; Nishimura Rick 
et al., 2017). Unfortunately, identifying ventricular decompensation is problematic as 
symptoms are frequently difficult to assess in the elderly and a fall in ejection fraction 
occurs late and is often irreversible (Braunwald, 1990; Chizner, Pearle, & deLeon, 
1980; Marc R. Dweck et al., 2012; Lassnigg et al., 2013; Turina, Hess, Sepulcri, & P 
Krayenbuehl, 1987).  
The rationale for a symptom-guided approach to AS is based largely on the landmark 
manuscript by Ross and Braunwald: well known to cardiologists worldwide (Ross & 
Braunwald, 1968). That manuscript, however, is now 50 years old, based largely upon 
retrospective observational/post-mortem data, and comprised predominantly male 
patients who on average developed symptoms at 60 years of age. Whether symptoms 
remain the best guide to LV decompensation and the timing of AVR in modern clinical 
practice is starting to be questioned(Kang, Park, et al., 2010; Kang, Rim, et al., 2010; 
Pellikka et al., 2005).  
Modern AS patients are certainly older, making symptom assessment even more 
challenging because of both their extensive co-morbidities and their limitations to 
physical exertion. Is the patient breathless because of valve disease or anemia or 
obstructive pulmonary disease? Similarly, is the patient who walks carefully with a 
stick truly asymptomatic? These issues have prompted many investigators to seek 
more objective biomarkers of LV decompensation to help guide the timing of AVR 
(Calvin W. L. Chin, Anoop S. V. Shah, et al., 2014). Several of these biomarkers are 
under active investigation including blood biomarkers (e.g., troponin, Btype natriuretic 
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peptide), echocardiographic strain data, and electrocardiograph changes as well as 
the mid-wall fibrosis on cardiac magnetic resonance (Attias et al., 2013; Clavel, 
Malouf, et al., 2014; Dahou et al., 2015; Dweck et al., 2011; Kearney et al., 2012). 
Importantly, these myocardial biomarkers provide more powerful prediction of long-
term outcomes after AVR than traditional valve assessments, indicating that the 
health of the myocardium at the time of surgery is a key determinant of long-term 
prognosis. 
Our current management strategy for aortic stenosis has major limitations that would 
be fundamentally enhanced by: 
(i) an improved understanding of the mechanisms underlying valve calcification and left 
ventricular decompensation,  
(ii) the development of novel medical therapies that could halt or regress the disease 
process and  
(iii) the identification of objective biomarkers of valve decompensation that can better 
guide AVR. 
 
1.4 Non-invasive imaging of Aortic Stenosis 
In the past decade non-invasive imaging techniques have enabled researchers to 
further characterize aortic stenosis (Chambers et al., 2016; Calvin W. L. Chin, Vassilis 
Vassiliou, et al., 2014; Dulgheru et al., 2016). In particular cardiovascular magnetic 
resonance (CMR), computed tomography (CT) and positron emission tomography 
(PET) have improved our understanding of the natural history of this valvular 
condition. The findings of observational trials focused on AS have provided hope that 
we now might be able to detect subtle progression within the valve and myocardium. 
Further, since assessment of the disease can be so accurate, nowadays performing 
interventional trials, testing new medication approaches can benefit from imaging-
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derived endpoints. Ultimately it is believed that the aforementioned imaging 
modalities could help clinicians better decide on the timing of aortic valve 
replacement. 
 
1.4.1 Insights from non-invasive imaging 
1.4.1.1 Aortic Stenosis – disease of the myocardium  
In conditions associated with left ventricular pressure overload such as aortic stenosis 
and hypertension, myocyte size and myocardial wall thickness increase to restore 
wall stress (M. R. Dweck, S. Joshi, et al., 2012). This hypertrophic response is initially 
adaptive maintaining cardiac output and systolic function. However, as hypertrophy 
increases, the left ventricle ultimately decompensates, leading to progressive 
impairment in ventricular performance and the development of symptoms and 
adverse cardiovascular events (B. A. Carabello, 2002; Gunther & Grossman, 1979). 
Preliminary histological studies have indicated that this pathologic transition from 
ventricular adaptation to decompensation is driven primarily by two processes: 
myocyte death and myocardial fibrosis (Hein et al., 2003). Myocyte death takes the 
form of oncosis (similar to necrosis) and apoptosis and is accompanied by signs of 
cellular stress manifest as increased autophagy (Kostin et al., 2003; Vigliano et al., 
2011). Although the trigger for these events remains unclear, it has been proposed 
that progressive myocyte cell death relates to neurohumoral mediators, such as 
angiotensin II and norepinephrine (Antonini-Canterin et al., 2003; Cote et al., 2010; 
Fujisaka et al., 2013; Helske et al., 2004). Alternatively, myocardial ischemia may act 
as the trigger, itself occurring as a consequence of increased myocardial oxygen 
demand (due to the increased myocardial mass and afterload) and reduced coronary 
reserve (due to impaired microcirculatory perfusion and inadequate expansion of 
coronary capillary density)(Galiuto et al., 2006; Marcus et al., 1983). Replacement 
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myocardial fibrosis is believed to occur in response to this cell death. Such fibrosis is 
irreversible and its accumulation in the left ventricle leads to progressive impairment 
of myocardial relaxation (diastolic dysfunction) and contraction (systolic dysfunction) 
driving the clinical progression to heart failure (Azevedo et al., 2010; Shirani, Pick, 
Roberts, & Maron, 2000; Weidemann et al., 2009)(Figure 1).  
Figure 1. The transition from a normal heart to LV decompensation in aortic valve 





1.4.1.2 Cardiovascular Magnetic Resonance Late Gadolinium Enhancement 
for Imaging Replacement Fibrosis 
Dedicated cardiovascular magnetic resonance (CMR) techniques have been 
developed for the direct visualization and quantification of myocardial fibrosis in 
patients and animal models (Lluri et al., 2017; Vassiliou et al., 2017). These involve 
the administration of gadolinium contrast, which accumulates in regions of fibrosis 
and increases signal in these areas on T1-weighted scans. On this basis, late 
gadolinium enhancement can identify replacement fibrosis within the 
decompensating myocardium in a mid-wall pattern that is easily differentiated from 
prior myocardial infarction.  
Several MRI studies have investigated the role of late gadolinium enhancement in 
aortic stenosis and confirmed that the mid-wall pattern acts as a direct measure of 
left ventricular decompensation (Dweck et al., 2011; Lluri et al., 2017; Vassiliou et al., 
2017). In a recent study consisting of 143 patients with moderate to severe aortic 
stenosis, Dweck et al. demonstrated that mid-wall fibrosis was present in a third of 
subjects and was associated with an advanced hypertrophic response and other 
markers of ventricular decompensation. Moreover, mid-wall fibrosis acted as an 
independent predictor of mortality providing incremental prognostic value over and 
above that of the ejection fraction. Indeed, patients with mid-wall fibrosis had an 8-
fold increase in all-cause mortality compared to those without, despite similar aortic 
stenosis severity and coronary artery disease burden (Dweck et al., 2011). Similar 
findings have been observed in patients following AVR, with the presence of mid-wall 
late gadolinium enhancement being associated with adverse ventricular remodelling 
and worse peri-operative and long-term outcomes following surgery (Barone-
Rochette et al., 2014; Quarto et al., 2012). Interestingly, replacement myocardial 
fibrosis as detected by cardiovascular magnetic resonance does not appear to be 
reversible following AVR suggesting that once observed in the ventricle, surgery 
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should be considered early before further irreversible fibrosis develops (Barone-
Rochette et al., 2014). Late gadolinium enhancement CMR appears to hold major 
advantages as a biomarker of left ventricular decompensation because of its ability 
to measure directly the key pathological process driving the ventricle towards heart 
failure. On this basis it was proposed it could become the central tool used in clinical 
practice to decide upon the timing of AVR. This hypothesis is currently tested in the 
context of the Early Valve Replacement Guided by Biomarkers of LV 
Decompensation in Asymptomatic Patients With Severe Aortic Stenosis 
(NCT03094143) randomized controlled trial.  
1.4.1.3 Computed Tomography 
The extent of aortic valve calcification can be assessed with non-invasive imaging. 
While echocardiography has been used to estimate the calcific burden for several 
decades more recently computed tomography has been utilized in this context (Cioffi 
et al., 2013; Rosenhek et al., 2004). This imaging modality is advantageous over 
conventional echocardiography as it provides superior reproducibility (Messika-
Zeitoun et al., 2004). Applying the widely utilized coronary calcium score protocol, an 
electrocardiography-gated non-contrast CT provides information regarding the 
density, volume and mass of macroscopic calcium deposits within the valve (T. 
Pawade et al., 2018). Employing such methodology, it was shown that the calcific 
burden measured in Agatston Units (AU) is closely correlated with hemodynamic 
echocardiography derived measurements which up to date are considered the golden 
standard for stenosis assessment (Agatston et al., 1990; Koos, Kuhl, Muhlenbruch, 
& Mahnken, 2006; F. Liu et al., 2006). Furthermore, more recently gender specific 
thresholds for severe aortic stenosis have been proposed. From a cohort of 646 
patients moderate to severe aortic stenosis patients Clavel et al. focused on those in 
whom echocardiographic findings were discordant (the calculated valve area and 
peak or mean velocity showed discrepancies classifying patients as having 
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moderate/severe disease). The authors showed that a threshold of 1275 AU in 
women and 2065 AU in men enables distinguishing severe aortic stenosis (Clavel et 
al., 2013). Moreover, utilization of these cut-off values for dichotomizing subjects was 
shown to act as an independent predictor of overall mortality (Clavel, Pibarot, et al., 
2014). More recently these promising thresholds were further validated in an 
international multicenter registry which included a wide range of patient populations, 
who underwent imaging on different scanner vendors (T. Pawade et al., 2018).  
The aforementioned studies suggest that computed tomography calcium scoring can 
be used for grading disease severity in aortic stenosis. This method provides insights 
into disease progression and can be used for risk stratification. Importantly while this 
approach enables disease burden assessment it does not allow for the assessment 






1.5 Left ventricular remodeling on cardiovascular magnetic resonance 
imaging 
1.5.1 Patterns of left ventricular remodeling 
In aortic stenosis the narrowing the valve leads to a hypertrophic response in the 
myocardium. As a result, myocytes enlarge and the left ventricular wall thickness and 
the overall mass increases. While initially wall stress is restored and systolic function 
can be maintained ultimately the hypertrophic response is maladaptive as it has been 
already linked to adverse outcome (Cioffi et al., 2011; Cioffi & Stefenelli, 2002; Gosse, 
2005; Gradman & Alfayoumi, 2006). Importantly there are wide differences in the 
degree of hypertrophy among patients with similar valve obstruction (M. R. Dweck, S. 
Joshi, et al., 2012). Moreover, distinct patterns of remodeling have been also 
reported. These have been described taking into consideration imaging measures of 
LV mass, the diastolic volumes and the relative wall thickness (which takes into 
account both wall thickness and the end-diastolic cavity dimension (Cioffi & Stefenelli, 
2002; Ganau et al., 1992). The four classical patterns of LV remodeling in AS are: 
normal ventricular geometry, concentric remodeling, concentric hypertrophy, and 
eccentric hypertrophy. Although both concentric remodeling and hypertrophy are 
considered as a physiological response to the increased afterload, this pattern of 
remodeling can be maladaptive (R. Capoulade et al., 2017). This is largely due to the 
development of myocardial fibrosis and irreversible myocardial dysfunction 
associated with it (Gaasch & Zile, 2011; Milano et al., 2012). Previous studies showed 
that severe LV hypertrophy is associated with adverse outcome both in subjects 
before aortic valve replacement and those in whom the stenosed valve has been 
removed (Cioffi et al., 2011; D. Cramariuc, Gerdts, Davidsen, Segadal, & Matre, 2010; 
Duncan et al., 2008; Greve et al., 2012; Holme et al., 2012; B. R. Lindman et al., 




1.5.1.1 Patterns of Left Ventricular Remodeling and Outcome  
To date, only one study assessed the impact of different LV remodeling patterns on 
all-cause mortality in AS patients with preserved LV ejection fraction. In a total of 747 
consecutive aortic stenosis patients Capoulade et al. showed that on 
echocardiography concentric hypertrophy is the most prevalent pattern of LV 
remodeling and can be found in over 50% of subjects (R. Capoulade et al., 2017). 
Concentric remodeling was detected in 23% of patients and eccentric hypertrophy 
was rare and found in 9% of cases. The study also demonstrated that older age, 
obesity, hypertension and more severe AS are associated with higher prevalence of 
concentric hypertrophy. Interestingly over a median of 6.4 years of follow-up this 
pattern of remodeling was independently associated with increased mortality even 
after adjustment for the factors mentioned above and for AVR. The six-year survival 
rate for concentric hypertrophy patients was 61% compared to 70% for a normal or 
eccentric LV pattern and 71% for concentric remodeling. The authors concluded that 
concentric hypertrophy may be associated with an outcome penalty despite 
successful AVR. The findings of the study support the usefulness of LV remodeling 
assessment for improving risk stratification in AS patients with preserved LVEF. 
The aforementioned study has not addressed all relevant questions regarding the 
hypertrophic response in aortic stenosis. For instance, asymmetric wall thickening 
which has been also reported in AS patients was not reported in the analysis (Hess 
et al., 1983a; Tuseth, Cramariuc, Rieck, Wachtell, & Gerdts, 2010). Actually, up to 
date this pattern of remodeling has not been considered by a vast majority of studies 
assessing the LV hypertrophic response in AS and as a result both its true prevalence 
and more importantly its impact on outcome have not been well understood. 
Moreover, when compared to cardiovascular magnetic resonance the assessment of 
left ventricular remodeling and hypertrophy by echocardiography has several 
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limitations. The former technique was shown to be more robust and reproducible in 
measuring left ventricular mass, volume and wall thickness (M. S. Maron et al., 2009; 
Myerson, Bellenger, & Pennell, 2002). Despite these clear advantages of CMR 
imaging we lack studies utilizing this superior modality for evaluating asymmetric wall 
thickening in AS.   
 
1.5.2 The role of diffuse myocardial fibrosis 
While in aortic stenosis replacement fibrosis quantified with late gadolinium 
enhancement on CMR is already established as a marker of adverse prognosis only 
recently an approach for assessing diffuse fibrosis was described (Barone-Rochette 
et al., 2014; Herrmann et al., 2018; Vassiliou et al., 2017). CMR T1 mapping showed 
hope in this regard (D. R. Messroghli, Greiser, Frohlich, Dietz, & Schulz-Menger, 
2007; Daniel R. Messroghli et al., 2004; Piechnik et al., 2010). The highlight of this 
technique is that compared to late gadolinium enhancement, T1-mapping generates 
an image of the myocardium based on the T1 relaxation time, which is a magnetic 
property of a given tissue and does not rely on relative signal differences. This is 
particularly relevant as diffuse fibrosis is believed to be a process involving the entire 
ventricle and therefore its assessment cannot require remote tissue as reference. The 
initial approach which was introduced by Messroghli et al., which is now known as 
native T1-mapping has evolved over the past years. Back in 2008 the partition 
coefficient which is a ratio of the T1 relaxation times in the myocardium and bloodpool 
after the administration of a gadolinium-based contrast agent was described 
(Jerosch-Herold et al., 2008). The authors showed that patients with dilated 
cardiomyopathy have higher partition coefficients than controls and suggested this 
might be due to expansion of the extracellular matrix presumably in the form of 
interstitial fibrosis. More recently, the extracellular volume fraction (ECV), a measure 
which takes into consideration both pre and post contrast T1 relaxation values 
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corrected by the blood-pool contrast load and hematocrit was developed (A. S. Flett 
et al., 2010). Importantly it was shown that this novel measure reflects the diffuse 
fibrosis burden quantified on endomyocardial biopsies.  
1.5.2.1 T1-mapping in Aortic Stenosis  
Using standardized methodology on a cohort of AS patients Chin et al have 
systematically compared commonly used T1 measures at multiple time points and in 
multiple regions across the left ventricle (C. W. L. Chin et al., 2014). The authors 
showed that pre-contrast T1 was limited by an inability to differentiate patients with 
aortic stenosis from healthy volunteers and post-contrast myocardial T1 lacked 
sufficient scan–rescan reproducibility. In comparison, the partition coefficient and the 
ECV demonstrated excellent reproducibility and were increased in patients with aortic 
stenosis when compared with healthy volunteers.  
Other studies suggested that pre-contrast T1 relaxation times can provide important 
insights in AS subjects. Bull et al demonstrated that non-contrast T1 values measured 
using the ShMOLLI CMR sequence correlate well with percentage collagen volume 
fraction as measured on histology in patients with AS. In their study, non-contrast T1 
values in AS increased with disease severity (Bull et al., 2013). In a prospective 
observational longitudinal study of 127 consecutive patients with moderate or severe 
AS followed up for a median of 27.9 months Lee et al showed that T1 mapping derived 
measures predicts outcome in individuals with aortic stenosis. The native T1 values 
were predictors of outcome independent of an established risk score (EuroSCORE 
II) and replacement fibrosis on CMR. On multivariate Cox regression analysis, every 
20-ms increase in native T1 was independently associated with a 28% increase risk 
of all-cause mortality and heart failure hospitalization (H. Lee et al., 2018).  
Further data on the prognostic value of ECV has been also published. The ECV was 
linked with outcome as Nadijiri et al showed that in patient pre- and post-transcatheter 
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aortic valve replacement ECV acts as a predictor of adverse events (Nadjiri et al., 
2016). Chin et al evaluated both extracellular expansion and replacement fibrosis in 
the myocardium of patients with aortic stenosis and healthy control subjects and 
showed that both are closely associated with the magnitude of the hypertrophic 
response, the presence of LV dysfunction, the functional capacity of the patient, and, 
ultimately, clinical outcome. The authors proposed a new classification of AS patients 
based purely on CMR derived assessment of the myocardium. Subjects were divided 
into three groups, those with: normal myocardium, extracellular expansion, and 
replacement myocardial fibrosis. Across these groups the investigators demonstrated 
a stepwise increase in all-cause mortality and concluded that T1-mapping has the 
potential to detect early, subclinical ventricular decompensation in aortic stenosis and 
ultimately might be able to guide decisions regarding the timing of aortic valve 
replacement (C. W. L. Chin et al., 2017). 
It is believed that diffuse fibrosis quantified with CMR has the potential to greatly 
improve our understanding of left ventricular decompensation (Nagel & 
Chandrashekhar, 2018; Neubauer & Bull, 2017). Assessment of the expansion of 
diffuse fibrosis can potentially provide valuable insights into disease progression at a 
stage when LV function is still maintained. Ultimately it was speculated that T1 
mapping indices could potentially predict LV decompensation in AS patients and 
assist in guiding the optimal timing of valve replacement. 
1.5.2.2 Challenges associated with longitudinal studies of fibrosis 
development 
Elucidating the exact time course of events in aortic valve stenosis with the aim of 
better understanding the timing and sequence in which diffuse fibrosis progress under 
pressure overload and regresses after load normalization is challenging. This is 
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primarily because collecting aortic stenosis natural history data in patients would take 
very many years if not decades (Rosenhek et al., 2010).  
Preclinical models are an alternative approach that have the potential to provide 
desired insights (Camacho, Fan, Liu, & He, 2016; Ku, Huelnhagen, Niendorf, & 
Pohlmann, 2018). The potential benefits of using an animal model are several fold. 
Firstly, the time when the trigger to hypertrophy started is known - this is impossible 
to gauge in human patients as aortic stenosis progresses over several years before 
manifesting clinically usually at the time of auscultation or echocardiography. The fact 
that the exact disease onset is known enables monitoring how the hypertrophic 
response develops and how the myocardium eventually decompensates. A second 
advantage is the much quicker time course that this sequence occurs over in 
laboratory animals (rodents). Finally, animal models allow for correlating the 
information provided by non-invasive biomarkers with detailed histological 
examination of the entire myocardium at multiple different time points. This therefore 
overcomes the sampling error associated with human biopsy samples, which are 
difficult to obtain in the earlier stages of disease and may not be representative of the 
left ventricle as a whole, given that remodelling often demonstrates regional variation 
(M. R. Dweck, S. Joshi, et al., 2012). Importantly given the fact that preclinical CMR 
offers excellent spatial and temporal resolution and enables acquisition of 
cinematographic and T1 mapping data the techniques for identifying LV 
decompensation are directly translatable to humans and are therefore of direct clinical 




Figure 2. Examples of various MRI sequences. Structural and functional MRI.   A - 
B: 2-chamber and 4-chamber cine scans of a mouse heart after induction of 
myocardial infarction. C and D, short-axis cine scan of the same animal at end-
diastole and end-systole, resp. Ejection fraction: 20%. E: LateGd MRI of the same 
mouse. Signal enhancement demarcating the infarct is clearly visible. F. MOLLI T1-
mapping scan raw data and fitted T1-maps before (G) and after (H) the injection of 






1.5.3 Gender discrepancies in aortic stenosis 
Interestingly in the past decade, important sex differences in the pathophysiology of 
AS are beginning to emerge, perhaps related to the influences of testosterone 
(Aurigemma & Gaasch, 1995; Carroll et al., 1992; P. S. Douglas et al., 1995; Rohde 
et al., 1997; Villari et al., 1995; Zhu et al., 2016). Most notably, recent data have 
suggested that women need less valvular calcium than men to develop severe AS 
(Aggarwal et al., 2013). Importantly, after taking into account that women have 
smaller bodies and smaller LVOT, even after normalization for these factors women 
present lower aortic valve calcium density than men for similar AS severity. This 
difference between sexes is also related to a steeper slope of AS severity increase 
with any given aortic valve calcium load or density increase in women than in men. 
Therefore, while valvular calcification is the mechanism of AS in both men and 
women, there are important pathophysiological differences between men and women 
that warrant specific clinical approaches and further research into disease 
mechanisms specific to each sex (Aggarwal et al., 2013). 
To date multiple studies showed that for a given degree of valve narrowing males 
present with a more pronounced LV hypertrophic response. Initial echocardiographic 
data showed that cardiac adaptation to aortic stenosis seems to be influenced by 
gender with males presenting larger left ventricular volumes and higher wall tension 
(Bech-Hanssen et al., 1999). These findings have been recently corroborated in 
cardiac magnetic resonance imaging studies (Dweck et al., 2012). While data on the 
myocardial response to pressure overload is largely concordant some discrepancies 
regarding the prognosis following successful aortic valve replacement in males 
versus females have been reported. In the SEAS study, women and men had similar 
rates of AS progression and AS-related events (Cramariuc et al., 2015). However, in 
that study women had lower total mortality and a ischaemic cardio-vascular event rate 
than men independent of confounders. Additionally, recently superior LV hypertrophy 
53 
 
regression and outcome were reported in elderly women compared with men 
undergoing transcutaneous aortic valve replacement from the prospective Placement 
of Aortic Transcatheter Valve (PARTNER) trial (Williams et al., 2014). In line with 
these findings Fuchs et al showed that although women referred to AVR are older 
and more symptomatic, operative and long-term mortality are not increased. In the 
oldest age group of 79 years and older, women even have a better outcome, 
presumably due to a longer mean life expectancy (Fuchs et al., 2010). 
On the other hand, in a retrospective study involving 577 consecutive patients who 
underwent aortic valve replacement Caballero-Borrego et al demonstrated that 
women more often suffered acute myocardial infarction perioperatively, had a low 
cardiac output in the postoperative period and experienced greater perioperative 
mortality than men (Caballero-Borrego et al., 2009). In line with these findings in a 
separate elegant analysis Pibarot et al. (2009) showed that the mismatch of patient 
and prosthesis, greater ventricular hypertrophy and the underestimation of symptoms 
in women are possible causes of the greater mortality in women with AVR. Another 
reason for less favorable outcomes in females might be the fact that women are more 
often present with paradoxical low flow low gradient aortic stenosis which is 
associated worse outcome, especially when treated medically (Hachicha et al., 2007 
& Barasch et al., 2008). 
 
Intriguing data derived from cardiovascular magnetic resonance imaging has been 
reported by Singh et al. According to this recent study gender differences may also 
exist in both the remodeling response of the left ventricle and in the development of 
symptoms. The authors provided cardiac magnetic resonance, transthoracic 
echocardiography, and biomarker analysis of 174 patients (133 men and 41 women) 
with moderate to severe AS coupled with detailed assessment of symptom status at 
baseline and after follow-up (Singh et al., 2017). With the data acquired across 
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multiple expert centers across the United Kingdom the authors demonstrated that, 
despite a similar severity of aortic valve narrowing, men had higher indexed left 
ventricular mass, increased LV volumes, and more concentric remodeling. 
Importantly, these differences in the degree of LV remodeling persisted after 
correction for size differences between the sexes and in a multivariable analysis. 
Having in mind that similar findings were reported in previous studies, it appears that 
for a given degree of AS men develop more advanced cardiac remodeling than 
women (Dobson et al., 2016; M. R. Dweck, S. Joshi, et al., 2012; J. M. Lee et al., 
2015). 
1.5.3.1 Gender difference in myocardial fibrosis 
Aside from the degree of hypertrophy, recent data suggests that further differences 
can be found in the degree of myocardial fibrosis. Singh et al have shown that men 
might have more LV late gadolinium enhancement and scarring than women. In part, 
these differences can be related to previous myocardial infarction (not unexpected 
given the sex differences in coronary artery disease), but in the study there was also 
a numerical difference in the mid-wall pattern of scarring that is more specific to AS. 
Similarly, men had increased levels of blood biomarkers related to fibrosis and 
reduced markers of LV performance (ejection fraction, longitudinal strain, 
circumferential strain)(Singh et al., 2017). While these findings are of interests it is 
important to have in mind that despite being a multicenter study, there were only 41 
females included in the analysis. With the Singh et al study somewhat limited by 
sample size and with many of the fibrosis observations of borderline significance 
larger studies are now required for confirmation. In particular, these could assess 
whether the mid-wall pattern of late gadolinium enhancement is indeed more 
prevalent in men and elucidate the information provided by T1 mapping, which 




1.5.3.2 Gender discrepancies in the development of symptoms and outcome 
The second key insight provided in the paper by Singh et al is the demonstration that, 
despite the more advanced LV remodeling and decompensation observed in men, it 
was women who were more likely to develop symptoms necessitating aortic valve 
replacement (AVR). Similar findings were reported in a recent report by Capoulade 
et al. In an echocardiographic study of 747 consecutive AS patients followed up for 
6.4 years the most prevalent pattern of LV remodeling – concentric hypertrophy was 
independently associated with increased risk of mortality in women, but not in men 
(R. Capoulade et al., 2017). While the association of adverse outcome and concentric 
hypertrophy persisted in the entire cohort, the fact that this relationship showed 
gender discrepancies supports the view that a sex specific approach in aortic stenosis 
is justified.  
The paper by Singh et al. also elucidates the relationship between symptom 
development and novel biomarkers of LV decompensation including Btype natriuretic 
peptide, echocardiographic strain and mid-wall fibrosis on cardiac magnetic 
resonance (Attias et al., 2013; Dahou et al., 2015; Kearney et al., 2012). On univariate 
analysis, symptom development prompting AVR was not associated with indexed LV 
mass, myocardial perfusion parameters, ejection fraction, myocardial strain 
assessments, or the presence/volume of mid-wall late gadolinium enhancement. 
Although symptom development was associated with B-type natriuretic peptide in 
men, it was not in women. Moreover, despite men having greater evidence of LV 
remodeling and decompensation by the vast majority of measures, it was women who 
developed symptoms more quickly and therefore proceeded to aortic valve 
replacement (Singh et al., 2017).  
The uncoupling of symptoms and markers of LV remodeling raises important 
questions. Can we rely on symptom development in modern clinical practice to guide 
AVR timing? Perhaps it is the biomarkers that are unreliable? Are we operating too 
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late in men, allowing them to develop excessive myocardial scarring? Ultimately, such 
questions regarding the optimal timing of surgery are not well answered by 
observational studies and will only be fully addressed in the context of randomized 
controlled trials. Fortunately, several such trials are under way (e.g., Early Valve 
Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic 
Patients With Severe Aortic Stenosis [NCT03094143], Evaluation of Transcatheter 
Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic 
Severe Aortic Stenosis [NCT03042104]), examining whether alternative strategies 
might improve the timing of AVR compared with symptom development. These 
randomized clinical trials are long overdue and their results highly anticipated.  
While we await these trials to report their findings the gender discrepancies in the 
fibrosis burden, in particular, in the T1-mapping derived measurements could easily 
be evaluated on large multicenter registry data. Up to date only one single center 
study showed a statistically significant difference in measures of diffuse fibrosis 
(Treibel, Kozor, et al., 2018). In a cohort of 168 patients with symptomatic severe AS 
referred for surgical AVR men showed more extracellular matrix expansion, 
calculated as the product of LV myocardial volume and ECV (28.5±8.8 ml/m2 vs. 
21.4±6.3 ml/m2 and a higher burden of replacement fibrosis as assessed with LGE 
(16.5±11.2 g vs. 10.5±8.9 g) than women. In the study, men more frequently showed 
concomitant coronary artery disease, which could partly explain increased myocardial 
fibrosis compared with women. Given the overall less favorable remodeling pattern 
and ventricular phenotype with more concentric and eccentric hypertrophy as well as 
lower LV ejection fraction, higher NTproBNP and hsTnT in men compared to women 
it is intriguing why only in females the maladaptive remodeling is associated with 
impaired survival after aortic valve replacement (J. M. Brown et al., 2009; Morris et 




1.6. Calcification activity on 18F-sodium fluoride PET 
18F – sodium fluoride has been used for decades in nuclear medicine to image bone 
malignancies (Jadvar, Desai, & Conti, 2015). In the skeleton, fluoride binding is 
facilitated through a chemical reaction with hydroxyapatite, a crystalline structure that 
is commonly known as the bone mineral. Importantly hydroxyapatite is also the main 
component of vascular atherosclerosis and valvular calcifications (Monte Blau, 
Ganatra, & Bender, 1972). In the context of cardiovascular imaging the binding of 18F-
NaF to microcalcification was studied in histological samples of human carotid 
plaques on three levels: with electron microscopy, autoradiography, and 
µPET/CT(Irkle et al., 2015; Vesey et al., 2017). It was demonstrated that 18F-NaF 
binds preferentially to microcalcification beyond the resolution of µCT and co-
localizes to regions of active mineralization within vascular tissue. The preferential 
binding to microcalcification is likely due to the high surface area of hydroxyapatite in 
regions where this nanocrystal builds up (Gasser, Voegel, & Gramain, 1993; J. Lin, 
Raghavan, & Fuerstenau, 1981). 
This imaging modality gained interest in the context of detecting cardiovascular 
calcification within coronary arteries, the abdominal aorta, carotid arteries and the 
aortic valve (M. R. Dweck, M. W. L. Chow, et al., 2012; M. R. Dweck, C. Jones, et al., 
2012; Forsythe et al., 2018; Lee et al., 2017; T. A. Pawade et al., 2016; Vesey et al., 
2017). It was shown that 18F-Fluoride is readily taken up by the valves of patients with 
aortic stenosis and on histology correlates with markers of calcification activity 
(Dweck et al., 2014). The ability to monitor calcification activity is particularly of 
interest as the calcific burden of the valve has been already linked to outcome (Clavel, 
Pibarot, et al., 2014; T. Pawade et al., 2018). With such encouraging initial studies 
nowadays 18F-NaF is utilized in randomized clinical trials evaluating therapies aimed 
at slowing the progression of aortic valve calcifications (Study Investigating the Effect 
of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis - 
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NCT02132026 and Bicuspid Aortic Valve Stenosis and the Effect of vitamin K2 on 
Calcium metabolism on 18F-NaF PET/MRI - NCT02917525).  
Aside from being able to predict progression of native aortic valve disease 18F-NaF 
PET has been recently shown to be a robust tool for imaging patients who underwent 
surgical aortic valve replacement. In our recent study we have identified 18F-NaF PET 
as the first noninvasive technique capable of detecting early bioprosthetic valve 
degeneration and of predicting future valve dysfunction (Cartlidge et al., 2019). In an 
extensive histological and state of the art ex vivo imaging validation we demonstrated 
increased 18F-NaF uptake in each of the failed bioprosthetic aortic valves examined, 
with PET activity colocalizing to areas of calcification, pannus, thrombus, and 
disrupted tissue architecture on histology. When applied to patients in the clinical 
setting, 18F-NaF PET identified early valve degeneration beyond the resolution of 
echocardiography or CT and outperformed conventional surveillance methods in 
predicting the development of new valvular dysfunction and overt valve failure within 
the 2-year follow-up period. 18F-NaF PET, appears to be a readily applicable measure 
of valve degeneration with the potential to transform how we monitor and treat the 
expanding population of patients living with surgical bioprosthetic valves. 
Given the growing population of patients who undergo transluminal aortic valve 
replacement (TAVR) and the finite lifespan of the implanted bioprothesis an imaging 
approach which would enable prediction of structural TAVR deterioration is desirable. 
While a combined CT angiography and 18F-NaF PET appear to be ideally suited for 
monitoring degeneration of TAVR, imaging TAVR presents unique challenges. After 
TAVR deployment, leaflets of the native valve are displaced against the aortic wall 
making it difficult to discern PET tracer uptake within the implanted bioprosthesis from 
the native valve. Similarly, distinguishing TAVR calcifications from stent struts and 
native valve calcium requires high quality CT angiography. In view of these 




Despite the growing enthusiasm, 18F-NaF cardiovascular PET remains a complex and 
challenging imaging approach. Before this promising modality reaches its full 
potential, several limitations need to be addressed (Thomas & Haraszti, 2014). These 
include small target lesions size, which for adequate count statistics requires long 
emission scanning. The duration of emission scanning has been set at 30 minutes 
and increases the risk of inter-scan patient motion as subjects may find it difficult to 
remain immobilized over the entire length of the acquisition. The measured uptake is 
also adversely affected by blurring of the tracer signal in target lesions by 
cardiorespiratory motion which occurs as a result of physiological tidal breathing and 
heart contractions. To reduce the effect of motion gating can by employed. To date it 
has only been widely utilized to ameliorate cardiac motion, with end-diastolic imaging 
(25% of PET counts) used for image analysis. Additionally, with the need for 
anatomical reference when evaluating uptake 18F-NaF PET requires multifaceted 
experience staff to acquire CT angiography. In view of the small target lesions size, 
joint effects of cardiorespiratory motion 18F-NaF PET would undoubtedly benefit from 
refinement of image acquisition, reconstruction and analysis. 
 
1.6.1 Delayed PET Imaging of cardiovascular disease  
The benefit of delayed PET acquisition for the detection of disease is widely 
appreciated in oncological applications with 18F-fluorodeoxyglucose (FDG)(Caoduro 
et al., 2013; Kubota et al., 2004; W. Y. Lin, Tsai, & Hung, 2005; Nishiyama et al., 
2005). There is good agreement that because background activity decreases on 
delayed imaging, the image quality improves. The lower background activity is a 
critical feature and advantage of delayed imaging, because it increases target to 
background ratios (Cheng, Torigian, Zhuang, & Alavi, 2013; Houshmand et al., 2016). 
It has been shown that a longer time window from injection to acquisition translates 
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to higher signal to noise and therefore facilitates visual analysis providing higher 
diagnostic accuracy (Kubota et al., 2001). For coronary PET imaging, it was 
suggested that the optimal timing for acquisition with FDG is 2.5-3h after tracer 
administration (Rudd et al., 2002). 
In the 1970s when 18F-NaF was first used for bone scanning, Blau et al suggested 
that the optimal scanning time for 18F-NaF is 2-4 hours post injection (M. Blau, Nagler, 
& Bender, 1962). Nevertheless, whole-body 18F-NaF PET is nowadays most often 
performed with imaging commencing 60 minutes after injection (Czernin, 
Satyamurthy, & Schiepers, 2010; Grant et al., 2008; Hawkins et al., 1992; Segall et 
al., 2010). In case of 18F-NaF PET bone imaging, since 18F-NaF has faster blood 
clearance and higher bone uptake compared to 99mTc-methylene diphosphonate, 
the SNM practice guideline recommends emission scanning for the axial skeleton as 
soon as 30-45 minutes after injection in patients with normal renal function to 
decrease the overall time of the study. However, a longer waiting time of 90-120 
minutes was recommended to acquire high-quality images of the extremities (Segall 
et al., 2010). 
In cardiovascular PET, in most studies to date assessing 18F-NaF uptake in 
atherosclerotic plaques and aortic valves, acquisition was performed 1-hour (1h) after 
tracer administration (Derlin et al., 2010; Derlin, Toth, et al., 2011; Derlin, Wisotzki, et 
al., 2011; Joshi et al., 2014). Although semi-quantitative analysis is feasible with 1h 
images, it can be difficult to discriminate plaques with 18F-NaF uptake from noise. In 
fact, compared to uptake in the bony skeleton, 18F-NaF uptake due to active 
microcalcification formation in coronary plaque and valve leaflets is very small in 
amount. Recently, it has been speculated that the optimal time for atherosclerotic 
plaque imaging with 18F-sodium fluoride might differ from the 1h post injection time-
point used for bone imaging (Derlin, Wisotzki, et al., 2011).  
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Longer delays for cardiovascular 18F-NaF PET imaging were evaluated by only one 
study to date. Blomberg et al. concluded that delayed 18F-NaF PET imaging does not 
improve quantification of vascular calcification. However, the authors measured only 
overall heart 18F-NaF activity (including blood pool) by placing regions of interest 
around the entire cardiac silhouette on ungated PET/CT images (excluding 18F-NaF 
activity originating from bones and cardiac valves) and averaged the SUV values 
derived from all slices. The study was performed without cardiac gating and motion 
correction. Further, with 2.5-minute scan time and a 2.2 MBq dose of 18F-NaF per 
kilogram of body weight the authors had approximately 16 times less counts 
compared to recent studies and ongoing clinical trials (which utilize a ~3.4MBq per kg 
dose and 30-min long acquisitions)(Björn A. Blomberg et al., 2014). 
There remains a need to comprehensively assess whether the optimal timing for 18F-
NaF cardiovascular PET is 1h post injection imaging. In particular the potential 
benefits of a delayed acquisition should be investigated. 
 
1.6.2 Anatomical reference for 18F-sodium fluoride uptake quantification 
Regardless of the delay from tracer injection to image acquisition in order to measure 
18F-NaF uptake anatomical reference is essential. For cardiovascular PET two 
approaches have been proposed (Bellinge, Francis, Majeed, Watts, & Schultz, 2018). 
The lesion specific method of analysis utilizes coronary CT angiography for 
anatomical reference (Joshi et al., 2014; Lee et al., 2017). Regions of interest can be 
delimited around coronary plaques so that single areas of increased tracer uptake are 
considered. Such an approach has several advantages as it provides lesion specific 
information: it enables assessing plaque composition and it can be used for guiding 
revascularization as luminal stenosis can also be evaluated. When compared to a 
global coronary method of analysis it is not prone to false positive findings in patients 
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with non-coronary 18F-NaF uptake. This approach is however more challenging from 
an acquisition point of view as it requires prospective ECG-gating of the PET 
acquisition, moreover CT and PET datasets need to be co-registered which is not 
always trivial. Furthermore, the lesion specific approach is highly dependent on the 
quality of the coronary CT angiography. The latter relies upon the staff expertise and 
the quality of the CT component of the hybrid PET/CT scanner.  
A more straightforward approach for 18F-NaF uptake quantification has also been 
described. The global coronary method of analysis utilizes the low-dose CT data 
acquired for attenuation correction purposes (Alavi, Werner, & Høilund-Carlsen, 
2017; Beheshti et al., 2011; B. A. Blomberg et al., 2015). Regions of interest are 
drawn around the entire heart and as a result both the PET acquisition and image 
analysis are simplified. There is no need for prospective ECG gating and the radiation 
dose is smaller. Image analysis can be performed by readers without experience in 
reporting coronary angiography. Unfortunately, this approach has several limitations. 
First of all, its specificity is suboptimal in all patients presenting with non-coronary 18F-
NaF uptake. For instance, it can be very difficult to distinguish valvular calcification 
that lays in close proximity from coronary plaques. This is often the case for the left 
main stem and aortic valve or the circumflex artery and the mitral annulus (Bellinge 
et al., 2018). Further since the global method does not provide insights into coronary 
anatomy it cannot be used to inform invasive angiography. Finally, because this 
approach averages the signal from the entire coronary vasculature it does not allow 
for appreciating single plaque activity and therefore fails to depict high-risk/ vulnerable 
plaques.  
While there are multiple advantages of using CT angiography for anatomical 
reference for analyzing 18F-NaF uptake it has several limitations which hamper its 
practical implementation into a meaningful clinical workflow. To date studies have 
utilized CT angiography acquired using hybrid PET/CT scanners during a single 
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imaging session. This approach, however, does not lend itself to patient selection for 
imaging based on prior CT angiography findings. If the 18F-NaF imaging becomes 
part of a clinical assessment strategy, it is likely that patients should be selected for 
18F-NaF PET based on the findings of a CT angiography performed for clinical 
purposes. Another key limitation of the single session hybrid PET/CTA protocol is that 
it may not allow for the use of optimal CT equipment for CT angiography which may 
only be available on standalone CT scanners. Finally, the use of hybrid PET/CTA 
requires multi-faceted staff expertise in both PET and coronary CT angiography 
during a single session. An acquisition protocol which would enable taking full 
advantage of CT angiography and in the same time mitigate the aforementioned 
limitations is desirable.  
1.6.3 Image reconstruction and optimal measure for 18F- sodium fluoride 
PET. 
Another potential aspect of 18F-NaF PET which requires attention is image 
reconstruction. It is widely recognized that successful imaging of microcalficiations 
requires not only an ideal radiotracer that reflects the biology of the disease but also 
the technology and a measurement system that is both accurate and precise. While 
in the near future improved spatial resolution and implementation of partial-volume 
correction on future PET/CT scanners may to some degree improve accuracy of 18F-
NaF PET, nowadays incorrect reconstruction approaches may distort the study 
results (Jacobo Cal-Gonzalez et al., 2018). 
The number of iterations, the use of filtering, applying point spread functions as well 
as taking full advantage of the time of flight and resolution recovery techniques all 
have a profound impact on the uptake values (Huet, Burg, Le Guludec, Hyafil, & 
Buvat, 2015; Jaskowiak, Bianco, Perlman, & Fine, 2005). In a recent study Doris et 
al. showed how particular settings affect the signal to noise ratio and influence image 
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quality. The authors demonstrated that while more iterations and no post-filtering 
result in higher SUVmax and TBR values, such images are excessively noisy and 
difficult to interpret (Mhairi K. Doris et al., 2018). It appears that standardization of 
reconstruction parameters would be an important step in disseminating 18F-NaF PET 
as it would enable making direct comparisons between centers. Uniform 
reconstruction parameters would also allow for establishing reference values (Figure 
3). 
Figure 3.  The effect of different PET reconstructions on visual image quality in the 
original diastolic, summed and motion-corrected images in a patient with a positive 
culprit lesion in the left main coronary artery. The PET reconstruction using 4 
iterations and 5-mm post-filtering was considered to provide superior image quality 
(TBR=1.92 for motion-corrected image). This figure was originally published in JNC 
under the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/). Doris MK, Otaki Y, Krishnan SK et al.: 
Optimization of reconstruction and quantification of motion-corrected coronary PET-




Similarly, standardization of the uptake measurement utilized would be beneficial. 
While target to background ratios (TBR) remain the most widely used measure, in the 
context of coronary imaging usually maximal TBR values (derived by dividing the 
target’s maximum SUV by the background mean) are used, at the same time for aortic 
valve mean TBR values have been shown to be more reproducible. Pawade et al. 
have systematically investigated the image analysis of 18F-fluoride PET imaging of 
the aortic valve. The authors showed that improved scan-rescan reproducibility can 
be achieved using mean TBR measurements in the valve (percentage error ±10%). 
They concluded that this encouraging reproducibility might have implications for 
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application to future clinical trials, with 18F-fluoride potentially providing a useful 
imaging end-point of drug efficacy (T. A. Pawade et al., 2016).  
While in cardiovascular PET TBR has been widely utilized, in patients undergoing 
PET/CT imaging for the initial staging or treatment response evaluation of 
malignancies the maximum standardized uptake value (SUVmax) is the most 
commonly used parameter for measuring lesion activity (Boellaard, Krak, Hoekstra, 
& Lammertsma, 2004; Thie, 2004). Recently Chen et al pointed out that despite the 
broad application of TBR in the literature, particularly in the field of atherosclerosis 
PET imaging, its biologic significance and physiologic or mathematic explanation 
have not been provided (Chen & Dilsizian, 2015). Huet et al argued that blood activity 
adds to plaque activity because of the spatial blurring of PET images (which occurs 
as a result of the imperfect spatial resolution)(Huet et al., 2015). It was suggested that 
to correct for blood uptake, subtraction of venous SUV from arterial SUV would be a 
more rational solution than dividing the 2 measured values. The rational supporting 
this approach is the fact that the clearance of PET tracers from the venous blood pool 
can be quite variable from subject to subject, as it depends on multiple factors. As a 
result, dividing the vascular wall SUV with the venous blood pool SUV may introduce 
more variability and confusion to the TBR measurement than confidence (Chen & 
Dilsizian, 2015). 
1.6.4 Gating for cardiovascular PET  
Positron emission tomography images are affected by physiological patient motion 
which degrades the images qualitatively and quantitatively. Three distinct motion 
patterns can be observed in cardiac PET scans: cardiac contraction, respiratory 
motion, and patient repositioning during the acquisition.  
Aside from the development of novel tracers, the improvement in the clinical 
assessment of cardiac disease has partly been facilitated through the continuous 
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improvement in the spatial resolution of the PET systems, which in current PET/CT 
systems offer resolutions of 2-5 mm at full-width at half maximum (FWHM)(J. Cal-
Gonzalez et al., 2018; Rahmim, Rousset, & Zaidi, 2007). Correction for point spread 
function as well as time-of-flight imaging has become standard in many modern PET 
systems, which offer improved localization of the annihilation event and, thus, 
improved spatial recovery of the tracer distribution (Armstrong, Tonge, & Arumugam, 
2014; Conti, 2011; Dasari et al., 2018; Slomka, Pan, Berman, & Germano, 2015). The 
high-resolution PET systems, in theory, permit accurate delineation of abnormal 
areas with a precision similar to the PET scanner’s spatial resolution (Blankstein et 
al., 2014; Nensa et al., 2018; Rubeaux, Doris, Alessio, & Slomka, 2017). 
Unfortunately, high-resolution imaging of the myocardium and foci of 
microcalcification within the coronary arteries and the aortic valve is hampered by 
motion during the acquisitions (Nehmeh & Erdi, 2008). The detrimental impact of 
motion during the PET-acquisition was recognized already in 1982 when it was 
proposed to divide the PET-data into motion-limited bins based on the 
respiratory/cardiac phase (Terpogossian, Bergmann, & Sobel, 1982).  
Since then several studies have investigated the effects of cardiac and respiratory 
motion (Chander et al., 2008; Manber et al., 2016; Rubeaux, Joshi, Dweck, Fletcher, 
Motwani, Thomson, Germano, Dey, Li, et al., 2016; Teras et al., 2010; Thielemans et 
al., 2014). Despite the fact that all motion patterns have equally detrimental effects 
on image quality, to date the focus has been primarily on cardiac contraction(Dawood 
et al., 2009; Shechter, Resar, & McVeigh, 2006).  One reason for this is the potential 
need for additional equipment to track motion patterns. The availability of ECG has 





1.6.4.1 Cardiac gating  
Nowadays in the clinical setting usually 3-lead ECG is utilized (Nekolla, Dinges, & 
Rischpler, 2013). With the lead data being directly transferred to the scanner both 
retrospective and prospective gating of the acquired PET is feasible. The use of 3-
lead electrocardiograms (ECG) is relatively easy, cheap and has been shown to be 
reproducible in many studies (Nekolla et al., 2013). Aside from the gating functionality 
it also serves to monitor the patient during the acquisition. The acquired ECG signal 
employs the R-wave as a reference to estimate the cardiac phase in which each 
coincidence was acquired, ultimately allowing the data to be sorted into near motion-
free cardiac gates (Figure 4). Cardiac gating in most modern systems is performed 
retrospectively. Prospective gating is mainly used in older PET systems where 
listmode storage is not feasible and relies on defining phases in relation to the peak 
of the R wave. Such phases can be defined as preceding the R wave (backward 
gating) of occurring after it (forward gating). In both scenarios, the annihilation events 
can be sorted into predefined sinogram buffers and reconstructed once the 




Figure 4. Principle of ECG-gating, here shown using a 10-bin ECG-gating. The 
acquired PET-data for each R-R interval is divided into a user-specified number of 





Cardiac gating can serve two functions: (1) it can be used for motion compensation 
of the myocardium  and (2) for functional assessment of the myocardium (Le Meunier 
et al., 2011). The functional assessment provides both diagnostic and prognostic 
value in the clinical assessment of global cardiac function (left ventricular ejection 
fraction, LVEF), regional wall motion abnormalities and myocardial dyssynchrony 
(AlJaroudi et al., 2012; Pazhenkottil et al., 2011). The motion-compensated images 
are mainly used for research purposes while the functional assessments are used in 
the clinical routine. Analyses of the functional parameters have shown that an 
increase in LVEF (from baseline to peak stress) is inversely related to the magnitude 
of ischemia and the extent of angiographic CAD (T. L. Y. Brown, Merrill, Volokh, & 
Bengel, 2008; Dorbala et al., 2007). In patients with multivessel CAD, LVEF often 
shows a blunted response or can even drop on stress imaging. The change in LVEF 
during peak stress has been shown to have value for risk prediction (Dorbala et al., 
2009; Lertsburapa et al., 2008). Importantly, cardiac gating has been proven a strong 
tool as a first approach in the assessment in the coronary plaques as the coronary 
arteries can shift up to 26 mm during the cardiac cycle  (Figure 5A)(Dilsizian et al., 
2016; Rubeaux, Joshi, Dweck, Fletcher, Motwani, Thomson, Germano, Dey, Berman, 
et al., 2016). ECG gating can be also leveraged to perform cardiac motion correction 
and therefore compensate for heart contractility. This approach has already been 
shown to improve signal to noise and TBR of coronary plaques (Figure 5B)(Rubeaux, 
Joshi, Dweck, Fletcher, Motwani, Thomson, Germano, Dey, Li, et al., 2016). More 
recently Doris et al showed that a similar algorithm can be utilized for aortic valve 18F-
NaF imaging. In a feasibility study the authors demonstrated that such motion 
correction improves both signal to noise and target to background ratios (M. K. Doris 




Figure 5. Displacement of the coronary arteries during the cardiac contraction. The 
right coronary artery shifts by 8-26 mm during cardiac contraction - yellow arrows (A). 
Motion correction of physiological motion of the right coronary artery (B). Systolic 
excursion of the tricuspid annular plane leads to displacement of the PET signal 
during the cardiac cycle (zoomed area of interest in blue squares). The difference in 
the shift of PET from reference is shown on the end-systolic (top-right) and late-
diastolic (mid right) images. Green arrows represent the vectors of mid RCA motion. 
By co-registration of all PET data to the reference end-diastolic gate, the final motion 
corrected image is corrected for the 14mm mid RCA motion (bottom-right). Panel B 
of this figure was originally published in JNC under the Creative Commons Attribution 
4.0 International License (http://creativecommons.org/licenses/by/4.0/). Doris MK, 
Otaki Y, Krishnan SK et al.: Optimization of reconstruction and quantification of 








1.6.4.2 Respiratory gating 
Respiratory gating is desired in the clinical settings to improve image quality but is 
not often utilized in many modern systems which only allow for one form of gating 
during the reconstruction (ECG or respiratory gating). In systems facilitating dual-
physiological trigger events (cardiorespiratory signals), the respiratory signal may be 
extracted using external markers such as piezo-electric respiratory belts or infra-red 
systems (Nehmeh & Erdi, 2008). Other solutions employing spirometers, and 
measurements of the nasal temperature/humidity have also been successfully tested 
(Buther et al., 2009). Respiratory gating employing external markers has several 
drawbacks. These include: a time-consuming imaging setup , potential malfunction 
during the acquisition and rather rigid monitoring of the respiratory signal which 
results in less robust monitoring in patients with changes in the respiratory baseline 
(Giraud & Garcia, 2010; M. L. Lassen, Rasmussen, Christensen, Kjaer, & Hasbak, 
2017; C. Liu, Pierce, Alessio, & Kinahan, 2009). Owing to the complex setups, the 
introduction of respiratory gating is still mainly a tool applied in research-studies 
primarily in centers with technical personnel who can maintain the systems.  
1.6.4.2.1 Data driven respiratory gating 
To overcome the drawbacks of the external markers, the tendency in recent research 
is to replace the external markers using data-driven methods (Adam L. Kesner et al., 
2014). The data-driven methods offer several benefits over the use of external 
markers: First, the data-driven methods do not require frequent calibrations as they 
extract the respiratory signal directly from the list files. Second, they allow for ad-hoc 
correction of all acquisitions acquired in listmode format, whereas careful planning is 
needed when using external markers. A third benefit is that the data-driven methods 
do not require the user to buy any additional hardware, which can be costly both to 
acquire and install.  
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In addition, the data-driven methods, in general, have the potential of facilitating 
accurate gating in patients with changes in the respiratory baseline, a frequent 
problem in myocardial perfusion imaging where stress scans are performed after 
administration of pharmaceutical agents. The common agents (adenosine, 
dipyridamole, and regadenoson) all have short half-lives, which require optimized 
stressing protocols such that the maximum effect is obtained during the infusion of 
the PET-tracer. Given the fast roll-off effect of the pharmaceuticals, it is not 
uncommon to encounter changes in the respiratory base-line during the acquisition 
(Memmott, Tonge, Saint, & Arumugam, 2018; Watt & Routledge, 1985). If not 
corrected for, the change in the respiratory baseline might introduce a degradation of 
the gated images in comparison to the non-gated images (Gould, 2017). Here, data-
driven gating approaches allow for tailored gating-approaches that fits the stress-
imaging protocol and, thus, have the potential of outperforming the use of the external 
markers which often are calibrated to the respiratory baseline at the beginning of the 
acquisition (Dawood, Buther, Lang, Schober, & Schafers, 2007; M. L. Lassen et al., 
2017).  
1.6.4.2.2 Sensitivity based methods 
The first attempts at extracting information of the respiratory motion directly from the 
PET-raw data (list files) were proposed by Bundschuh et al and He et al (Bundschuh 
et al., 2007; He et al., 2008). These methods, in brief, are based on the 
heterogeneous sensitivity profiles that exist in all PET-systems. The sensitivity profile 
is partly introduced by the geometry of the system and partly by the detector materials 
used (Eriksson et al., 2007). Owing to the geometry in the PET system, the highest 
sensitivity is obtained in the center of the field of view. Heterogeneous objects moving 
in and out of the center field of view will result in changes in the obtained count rates 
equivalent to the motion in the scanners axial direction. For patient scans, the 
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heterogeneous uptake rates are obtained through differences in the tracer distribution 
as well as differences in the linear attenuation coefficients in the lungs and diaphragm.  
1.6.4.2.3 Center-of-Mass/centroid-of-mass based methods 
The center-of-mass or centroid-of-mass (CoM) based approaches have gained 
substantial interest in imaging of organs with focal uptake and high contrast to 
background ratio, such as myocardial scans and in studies of non-small cell lung 
cancers. Several methods relying on this assessment have been proposed, using 
either the full field of view or through detection of localized motion vector fields (Buther 
et al., 2009; Buther et al., 2010). The CoM assessment, in brief, evaluates the centroid 
of the counts obtained in the region of interest using single-slice rebinned sinograms 
(SSRB), which are marked by the user in most cases (Daubewitherspoon & 
Muehllehner, 1987). The SSRB algorithm, in short, is an algorithm that compresses 
the full 3D sinograms into a reduced 3D sinogram. By performing the compression, 
the noise is reduced and provides a more stable respiratory signal. This omits the 
varying sensitivity profiles and, thus, provides a more stable measurement of the 
respiratory cycle even for lesions slightly misplaced from the center of the systems 
field of view.  
1.6.4.2.4 Sinogram Fluctuation model 
The sinogram fluctuation model evaluates the fluctuations obtained in sinograms with 
short time duration (~500ms). Following their binning, the sinograms can be 
evaluated for the periodicity of the signal changes in each of the short time-duration 
datasets, thus, permitting extraction of the respiratory signal using only data with 





1.6.4.2.5 Respiratory gating: Phase vs amplitude  
Once acquired, the respiratory signal can be used for gating in multiple ways where 
phase-based/time-based (similar to the ECG-based gating approaches) and 
amplitude-based gating are the two most common approaches (Figure 6)(Dawood et 
al., 2007).  
 
1.6.4.2.5.1 Time-based / Phase-based gating 
The phase-based method is the most simplistic method of the two, where each 
respiratory phase is divided into a user-defined number of phases, each with equal 
time-duration (Dawood et al., 2007). This ensures homogeneous noise-levels for all 
gates, which is beneficial in the subsequent analyses. Unfortunately, this method 
does not allow for differentiating between normal tidal breathing and sudden 
excessive in/expiratory breath-holds or changes in the respiratory baseline.  
1.6.4.2.5.2 Amplitude-based gating 
The amplitude-based gating offers more accurate gating than the time-based/phase-
based gating approach. Despite the superiority in providing high spatial differentiation 
of data from different respiratory amplitudes, this technique also has its limitations. 
The highly dynamic range of respiratory signals often hampers its functionality and, 
thus, most often requires truncation or discarding of data outside the normal range to 
ensure enough counts to provide clinical image-qualities. In addition, the 
asynchronous respiratory cycle will often introduce inhomogeneities in the noise-
characteristics in the resulting gated images with the best quality often obtained in 
the end-expiratory phase. Due to this, it has been proposed to use the optimal 
respiratory gate, which only employs data from the end-expiratory phase – known as 
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the optimal respiratory phase, which typically can contain up to 35% of all image 




Figure 6. Time-based (phase-based) gating and amplitude-based gating techniques 
demonstrated using 4 respiratory gates. Time-based method divides the data into 
equally time-divided bins that will have the same noise properties (equal time-
duration, A). Amplitude-based gating divides the data into bins with the same 
respiratory amplitude, and thereby pose the risk of having noise-variated gates in the 
following assessments, as can be observed for the third respiratory cycle which does 





1.6.4.3 Dual gating 
The single gating techniques have been proven suboptimal for many PET-scans as 
the non-corrected motion-pattern is still embedded in the resulting images. Dual-
gating approaches, which combine the cardiorespiratory motion, have been proposed 
(Gigengack et al., 2012; Hyun, Gerlach, Rubeaux, & Slomka, 2017; Lamare et al., 
2014; Teras et al., 2010). The combination of the two gating techniques ensures 
virtually motion-free images, with only little intra-gate motion present (Figure 7). 
Unfortunately, this requires sufficient image quality (count rates per single gate) in the 
subsequent reconstructions, as often up to 16-64 gates are being utilized. The exact 
number depends on how many respiratory and cardiac gates are used (N Respiratory 
gates × N cardiac gates) with N being the number of the respective gates (Martinez-




Figure 7. Dual-gating scheme. Example of a dual gating scheme employing 4 ECG 
and 8 respiratory bins, which creates a total of 24 virtually motion-free images. Each 
of the gated images can be co-registered to obtain images with reduced noise 
properties when compared to the noise in each individual gate. This research was 
originally published in JNM. Slomka PJ, Rubeaux M, Le Meunier L, et al. Dual-Gated 
Motion-Frozen Cardiac PET with Flurpiridaz F18. J Nucl Med. 2015;56(12):1876-
1881. © SNMMI. 
 
1.6.4.4 PET attenuation correction issues resulting from motion 
Attenuation correction (AC) is an important prerequisite for absolute quantification in 
all PET imaging. Several attenuation correction techniques have been proposed, 
depending on the modality (PET-only, PET/CT or PET/MRI)(Chesler, 1971; Kinahan, 
Hasegawa, & Beyer, 2003; Martinez-Moller et al., 2009). Several drawbacks and 
limitations have been described for the AC maps, disregarding the acquiring modality. 
The drawbacks include both physiological and technical aspects such as beam-
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hardening, misalignment, truncation as well as non-physiological artifacts. In the 
context of gating, especially the misalignment artifacts are particularly relevant. 
Misalignment of the PET-emission data and the AC-images can be classified either 
as repositioning events where the patient moves between the acquisition of the AC 
maps and the PET-emission data, differences between the respiratory-gated PET-
images and the corresponding AC maps or as breathing during the AC acquisition 
(Figure 8)(Gould et al., 2007; Martin Lyngby Lassen et al., 2017; Martinez-Moller, 
Souvatzoglou, Navab, Schwaiger, & Nekolla, 2007).  
Respiratory motion during the PET-images translates the heart up by up to a few 
centimeters. Due to the fast acquisition times of the AC images (a few seconds in 
CT), respiratory motion during the acquisition is often not a problem regardless 
whether a free-breathing or end-expiratory breath-hold acquisition protocol is utilized 
(Beyer et al., 2016). Employing cine CT for PET/CT has been suggested (Pan et al., 
2006). This allows reconstructing a respiratory-averaged AC map with the same 




Figure 8. Displacement of PET-emission data and the attenuation correction (AC) 
maps (A) can cause local changes of more than 80% in the quantitative assessment 
(B, C). Correction for the misalignment of the AC maps and PET-data reduced the 
extent and severity of the hypometabolic region (D, E). The displacements can be 
introduced through respiratory motion during the PET-acquisition or by patient 
repositioning between the acquisition of the AC map and the PET data. This figure 
was originally published in JNC under the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/). Lassen ML, 
Rasul S, Beitzke D, et al.: Assessment of attenuation correction for myocardial PET 





1.6.4.5 Future directions 
Cardiorespiratory motion has been investigated by many researchers and several 
gating approaches have been proposed. The use of external markers has been used 
in the conventional assessment of the displacement during the acquisition. However, 
recent trends indicate that data-driven gating techniques are an emerging technology 
that will permit marker-less motion detection in clinical routine. These gating 
techniques mainly focus on respiratory motion detection, though cardiac gating might 
also be possible as demonstrated for the first time in 2009(Buther et al., 2009; Adam 
L. Kesner et al., 2014). While these established techniques might replace the 
conventional external marker methods, the potential of data-driven detection of 
patient repositioning events is another interesting field of research. A recent pilot 
study has shown that such techniques are feasible in coronary plaque studies, in 
which gross patient motion has a detrimental effect on the quantitative accuracy 
(Martin Lyngby Lassen et al., 2018). Furthermore, it is believed that also tracer-kinetic 
studies for novel PET-tracers which scanning protocols can last up to one hour or 
more will benefit from patient repositioning detection, ultimately enabling triple-gating 
or application of sophisticated combinations of various gating techniques (Piccinelli, 
Votaw, & Garcia, 2018).  
Moreover, the use of gated images is expected to be implemented in motion 
compensation techniques, either during or before image-reconstruction. This will 
improve the image quality of the static images, where accurate definition of 
pathophysiological changes can be difficult in the gated images due to the increased 
noise levels. By correcting for the motion during image-reconstruction, it is possible 
to obtain a fully motion compensated image with the spatial resolution similar to gated 
images, with the noise characteristics of the static image-acquisitions. In addition, the 
motion compensated images can also reduce the respiratory blur in the ECG-gated 
reconstructions and, thus, lead to improved quantification of left ventricular volumes 
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for function assessments.  Therefore, gating will become increasingly important in the 
future not only for the definition motion but also in the pursuit of accurate assessment 





1.7 Thesis aims and hypotheses 
The over-arching aim of this multimodal thesis is to investigate the potential of 
cardiovascular magnetic resonance imaging to refine risk prediction and to improve 
the imaging protocol of 18F-NaF PET for aortic stenosis. 
 
The aims of the thesis are: 
 
1. To assess asymmetric wall thickening in patients with aortic stenosis using both 
cardiovascular magnetic resonance and echocardiography and characterize the 
factors associated with this pattern of remodelling, its relationship with markers of left 
ventricular decompensation and to evaluate its prognostic implications. 
 
2. To develop a mouse model of left ventricular hypertrophy and reverse remodelling in 
response to a reversible state of increased left ventricular afterload. Ultimately, we 
aimed to create a model to provide insight in to the optimal timing for aortic valve 
implantation. 
 
3. To assess the gender differences and determinants of diffuse and focal myocardial 
fibrosis in patients with aortic stenosis. 
 
4. To assess the feasibility of utilizing a previously acquired CT angiography with a 
subsequent PET-only 18F-NaF scan for the evaluation of cardiac 18F-NaF PET uptake. 
 
5. To quantitatively assess whether delayed 3-hour post-injection state-of-the-art PET 





The hypotheses of the thesis are: 
1. Asymmetric wall thickening is a distinct pattern of LV remodeling under pressure 
overload and particular imaging modalities differ in their capacity to depict it. 
 
2. By inducing increased afterload mice hearts undergo adverse remodeling which 
resembles the transition from a normal heart to decompensation as observed in 
patients with aortic stenosis.  
 
3. The burden of diffuse and replacement fibrosis is different in females compared to 
males suffering from aortic stenosis. 
 
4. CT angiography acquired before 18F-NaF PET used for anatomical reference enables 
reliable assessment of the PET tracer uptake.  
 
5. Delayed: 3-hour post injection 18F-NaF PET improves image quality and uptake 









Chapters 3 and 5 have been based on an analysis of ongoing prospective 
observational cohort studies. Chapter 4 was a preclinical study conducted on small 
rodents (mice). Chapters 6 and 7 have been based on data collected for a randomized 
controlled trial and multicenter prospective observational study. The specific study 
designs and methodology for each of the cohorts are described in detail in the 
following chapters. Below I present an overview of the patient populations and 
imaging modalities utilized in these studies. 
 
2.2 Patient population 
 





2.2.1 Patients with Aortic Stenosis 
2.2.1.1 Inclusion criteria  
Patients with at least mild AS (peak aortic jet velocity [Vpeak] ≥2.0 m/s) were recruited 
from two prospective observational cohort studies (Metabolic Determinants of the 
Progression of Aortic Stenosis (PROGRESSA) NCT01679431; Quebec Heart and 
Lung Institute and Role of Fibrosis in Aortic Stenosis NCT01755936; Edinburgh Heart 
Centre, United Kingdom) 
2.2.1.2 Exclusion criteria  
We excluded patients with other forms of valvular heart disease (moderate or severe 
in nature), end-stage heart failure, advanced malignancies or other comorbidities with 
a life expectancy < 2 years, cardiomyopathies (including previous myocarditis), and 
contraindications to gadolinium enhanced magnetic resonance, such as 
ferromagnetic foreign bodies and estimated glomerular filtration rate< 30mL/min/1.73 
m2. Coronary artery disease was defined as previous myocardial infarction, 
documented evidence of myocardial ischaemia or a> 50% stenosis of the coronary 
artery lumen. 
2.2.2 Patients with Coronary Artery Disease 
We recruited patients within a prespecified reproducibility substudy of an ongoing 
randomized clinical trial - DIAMOND (Dual antiplatelet therapy to Inhibit coronary 
Atherosclerosis and MyOcardial injury in patients with Necrotic high-risk coronary 
plaque Disease) and an observational study of stable patients with borderline 
coronary stenosis in the main epicardial vessels on CTA and high-risk plaque features 
by visual and quantitative plaque analysis – Vulnerable Plaque study. 
2.2.2.1 Inclusion criteria 
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For DIAMOND patient inclusion required the presence of multi-vessel coronary artery 
disease (defined as at least two major epicardial vessels with any combination of 
either >50% luminal stenosis, or previous revascularization (percutaneous coronary 
intervention or coronary artery bypass graft surgery on invasive angiography in the 
context of stable coronary artery disease. 
In the vulnerable plaque study patient inclusion required a coronary HRP defined by 
having at least three of the following adverse plaque features by quantitative plaque 
analysis of CTA performed for clinical purposes in stable subjects: 1) positive 
remodeling (remodeling index >1.1); 2) low attenuation plaque (LAP) (<30 HU); 3) 
obstructive coronary stenosis defined by a vessel stenosis ≥50% or contrast density 
difference (the difference between the lumen opacity proximal and distal to the 
plaque) ≥25% (13); 4) plaque volume >100mm3 or plaque burden (lesion volume 
normalized to the vessel volume) ≥40%; 5) spotty calcification on visual CTA 
assessment. Those who displayed HRP on CTA were invited to participate in a 




2.2.2.2 Exclusion criteria 
For the DIAMOND trial exclusion criteria included an acute coronary syndrome within 
the previous 12 months, renal dysfunction (eGFR ≤30 mL/min/1.73 m2) and 
contraindication to iodinated contrast agents. 
From the second cohort we excluded patients younger than 18 years, with elevated 
creatinine>1.5 mg/dL, pregnant or breastfeeding females, subjects with significant 
arrhythmia including multiple premature ventricular or atrial contractions, patients with 
an ejection fraction <35% or class III congestive heart failure. Finally, individuals who 
had a known iodine contrast allergy, were unable to take beta blockers or were unable 




2.3 Magnetic Resonance Imaging 
Imaging was performed with 1.5 and 3 Tesla scanners (Quebec: Philips Achieva or 
Philips Ingenia, Philips Healthcare, Best, The Netherlands; Edinburgh: Magnetom 
Verio, Siemens AG, Erlangen, Germany). A balanced steady-state free precession 
sequence was used for short-axis cine imagining.  
T1 mapping was performed using the Modified Look-Locker Inversion recovery 
sequence for the assessment of diffuse myocardial fibrosis. Short-axis T1 maps of 
the mid-cavity were acquired in diastole before and 20min after the administration of 
0.1mmol/kg of gadobutrol (Gadovist, Bayer Pharma AG, Germany) using a dedicated 
32-channel anterior-posterior cardiac array. 
Late gadolinium enhancement (LGE) was used for detection of focal replacement 
fibrosis. Acquisition was performed between 8 and 15 min after gadobutrol (Gadovist, 
Bayer Pharma AG, Germany) administration using an inversion recovery fast 
gradient-echo sequence and a phase sensitive inversion recovery sequence in two 
phase-encoding directions in order to distinguish true enhancement from artefact. 




2.3.1 Image analysis  
Image analysis was performed offline (cvi42, Circle Cardiovascular Imaging Inc., 
Calgary, Canada) in core laboratories using standardized approaches by trained 
operators supervised by Eric Larose in Quebec and Marc Dweck in Edinburgh 
following the current guidelines (Le Ven et al., 2016). The left ventricular longitudinal 
function was determined by measuring the difference in mitral annular displacement 
between end-systole and end-diastole. On short-axis cine images, epicardial and 
endocardial contours were carefully identified and planimetered in end-systole and 
end-diastole for left ventricular volume quantification. The left ventricular mass was 
calculated from the total myocardial volume (excluding trabeculations and papillary 
muscles) multiplied by the density of the myocardium (1.05 g/mL). All volumes and 
mass values were indexed to body surface area (calculated using the Du Bois 
formula). Focal replacement fibrosis and extracellular volume (ECV) fraction were 
assessed using late gadolinium enhancement (LGE) and T1 mapping respectively. 
LGE was performed 15 min following administration of gadobutrol (Gadovist, Bayer 
Pharma AG, Germany; 0.2 mmol/kg [Quebec], 0.1 mmol/kg [Edinburgh]). The 
presence of LGE was determined both qualitatively and quantitatively, and its 
distribution recorded. T1 mapping was performed using the Modified Look-Locker 





All participants underwent a transthoracic echocardiographic examination for the 
assessment of aortic stenosis and cardiac function on iE33, Philips Medical Systems, 
The Netherlands. The severity of aortic stenosis was classified on the basis of the 
aortic jet peak velocity, the mean pressure gradient and the aortic valve area derived 
using the continuity equation. All assessments were conducted in accordance with 
European Association of Echocardiography/American Society of Echocardiography 
(ASE) guidelines (Baumgartner et al., 2009). Transmitral early (E) and late diastolic 
velocities and deceleration time were measured at the tips of mitral valve leaflets 
using pulse wave Doppler. Pulse-wave tissue Doppler imaging was used to evaluate 
the early (e’) diastolic velocities of the medial and lateral mitral annulus. Diastolic 
function was determined using the E/e’ ratio. The left ventricular mass was calculated 
using wall thickness measurements and cavity dimensions (ASE formula) and 
indexed to body surface area (Lang et al., 2015). Cut-off values of 115 g/m2 for males 





2.5 Positron emission tomography – computed tomography imaging 
2.5.1 Coronary CT angiography  
Diamond trial patients had the coronary CT angiography (CTA) scan performed on 
the 128-slice Biograph mCT scanner (Siemens Medical Systems, Erlangen, 
Germany) using the following settings: 330 ms rotation time, 100 or 120kV (depending 
on body mass index), 160-245 mAs. The second cohort underwent CTA on a dual 
source CT scanner (Definition; Siemens Medical Systems, Erlangen, Germany). The 
scan parameters were as follows: 330 ms gantry rotation time, reference tube current 
of 400 mAs per rotation, and a tube voltage of 120 kVp.  Patients in both cohorts 
received beta blockers (orally or intravenously) to achieve a target heart rate 
<60beats/min and sublingual nitrates. A bolus of 60-100 mL of contrast (300-400 
mgI/mL; Iomeron) was power injected intravenously at 6 mL/s, after determining the 
appropriate trigger delay with a test bolus of 20 mL contrast. Transverse images were 
reconstructed using filtered back projection with 0.75/0.6 mm slice thickness, 0.4 mm 




2.5.2 18F-sodium fluoride PET 
Prior to the PET imaging, 250 MBq of 18F-sodium fluoride was injected intravenously 
and patients rested in a quiet environment for 60 minutes. Because emission 
scanning was followed by CTA during that hour subjects were administered with beta-
blockers. Patients were acquired on 2 different PET/CT scanners 128-slice Biograph 
mCT, Siemens Medical Systems (DIAMOND cohort) and 128-slice Discovery 710 
(GE Healthcare, Milwaukee, WI, USA (Cohort 2). In both cohorts low-dose CT 
attenuation correction scan (120 kV, 50 mAs, 3 mm slice thickness), a 30-min single 
bed position PET acquisition with ECG-gating in list mode was performed.  Image 
corrections were applied for attenuation, dead time, scatter, and random 
coincidences. In DIAMOND patients PET data were reconstructed using a Siemens 
implementation of iterative reconstruction algorithm (Ultra-HD; with Point Spread 
function correction and time of flight reconstruction, matrix 256, Gaussian filter of 5 
mm and 2 iterations and 21 subsets). In Cohort 2 data were reconstructed with GE 
implementation of iterative reconstruction algorithm (Sharp IR with Point Spread 
function correction and time of flight reconstruction, matrix 256, Gaussian filter of 5 
mm and 4 iterations and 24 subsets)(Mhairi K. Doris et al., 2018). 
In both cohorts, a CTA was obtained on the hybrid scanner with patient remaining on 
the table in the same position. In Cohort 1 identical acquisition and reconstruction 
parameters as CTA1 were utilized with imaging performed on the same scanner. In 
Cohort 2 CTA (CTA2) was acquired with rotation time 350ms, tube voltage 120 kV, 
tube current 150-250 mAs) and reconstructed using an adaptive statistical iterative 
reconstruction algorithm with 0.625 mm thick slices, a 0.625 mm increment and a 




2.5.2.1 Motion Correction 
Cardiac motion correction was performed for the PET/CT images. This novel 
technique compensates for coronary artery motion by aligning all gates to the end-
diastolic position, thus allowing utilization of radioactivity throughout the cardiac cycle. 
This method has been shown to reduce image noise and improve target to 
background ratios (Rubeaux, Joshi, Dweck, Fletcher, Motwani, Thomson, Germano, 
Dey, Li, et al., 2016). In the first step of motion correction, anatomic coronary artery 
data was extracted from coronary CTA by applying a vessel tracking algorithm based 
on Bayesian maximal paths (Autoplaque version 2.0). Second, a diffeomorphic mass-
preserving image registration algorithm was used to align the 10 gates of PET data 
to the end-diastolic gate (FusionQuant Software, Cedars Sinai Medical Center, Los 
Angeles). After motion correction, the 10 gates were summed together to build a 
motion-free image containing counts from the entire PET acquisition.  
2.5.3 Image analysis  
Coronary 18F-NaF image analysis was performed on axial images using FusionQuant 
software. PET and CTA reconstructions were reoriented, fused and systematically 
co-registered in all 3 planes. Key points of reference were the sternum, vertebrae, 
blood pool in the ventricles and the great vessels. For each scan, plaque activity was 
measured by delimiting 3-dimensional volumes of interest on lesions. On motion 
corrected images all segments with coronary plaque (at least a >25% stenosis) that 
were suitable for Autoplaque analysis (had a lumen diameter ≥2 mm) were 
interrogated. The maximum standard uptake value (SUVmax) was recorded from 
these regions. Background blood pool activity was measured by delimiting a 
cylindrical volume of interest (radius = 10 mm, thickness = 5 mm) in the right atrium 
on the level of the right coronary artery orifice. Target to background ratios (TBRs) 
were calculated by dividing SUVmax by averaged background blood pool activity. 
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Coronary plaques were considered positive for 18F-NaF if they presented with focal 
tracer uptake arising from the coronary plaque which followed the course of the vessel 




2.6 Preclinical model of pressure overload  
Continuous angiotensin II infusion is an established model of pressure overload heart 
disease (Lawrence et al., 1963 & Brown et al., 1981). It has been successfully used 
for evaluating the impact of particular genes on angiotensin mediated hypertension, 
the vascular results of angiotensin II including: abdominal aorta aneurysms 
progression, the impact of oxidative stress on the cardiovascular system and 
atherosclerosis development (Cassis et al., 1999; Rateri et al., 2011; Daugherty et 
al., 2000; Kawada et al., 2002; Bruemmer et al., 2003 & Weiss et al., 2001). 
In our study we used this well described model for exploring the myocardial response 
to pressure overload and reverse remodeling which occurs after load normalization 
with advanced cardiac imaging. To date such data is not available and hence we lack 
detailed insights into the adverse remodeling which occurs under pressure overload. 
With serial imaging our study aimed to explore the complex interplay between left 
ventricular hypertrophy, concomitant diffuse and focal fibrosis and LV 
decompensation. 
 2.6.1 Study Protocol 
Thirty-one male C57BL/6J mice (Envigo, UK) were subjected to a continuous 
Angiotensin II infusion at a 480±34ng/kg/min dose. Animals were split into three 
groups with varying duration of infusion: 2 weeks (n=5), 4 weeks (n=3), 6 weeks 
(n=23). Additionally, 9 animals of those receiving Angiotensin II for 6 weeks were kept 
for 28 days after the infusion came to an end to monitor reverse remodelling after 
relief of the increased afterload. Nine animals received sterile saline infusion instead 
of angiotensin II and these comprised the control group.  
All animals underwent serial CMR imaging to assess left ventricular structure and 
function as well as myocardial fibrosis. CMR was performed initially at baseline before 
the onset of pressure overload, and then every 2-weeks during Angiotensin II infusion. 
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In a subgroup, CMR was performed a final time 4 weeks after the end of infusion. At 
the end of the final imaging session, animals were culled by exsanguination under 
deep anaesthesia with the heart stored for further analysis. Throughout the 
experiments, animals were on a regular chow diet, we housed 5 mice per cage in a 
12h:12h light/dark cycle in animal facilities at the University of Edinburgh. All 
procedures conformed to Home Office guidance on the use of the animals (Scientific 
Procedures) Act of 1986 and were approved by the University of Edinburgh Animal 
Welfare and Ethical Review Board. 
 
2.6.2 Animal model of pressure overload 
To subject animals to pressure overload, subcutaneously implanted osmotic 
minipumps (Alzet, Cupertino, CA) were used (Gong et al., 2014). Minipumps were 
prepared to deliver Angiotensin II (Sigma-Aldrich, Darmstadt, Germany) at the rates 
and over a time which is characteristic for a given pump model. Implantation was 
performed surgically under anaesthesia. To monitor pressure overload animals 
underwent serial blood pressure measurements. These were carried using the Letica 
LE 5002 Non-Invasive Blood Pressure System (Panlab, Cornellá, Spain) which 
operates on the same basis as clinically used sphygmomanometers (tail cuff method). 
Prior to the start of the experimental protocol mice were trained to tail cuff 
plethysmography in order to decrease the load of stress related to taking the 
measurements and to improve reproducibility. During the experimental period 
animals were subjected to plethysmography after every imaging session. After 2 
preliminary measurements, at least three recordings of systolic, diastolic and mean 





After the final imaging session, animals were kept under anaesthesia and euthanized. 
Hearts were removed and transferred into 10% neutral buffered formalin (Cellstor, 
CellPath, Newton, UK) for fixation for at least 20 hours. Subsequently hearts were 
processed and embedded in paraffin in a short axis orientation so that the sections 
cut would all show the ventricle lumen. Slides were stained in a 0.1% sirius red 
solution in saturated picric acid (Picrosirius red, Sigma, Dorset, UK). Slide images 
were acquired on the AxioScan Z1 (Carl Zeiss, Oberkochen, Germany) and analysed 
using a dedicated software package Image-Pro Premiere 9.1 (MediaCybernetics, 
Rockville, MD, USA) using tissue specific threshold. The area of fibrosis was 
expressed as a percentage of the total myocardium area. 
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2.6.4 Preclinical magnetic resonance imaging 
All MRI scans were performed on a 7 Tesla preclinical horizontal-bore MRI system 
(Agilent Technologies, Yarnton, UK) equipped with a 33mm inner diameter 
radiofrequency coil for mice (Rapid Biomedical, Rimpar, Germany). 
Prior to imaging animals were anaesthetised using isoflurane and an Anicath 26G 
cannula (Millpledge Veterinary, Clarborough, UK) was placed intraperitoneally for 
administration of the gadolinium-based contrast agent. Animals were placed in an 
MRI cradle with electrocardiogram (ECG) leads placed subcutaneously. The animals 
were positioned supine with hearts in the centre of the coil, and in the centre of the 
MRI scanner. A pressure transducer was placed under the torso for constant 
monitoring of respiration (MR-compatible Small Animal Monitoring and Gating 
System, SA Instruments, Stony Brook, NY), and a rectal probe was inserted to 
monitor and maintain body temperature at 37 ± 0.5 °C via a feedback-controlled warm 
air system. Throughout the imaging session special care was taken to keep the heart 
rate stable at 530-600 beats/min and maintain a respiratory rate at 45-75 breaths/min.  
Scout images were taken to confirm correct positioning and to orientate 1.0 mm short 
axis slices covering the heart. T1 mapping was performed using a Small Animal 
Modified Look-Locker Inversion recovery sequence with short-axis T1 maps of the 
mid-cavity acquired in systole (Daniel R. Messroghli et al., 2004). Such T1-mapping 
datasets before and after contrast injection were acquired at end-systole with the 
following imaging parameters: repetition time (TR): 2.8 ms, echo time (TE): 1.4 ms, 
trigger delay (TD): 40-60ms individually adjusted according to the equation TD=(RR 
interval/2) - 15ms, initial inversion time (TI) 130-165ms according to the formula: TD 
+ RR interval, matrix size 128 x 128, field of view: 30 x 30 mm, number of signal 
averages: 8, flip angle: 10°, slice thickness 1.5 mm. Eight phase-encoding echos were 
acquired per segment. Subsequently gadobenate dimeglimine was injected via the 
intraperitoneal cannula, before a second T1-mapping dataset was acquired at 20 
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minutes post-injection. During the time between the T1-mapping acquisitions, cine 
images were acquired in the same orientation for structural and functional 
assessment. The short axis, vertical and horizontal long axis cardiac images were 
acquired using an ECG triggered and respiratory-gated gradient echo sequence 
(TR/TE = 5.2/1.3 ms, flip angle: 15°) with gradient and radiofrequency spoiling. 
Eighteen phases were acquired with a field of view of 30x30 mm, a 128x128 matrix, 
and 2 averages were used. For the left ventricular short axis, nine consecutive 1-mm-
thick slices were acquired, which encompassed the entire heart from base to apex. 
Late gadolinium enhancement imaging was performed between 12 and 18 minutes 
after contrast administration with a short-axis cardiac-gated T1-weighted gradient 
echo inversion-recovery scan with the following imaging parameters: TR: 595ms, TE: 
1.45 ms, field of view: 30 x 30 mm, number of signal averages: 4, inversion time: 560 




2.6.4.1 Image analysis 
Data were analysed using certified software (cvi42, Circle CVI, Calgary, Alberta, 
Canada). The short axis cine images of the LV were used for the assessment of left 
ventricular volumes, mass and ejection fraction. The epicardial and endocardial 
contours were carefully identified and planimetered in end-systole and end-diastole 
for left ventricular volume quantification. The left ventricular mass was calculated from 
the total myocardial volume (excluding trabeculations and papillary muscles) 
multiplied by the density of the myocardium (1.05 g/mL). Maximal wall thickness was 
evaluated in all 17 segments of the LV from cine images of the LV in end-diastole (1). 
For diffuse fibrosis, we calculated the extracellular volume fraction (ECV%) derived 
from pre- and post-contrast myocardial T1 values corrected for blood-pool T1. The 
ECV% was calculated according to: ECV% = partition coefficient x [1-hematocrit]; 
where partition coefficient = [∆R1myocardium/∆R1blood-pool] and ∆R1 = (1/post-
contrast T1-1/pre-contrast T1). In order to evaluate the total amount of interstitial 
fibrosis in each animal, we calculated the indexed ECV (iECV) in each animal using 
the following equation: ECV% x left ventricular myocardial volume, where left 
ventricular myocardium volume = left ventricular mass divided by the gravity of 
myocardium (1.05g/ml). To avoid blood-pool contamination and partial volume effects 
we used a mid-myocardial region of interest for the T1-mapping analysis. A two-pixel 
wide myocardium and ventricular boundary zone was excluded from all applicable 
slices. Late gadolinium enhancement was used for detection of focal replacement 
fibrosis. Where present, it was quantified as an area of myocardium with a signal 
intensity exceeding the threshold of two standard deviations above the mean value 
of normal myocardium. All areas of inversion artefact or myocardial regions 




2.6.4.2 Reproducibility of T1 mapping measurements 
Since T1-mapping for exploring the extracellular myocardial compartment in small 
rodents is not a well-established technique prior to conducting the main study we 
performed experiments aimed at optimizing the acquisition protocol. In particular we 
were interested to explore how stable are the T1 post relaxation times following 
contrast injection. By carrying out repeated modified look-locker inversion recovery 
acquisitions we found that as soon as 20 minutes after intraperitoneal injection of a 
gadolinium-based contrast agent T1 relaxation times plateau and remained stable up 
to 50 minutes post injection. To reduce the length of acquisition (and hence limit the 
time our experimental animals were anesthetized) we decided to conduct imaging at 
20 min post contrast agent infusion. 
 
Figure 10. Variation of myocardium T1 relaxation. Post-contrast T1 values are 
dramatically reduced with the administration of contrast, followed by an exponential 
increase in values towards baseline. Significant changes in T1 were observed in the 
first 20 min following contrast administration, while a plateau phase was observed 
between 20 and 50 min where values remained relatively unchanged. 
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2.7 Statistical analysis  
Continuous variables were tested for distribution with the Shapiro-Wilk test. Data are 
presented as mean±SD, median [interquartile range] or percentages were 
appropriate. Differences between variables were assessed with the use of a 2-sided 
Student T test, paired Student T test, ANOVA or the Mann-Whitney, Wilcoxon rank-
sum and the Kruskall–Wallis test were appropriate. We presented all categorical 
variables as percentages and used the chi-square test for comparison. We used 
Bland-Altman plots to visualize reproducibility of PET tracer uptake measurements. 
The 95% normal range for differences between sets of SUV and TBR measurements 
(the limits of agreement) were estimated by multiplying the SD of the mean difference 
by 1.96 (W. A. Weber, Ziegler, Thödtmann, Hanauske, & Schwaiger, 1999). Intra-
class correlation coefficients with 95% confidence intervals (CIs) were calculated for 
PET/CTA1 vs. PET/CTA2 scan variation. The Pitman-Morgan test was used to 
compare the homogeneity of variance between uptake measurements derived from 
diastolic gate and motion corrected datasets. In our per lesion analysis we assumed 
independence of lesions within patients. In the outcome analysis of patients with 
aortic stenosis we used Kaplan–Meier curves to elucidate the survival distributions 
with regard to all cause mortality and AVR. Differences in the outcome of patients 
with and without given remodeling patterns were assessed using the log-rank test. A 
Cox proportional hazard regression with adjustment for potential confounders was 
performed to determine the predictors of worse outcome. A 2-sided p value <0.05 
was regarded as statistically significant. Statistical analysis was performed with SPSS 
software (version 24, SPSS, Inc., Chicago, Illinois).  
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Chapter 3. Adverse Prognosis Associated with Asymmetric 
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Asymmetric wall thickening has been described in patients with aortic stenosis. 
However, it remains poorly characterised and its prognostic implications are unclear. 
We hypothesized this pattern of adaptation is associated with advanced remodelling, 
left ventricular decompensation and a poor prognosis.  
In a prospective observational cohort study, 166 patients with aortic stenosis (age 69, 
69% males, mean aortic valve area 1.0±0.4cm2) and 37 age and sex-matched 
healthy volunteers underwent phenotypic characterisation with comprehensive 
clinical, imaging and biomarker evaluation. Asymmetric wall thickening on both 
echocardiography and cardiovascular magnetic resonance was defined as regional 
wall thickening ≥13 mm and >1.5-fold the thickness of the opposing myocardial 
segment.  
Although no control subject had asymmetric wall thickening, it was observed in 26% 
(n=43) of patients with aortic stenosis using magnetic resonance and 17% (n=29) 
using echocardiography. Despite similar demographics, co-morbidities, valve 
narrowing, myocardial hypertrophy and fibrosis, patients with asymmetric wall 
thickening had increased cardiac troponin I and brain natriuretic peptide 
concentrations (both p<0.001). Over 28 [22, 33] months of follow-up, asymmetric wall 
thickening was an independent predictor of aortic valve replacement or death whether 
detected by magnetic resonance (HR=2.15; 95 CI 1.29 to 3.59; P=0.003) or 
echocardiography (HR=1.79; 95 CI 1.08 to 3.69; p=0.021).  
Asymmetric wall thickening is common in aortic stenosis and is associated with 
increased myocardial injury, left ventricular decompensation and adverse events. Its 






Aortic stenosis is not only characterised by progressive valve narrowing but also by 
the hypertrophic response of the left ventricle that ensues(Carabello Blase, 2013). 
Indeed the development of symptoms and adverse events appears as much related 
to events in the myocardium as the valve(Marc R. Dweck et al., 2012). New 
techniques for assessing adverse patterns of remodelling are therefore of major 
interest (Calvin W. L. Chin, Vassilis Vassiliou, et al., 2014).  
 
Echocardiography is the most common imaging technique to assess patients with 
aortic stenosis and can provide assessments of wall thickness that can be used to 
calculate left ventricular mass index. Cardiovascular magnetic resonance is less 
widely employed but provides the gold standard assessment of left ventricular mass 
and wall thickness with the unique ability to identify myocardial fibrosis. Asymmetric 
wall thickening is most commonly associated with hypertrophic cardiomyopathy (B. J. 
Maron, 2002; M. S. Maron et al., 2009). However this form of remodelling has recently 
been described in patients with increased afterload such as hypertension and aortic 
stenosis (M. R. Dweck, S. Joshi, et al., 2012; B. J. Maron et al., 1977; Panza & Maron, 
1988; Tuseth et al., 2010). An initial magnetic resonance study suggested that 
asymmetric wall thickening could be observed in around a quarter of patients. 
However this study was hampered by referral bias and did not involve detailed tissue 
characterization (M. R. Dweck, S. Joshi, et al., 2012). Echocardiographic studies have 
suggested a lower prevalence of around 10%, with the prognostic implications of this 
observation remaining unclear (B. J. Maron et al., 1977; Panza & Maron, 1988). 
In this study, we sought to assess asymmetric wall thickening in patients with aortic 
stenosis using both cardiovascular magnetic resonance and echocardiography. In 
particular, we aimed to investigate in depth the factors associated with an asymmetric 
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pattern of wall thickening, its relationship with other markers of left ventricular 
remodelling and decompensation and to assess its prognostic implications.  
3.3 Methods 
3.3.1 Patient Population 
We performed a prospective observational cohort study of stable subjects with mild, 
moderate and severe aortic stenosis recruited from the Edinburgh Heart Centre. All 
patients who attended the institution between March 2012 and August 2014 were 
invited to participate. We excluded patients with other forms of valvular heart disease 
(moderate or severe in nature), end-stage heart failure, advanced malignancies or 
other comorbidities with a life expectancy <2 years, cardiomyopathies (including 
previous myocarditis) and contraindications to gadolinium-enhanced magnetic 
resonance, such as ferromagnetic foreign bodies and estimated glomerular filtration 
rate <30 mL/min/1.73 m2. Coronary artery disease was defined as previous 
myocardial infarction, documented evidence of myocardial ischemia or a >50% 
stenosis of the coronary artery lumen. The blood sampling and analysis protocols are 
described in the supplementary data.  
Both the clinical and imaging assessments were carried out at the Clinical Research 
Facility and the Clinical Research Imaging Centre, Edinburgh. The study was 
conducted in accordance with the Declaration of Helsinki and approved by the local 








3.3.2 Cardiovascular Magnetic Resonance  
Cardiovascular magnetic resonance was performed using a 3T scanner 
(MAGNETOM Verio, Siemens Healthcare GmbH, Erlangen, Germany). A balanced 
steady-state free precession sequence was used for short-axis cine imagine of the 
left ventricle and assessment of left ventricular volumes, mass and ejection fraction 
(Argus software, Siemens AG, Healthcare Sector). LV longitudinal function was 
determined by measuring the difference in mitral annular displacement between end-
systole and end-diastole. On short-axis cine images epicardial and endocardial 
contours were carefully identified and planimetered in end-systole and end-diastole 
for left ventricular volume quantification. The left ventricular mass was calculated from 
the total myocardial volume (excluding trabeculations and papillary muscles) 
multiplied by the density of the myocardium (1.05 g/mL). All volumes and mass values 
were indexed to body surface area (calculated using the Du Bois formula). The left 
ventricular mass/volume ratio (M/V) was calculated by dividing the left ventricular 
mass by the left ventricular end-diastolic volume. This parameter indexes the left 
ventricular mass to cavity size, with M/V values >1.16 g/mL identifying patients with 
a relative increase in wall thickness (M. R. Dweck, S. Joshi, et al., 2012). Left 
ventricular hypertrophy was defined as an indexed left ventricular mass ≥95th centile 
of the normal range corrected for age and gender (Petersen et al., 2017). Maximal 
wall thickness was evaluated in all 17 segments of the left ventricle from cine images 
of the left ventricle in end-diastole (again excluding ventricular trabeculations). 
Asymmetric left ventricular wall thickening was defined as a regional wall thickening 
≥13 mm that was also ≥1.5-fold the thickness of the opposing myocardial segment 
(M. R. Dweck, S. Joshi, et al., 2012). Such criteria had to be fulfilled on two adjacent 




3.3.3 Fibrosis Assessment 
Late gadolinium enhancement was used for detection of focal replacement fibrosis. 
Acquisition was performed between 8 and 15 min after gadobutrol (Gadovist, Bayer 
Pharma AG, Germany) administration using an inversion recovery fast gradient-echo 
sequence and a phase-sensitive inversion recovery sequence in two phase-encoding 
directions in order to distinguish true enhancement from artefact. The inversion time 
was optimized to achieve adequate nulling of the myocardium. The presence of LGE 
was evaluated visually by two experienced operators (MRD and CWLC). Where 
present, it was quantified using QMASS software (Medis, Leiden, The Netherlands) 
as an area of myocardium with a signal intensity exceeding the threshold of 2 
standard deviations above the mean value of normal myocardium. All areas of 
inversion artefact or myocardial regions contaminated by blood pool or epicardial fat 
were excluded.  
T1 mapping was performed using the Modified Look-Locker Inversion recovery 
sequence for the assessment of diffuse myocardial fibrosis. Short-axis T1 maps of 
the mid-cavity were acquired in diastole before and 20 min after the administration of 
0.1 mmol/kg of gadobutrol (Gadovist, Bayer Pharma AG, Germany) using a dedicated 
32-channel anterior-posterior cardiac array. T1 maps were analysed using OsiriX 
4.1.1 software (Geneva, Switzerland). For diffuse fibrosis, we calculated the 
extracellular volume fraction (ECV) derived from pre- and post-contrast myocardial 
T1 values corrected for blood-pool T1 and hematocrit. The ECV was calculated 
according to: ECV = partition coefficient x [1-hematocrit], where partition coefficient = 
[∆R1myocardium/∆R1blood-pool] and ∆R1 = (1/post-contrast T1-1/pre-contrast T1). 
In order to evaluate the total amount of interstitial fibrosis in our study cohort, we 
calculated the indexed fibrosis volume (IFV) in each patient using the following 





All participants underwent a transthoracic echocardiographic examination for the 
assessment of aortic stenosis and cardiac function on iE33, Philips Medical Systems, 
The Netherlands. The severity of aortic stenosis was classified on the basis of the 
aortic jet peak velocity, the mean pressure gradient and the aortic valve area derived 
using the continuity equation. All assessments were conducted in accordance with 
European Association of Echocardiography / American Society of Echocardiography 
(ASE) guidelines (Baumgartner et al., 2009). Trans-mitral early (E) and late diastolic 
velocities and deceleration time were measured at the tips of mitral valve leaflets 
using pulse wave Doppler. Pulse-wave tissue Doppler imaging was used to evaluate 
the early (e’) diastolic velocities of the medial and lateral mitral annulus. Diastolic 
function was determined using the E/e’ ratio. The left ventricular mass was calculated 
using wall thickness measurements and cavity dimensions (ASE formula) and 
indexed to body surface area (Lang et al., 2015). Cut-off values of 115 g/m2 for males 
and 95 g/m2 for females were used to distinguish subjects with left ventricular 
hypertrophy. Relative wall thickness (RWT) calculated according to the formula: 
RWT=2PWTd/LVEDD (PWTd posterior wall thickness at end-diastole; LVEDD left 
ventricle end-diastolic dimension) was used in a similar fashion to M/V to classify 
subjects into the different patterns of remodelling and hypertrophy (Table 1). To 
assess the presence of asymmetric wall thickening both long and short-axis images 
were screened by two experienced operators blinded to the magnetic resonance data 
(AGJ and JK). Similar to magnetic resonance assessments asymmetric left 
ventricular wall thickening was defined as a regional wall thickening ≥13 mm that was 





3.3.5 Patterns of Left Ventricular Adaptation   
Using both echocardiography and CMR we categorized patients with aortic stenosis 
into six groups of anatomic adaptation based on the left ventricular mass index, the 
indexed left ventricular end-diastolic volume, M/V and the presence of asymmetric 
wall thickening (M. R. Dweck, S. Joshi, et al., 2012). Normal ventricular structure, 
concentric remodelling, asymmetric remodelling, concentric hypertrophy, asymmetric 




Table 1. Magnetic resonance and echocardiographic definitions of six patterns of left 
ventricular adaption in aortic stenosis. Asymmetric wall thickening on both modalities 
was defined by a maximal wall thickness ≥13 mm that was also ≥1.5-fold the thickness 
of the opposing myocardial segment. 


















LV mass index, above 
age & gender normal 
values 
- - ✓ - ✓ ✓ 
LV Mass/EDV  
≥1.16 g/mL 
- ✓ ✓ ✓ ✓ - 
Asymmetric wall 
thickening 
- - - ✓ ✓ - 
LVEDVi above age & 
gender normal values 
- - - - - ✓ 
ECHOCARDIOGRAPHY 
LV mass index,  
≤95 g/m2 for females  
≤115 g/m2 for males 
 
- ✓ - ✓ ✓ 
Relative wall thickness 
>0.42 
- ✓ ✓ ✓ ✓ - 
Asymmetric wall 
thickening 
- - - ✓ ✓ - 





3.3.6 Blood sampling and analysis 
Plasma cardiac troponin I (cTnI) concentrations were measured using the Abbott 
Architect Stat high-sensitivity cTnI assay (Abbott Laboratories, Abbott Park, Il, USA). 
The lower limit of detection of this assay is 1.2 ng/L whilst the 99th centile from the 
reference population is 16ng/L for females and 34ng/L for males. We have previously 
shown that the analytical variability of the Architect Stat assay is low with a coefficient 
of variation for duplicate samples of 10% at 6 ng/L.1 Brain natriuretic peptide (BNP) 
concentrations were measured using the Triage BNP assay (Biosite, Inc., San Diego, 
CA, USA). The inter-assay coefficient of variation was 10% at 28.8 pg/mL, with a 
detection range of 5–1300 pg/mL. 
3.3.7 Clinical Endpoints 
The primary endpoint of the study was aortic valve replacement and all-cause 
mortality. In the subgroup of subjects that subsequently underwent aortic valve 
replacement, we determined the impact of asymmetric thickening on 30-day peri-
operative cardiovascular outcomes (myocardial infarctions, congestive heart failure, 
new episodes of atrial or ventricular arrhythmia, perivalvular leaks, permanent 
pacemaker insertion, cardiac tamponade). Patients that underwent AVR were 
censored for survival analysis and considered as withdrawn alive. All the mortality, 
surgery and in-hospital complications data were obtained from the National Strategic 
Tracing Service, which is a national database for all National Health Service patients 
in United Kingdom.  
3.3.8 Statistical analysis 
We assessed the distribution of all continuous variables using the Shapiro-Wilk test, 
and presented them as mean±standard deviation or median (interquartile range). 
Comparisons were made using one-way analysis-of-variance to compare continuous 
parametric data and the Kruskall–Wallis test for non-parametric data. Chi-square 
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tests were used for categorical baseline characteristics. The association between 
biomarkers and asymmetric wall thickening was assessed using linear regression 
analyses with adjusting for potential confounders. Kaplan-Meier curves were used to 
elucidate the survival distributions with regard to all-cause mortality and AVR. 
Differences in the outcome of patients with and without asymmetric wall thickening 
were assessed using the log-rank test. A Cox proportional hazard regression with 
adjustment for potential confounders was performed to determine the predictors of 
worse outcome. A two-sided P<0.05 was considered statistically significant. All 
statistical analysis has been performed using SPSS Version 20 (IBM Corp., Armonk, 





3.4 Results  
3.4.1 Study population 
The study group comprised 166 patients with aortic stenosis (69 [63,75] years old, 
68% males) and 37 age- and sex-matched healthy volunteers (68 [63,74] years; 65% 
males). In the patient group, 34 (20%) had mild, 45 (27%) moderate, and 87 (53%) 
severe aortic stenosis. The mean peak aortic jet velocity and aortic valve area were 
3.8±0.9 m/s and 1.0±0.4cm2 respectively. Among patients with aortic stenosis, 4 (2%) 
had an ejection fraction <50% (45±2%). Overall 112 (67%) patients had a history of 
hypertension (mean systolic blood pressure 151±21 mmHg), 25 (15%) had diabetes 
mellitus and 59 (35%) had coronary artery disease. A comprehensive overview of 
patients’ demographics, aortic stenosis severity, left ventricular characteristics and 




Table 2. Comparison of patient characteristics between those with concentric wall 
thickening and asymmetric wall thickening on magnetic resonance. 






  (n=67) (n=43) P Value 
BASELINE CHARACTERISTICS  
Age, years 70 [65,77] 72 [67,75] 0.56 
Males, n (%) 52 (77) 31 (72) 0.52 
CAD, n (%) 22 (33) 20 (47) 0.16 
Diabetes, n (%) 9 (13) 7 (16) 0.80 
Hyperlipidaemia, n (%) 38 (57) 22 (51) 0.84 
Hypertension, n (%) 48 (72) 33 (77) 0.56 
SBP, mmHg 150±20 153±22 0.53 
Six-minute walk, distance (m) 369±96 358±124 0.64 
Symptomatic AS, n (%) 16 (24) 14 (32) 0.31 
ECHOCARDIOGRAPHY 
AVA, cm2 0.8 [0.7,1.1] 0.8 [0.7,1.0] 0.15 
AVA indexed, cm2/m2 0.44 [0.38,0.58] 0.43 [0.36,0.50] 0.08 
Dimensionless index 0.25 [0.21,0.30] 0.23 [0.19,0.28] 0.06 
Vm, m/s 3.9 [3.4,4.5] 4.2 [3.8,4.8] 0.01 
MPG, mmHg 35 [24,44] 41 [34,50] 0.01 
- Mild, n (%) 
- Moderate, n (%) 
- Severe, n (%) 
10 (15) 1 (2) 0.02 
18 (27) 9 (22) 0.47 
39 (58) 33 (76) 0.05 
Indexed SV <35mL/m2, n (%) 13 (19) 9 (21) 0.85 
E/A 0.81 [0.68, 1.00] 0.82 [0.63, 1.16] 0.68 
Deceleration Time 206 [169, 254] 217 [196, 247] 0.41 
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CAD, coronary artery disease; SBP, systolic blood pressure; MPG, mean pressure gradient; 
LVOT, left ventricular outflow track; EDV, end diastolic volume; ESV, end systolic volume; 
SV, stroke volume; HS-cTnI, high-sensitivity cardiac troponin I; AVR, aortic valve 
replacement 
E/e' 12.6 [9.8,16.7] 14.2 [11.5,18.5] 0.05 
LVOT Vm, m/s 1.0 [0.9,1.1] 1.0 [0.9,1.2] 0.29 
Bicuspid Aortic Valve n (%) 26 (39) 14 (33) 0.51 
CARDIOVASCULAR MAGNETIC RESONANCE 
Indexed EDV, mL/m2 67 [60,74] 68 [62,78] 0.15 
Indexed ESV, mL/m2 22 [16,26] 22 [18,26] 0.42 
Indexed SV, mL/m2 46±9 48±9 0.26 
Indexed SV <35mL/m2, n (%) 6 (9%) 4 (8%) 0.94 
Max Wall Thickness, mm 12 [10,13] 16 [14,17] <0.001 
Indexed left ventricular mass, g/m2 92 [81,103] 96 [80,106] 0.49 
Left ventricular mass/EDV, g/mL 1.34 [1.24,1.56] 1.36 [1.21,1.50] 0.39 
Mid-wall Fibrosis, n (%) 25 (37) 21 (48) 0.24 
Extracellular volume fraction, % 27.6±2.9 28.1±2.6 0.29 
Indexed Fibrosis volume, mL/m2 24.5 [20.7,29.4] 26.6 [21.1,30.4] 0.28 
Ejection fraction, % 68 [64,72] 67 [64,73] 0.92 
Longitudinal function, mm 11.8±3.0 11.1±2.6 0.18 
BIOMARKERS 
HS-cTnI, ng/L 6.6 [4.3,10.38] 13.5 [8.1,32.8] <0.001 
BNP, pg/mL 20.9 [8.1,51.8] 56.3 [25.5,112] <0.001 
OUTCOMES 
Combined Primary Outcome, n (%) 







Aortic Stenosis - related death, n (%) 2 (3) 2 (5) 0.78 
All cause death, n (%) 7 (10) 6 (14) 0.58 
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3.4.2 Cardiovascular magnetic resonance 
3.4.2.1 Patterns of left ventricular adaptation  
Using magnetic resonance criteria, thirty-nine patients with aortic stenosis (23%) had 
normal left ventricular structure. Thirty-four (20%) patients with aortic stenosis had 
left ventricular remodelling with 22 having a concentric pattern (13%) and 12 (7%) an 
asymmetric pattern. Among the 93 (58%) patients with left ventricular hypertrophy, 
the most frequently occurring adaptation pattern was concentric left ventricular 
hypertrophy detected in 45 individuals (27%), whilst asymmetric left ventricular 
hypertrophy was observed in 31 subjects (19%). Seventeen (10%) patients with aortic 
stenosis had an eccentric pattern of hypertrophy, with these patients often having 
associated aortic regurgitation (n=13), mitral regurgitation (n=2) or a history of 
myocardial infarction (n=2). All 37 healthy volunteers that comprised the control group 
had normal left ventricular structure. 
3.4.2.2 Asymmetric Wall Thickening 
Overall 43 (26%) of our patients with aortic stenosis demonstrated evidence of 
asymmetric wall thickening on magnetic resonance (Figure 9). Twelve patients had 
asymmetric remodelling and 31 had asymmetric hypertrophy. Importantly none of the 
healthy volunteers exhibited such a pattern of left ventricular adaptation. The site of 
asymmetric wall thickening was almost universally in the septum: at the basal level in 
33 patients (77% of those with asymmetric wall thickening) and at the mid-cavity in 
27 (63%) (Figure 10A). In 2 patients (5%) the regional wall thickening was observed 
in the anterior wall, it was never observed in the lateral or inferior walls. In 13 patients 
(30%) regional thickening affected just 1 segment of the 17-segment model, 16 
subjects (37%) had 2 segments of asymmetric thickening whilst 14 patients (33%) 




















  (n=39) (n=22) (n=12) (n=45) (n=31) (n=17)  
BASELINE CHARACTERISTICS          
Age, years 69 [55,.75] 71 [66,.76] 72 [67,.73] 70 [64,.78] 72 [66,.77] 68 [65,.77] 0.40 
Males, n (%) 21 (58) 20 (91) 10 (83) 32 (71) 21 (68) 9 (56) 0.06 
CAD, n (%) 12 (33) 7 (32) 5 (42) 15 (33) 15 (48) 4 (21) 0.49 
Diabetes, n (%) 5 (14) 5 (23) 0 (0) 4 (9) 7 (23) 3 (16) 0.31 
Hyperlipidaemia, n 
(%) 
13 (37) 13 (59) 8 (67) 20 (44) 14 (45) 7 (39) 0.34 
Hypertension, n (%) 20 (56) 17 (77) 9 (75) 31 (69) 24 (77) 11 (58) 0.22 
SBP, mmHg 147±23 149±18 148±20 151±22 155±22 154±19 0.71 
Six minute walk, 
distance (m) 
424±73 368±63 380±90 370±111 345±135 389±50 0.04 
Symptomatic AS, n 
(%) 




Vm, m/s 3.0 [2.5, 3.8] 3.5 [2.9, 3.9] 4.1 [3.9, 4.6] 4.1 [3.5, 4.6] 4.2 [3.8, 4.9] 3.7 [3.2, 4.0] <0.001 
MPG, mmHg 20 [14, 32] 28 [17, 37] 40 [36, 46] 36 [28, 48] 41 [31, 54] 27 [22, 38] <0.001 
    - Mild, n (%) 19 (49) 5 (23) 1 (8) 5 (11) 0 0 <0.001 
    - Moderate, n (%) 9 (23) 8 (36) 2 (17) 10 (22) 7 (23) 9 (53) 0.265 
    - Severe, n (%) 8 (21) 9 (41) 9 (75) 30 (67) 24 (77) 8 (47) <0.001 
AVA, cm2 1.0 [0.8, 1.3] 1.0 [0.8, 1.2] 0.8 [0.7, 1.0] 0.8 [0.7, 1.0] 0.8 [0.7, 1.0] 1.0 [0.8, 1.1] 0.002 























<35mL/m2, n (%) 














188 [167, 225] 206 [163,277] 217 [150,246] 198 [171, 250] 227 [187, 248] 186 [166, 231] 0.050 
E/e' 11.4 [8.9, 13.7] 11.0 [9.0, 12.8] 
12.4 [10.4, 
16.9] 




LVOT Vm, m/s 1.0 [0.9, 1.1] 1.0 [0.9, 1.1] 0.9 [0.9, 1.1] 1.0 [0.9, 1.2] 1.0 [0.9, 1.2] 0.9 [0.9, 1.2] 0.82 
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Bicuspid Aortic Valve 
n (%) 
13 (36) 8 (36) 3 (25) 
18 (40) 11 (35) 4 (21) 0.75 
CARDIOVASCULAR MAGNETIC RESONANCE     
Indexed EDV, mL/m2 68 [60, 77] 61 [50, 68] 61 [50, 67] 69 [62, 78] 75 [64, 84] 88 [71, 114] <0.001 
Indexed ESV, mL/m2 24 [20, 27] 17 [13, 23] 18 [14, 22] 22 [18, 27] 24 [21, 27] 26 [24, 40] <0.001 
Indexed SV, mL/m2 45±8 42±7 42±7 47±10 50±9 59±12 <0.001 
Indexed SV 
<35mL/m2, n (%) 
2 (6%) 2 (9%) 2 (16%) 4 (9%) 2 (6%) 0 (0%)   NA 
Ejection fraction, % 66 [62, 68] 70 [64, 73] 69 [66, 75] 67 [63, 71] 67 [64, 72] 65 [62, 69]    0.08 
Longitudinal function, 
mm 
13.5±2.6 13.0±2.6 11.0±2.5 11.1±3.0 11.1±2.6 13.6±2.8 <0.001 
Max Wall Thickness, 
mm 
8 [6, 9] 10 [9, 12] 15 [14,16] 12 [11, 14] 17 [15, 18] 10 [8, 12] <0.001 
Indexed left 
ventricular mass, g/m2 













Mid-wall Fibrosis, n 
(%) 
5 (14) 4 (18) 2 (17) 21 (47) 19 (61) 8 (50) <0.001 
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CAD, coronary artery disease; SBP, systolic blood pressure; MPG, mean pressure gradient; LVOT, left ventricular outflow track; 


















HS-cTnI, ng/L 3.1 [1.5, 4.3] 5.3 [3.7, 7.4] 13.5 [7.4, 33.0] 8.0 [4.4,15.2] 13.8 [8.2, 28.0] 6.3 [3.3, 9.9] <0.001 
BNP, pg/mL 21.9 [8.3,.40.1] 13.6 [5.9,.33.9] 
27.2 
[14.0,.41.4] 
21.6 [11.0,.54.1] 65.6[30.2,123.8] 27.5 [8.4,.56.3] 0.001 
OUTCOMES 
Combined Primary 
Outcome, n (%) 
6 (15) 11 (50) 10 (83) 23 (51) 25 (81) 6 (38) <0.001 
AVR, n (%) 6 (15) 9 (41) 9 (75) 19 (42) 22 (71) 6 (38) <0.001 
AS-related death, n 
(%) 
0 1 (5) 0  1 (2) 2 (6) 0  NA 
All-cause death, n (%) 0 2 (9) 1 (8) 5 (11) 5 (16) 1 (6) 0.09 
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Figure 11. Asymmetrical Wall Thickening on Both Magnetic Resonance and 
Echocardiography. Images demonstrating asymmetric wall thickening in patients with 
aortic stenosis. Cardiovascular magnetic resonance short-axis cine images showing an 
abnormally thickened septum: in a patient with asymmetric remodelling (A) and two 
subjects with asymmetric hypertrophy (B) & (C). Echocardiographic parasternal long-axis 
images demonstrating thickening of the septum in two further patients with asymmetric 
remodelling (D) & (E). Echocardiographic apical 4-chamber image in a subject with 







We compared patients with asymmetric wall thickening on CMR to patients with 
concentric patterns of remodelling or hypertrophy (Table 2). As expected, patients in the 
asymmetric group had increased maximal wall thickness compared to the concentric 
groups (16 [14,17] vs. 12 [10,13] mm, p<0.001) but interestingly they also had similar 
aortic stenosis severity. Indeed, there was no difference between the groups in terms of 
the aortic valve area (0.8 [0.7,1.1] vs. 0.8 [0.7,1.0] cm2, respectively, p=0.15), the indexed 
aortic valve area (0.43 [0.36,0.50] vs. 0.44 [0.38,0.58] cm2/m2, p=0.08) nor the 
dimensionless index (0.25 [0.21,0.30] vs. 0.23 [0.19,0.28], p=0.06). Whilst slightly higher 
peak aortic jet velocities (4.2 [3.8,4.8] vs. 3.9 [3.4,4.5] m/s, p=0.01) and mean gradients 
(41([34,50] vs. 35 [24,44], p 0.01) were observed in those with asymmetric wall thickening 
these differences were small. No differences were observed between the two groups in 
terms of comorbidities, the magnitude of the hypertrophic response nor the degree of 
myocardial fibrosis (all p>0.15). Despite these similarities patients with an asymmetric 
pattern had double the plasma concentrations of troponin I (13.5 [8.1,32.8] vs. 6.6 
[4.3,10.4] ng/L, p<0.001) and BNP (56.3 [25.5,112.2] vs. 20.9 [8.1,51.8] pg/mL, p<0.001) 
compared to subjects with concentric wall thickening. Indeed asymmetric wall thickening 
was associated with both troponin and BNP levels independent of age, sex, systolic blood 





3.4.2.3 Asymmetric wall thickening resolution  
Out of the 31 subjects with asymmetric wall thickening who underwent aortic valve 
replacement, 12 had a repeat magnetic resonance imaging 1-year following surgery. In 
these patients the left ventricular mass index decreased on repeat imaging (from 97 
[86,102] to 68 [65, 80] g/m2; p<0.001) as did maximum wall thickness (from 15 [14,16] to 
13 [11,14] mm; p=0.006) with an observed tendency to reduced high-sensitivity troponin 
I levels (from 9.0 [4.9,20.8] to 4.0 [1.8,10.0] ng/L; p=0.073) (Figure 10B). Overall 6 of the 
12 patients had complete resolution of their regional wall thickening and no longer fulfilled 




Figure 12. Prevalence, Distribution and Resolution after Aortic Valve Replacement of 
Asymmetric Wall Thickening. (A) 17-segment model of the left ventricle demonstrating 
the site of asymmetric wall thickening as detected by both magnetic resonance and 
echocardiography. Magnetic resonance was more sensitive in detecting asymmetric wall 
thickening (43 cases) than echocardiography (29 cases). On both modalities asymmetric 
wall thickening was almost universally confined to the basal and mid-cavity segments of 
the septum. (B) Patient with asymmetric wall thickening at baseline, which resolved when 







Figure 13. Characteristics of Patients with Asymmetric vs Concentric Wall Thickening. 
Boxplots presenting: Aortic Valve Area (A), Indexed Left Ventricular Mass (B), High 
Sensitivity Cardiac Troponin I (C) and Brain Natriuretic Peptide (D) concentrations in 
aortic stenosis patients with asymmetric and concentric patterns of wall thickening. 
Despite no difference in AVA and left ventricular mass index (p=0.15 and p=0.49 
respectively) patients with asymmetric wall thickening had higher cardiac troponin and 





3.4.2.4 Fibrosis  
Asymmetric wall thickening was associated with higher ECV and replacement fibrosis 
compared to healthy controls and AS subjects with a normal left ventricle (28.1±2.6% 
and 48% vs 26.5±1.3% & 0% and 27.2±2.0 & 14% respectively, all p<0.05). Interestingly 
there was no significant difference in the fibrosis burden between subjects with an 
asymmetric and concentric pattern of LV adaptation (28.1±2.6% and 48% vs 27.6±2.9 




Table 4. Comparison of patient characteristics between subjects with left ventricular 
remodelling and left ventricular hypertrophy on magnetic resonance.  Patients with 








 (n=34) (n=76)  P Value 
BASELINE CHARACTERISTICS  
Age, years 71 [67, 75] 72 [65, 78]  0.78 
Males, n (%) 30 (88) 53 (70)  0.03 
CAD, n (%) 12 (35) 30 (39)  0.68 
Diabetes, n (%) 5 (15) 11 (14)  0.97 
Hyperlipidaemia, n (%) 21 (62) 34 (45)  0.10 
Hypertension, n (%) 26 (76) 55 (72)  0.65 
SBP, mmHg 148±19 152±21  0.33 
Six minute walk, distance (m) 374±73 360±121  0.47 
Symptomatic AS, n (%) 9 (26) 21 (27)  0.90 
ECHOCARDIOGRAPHY 
AVA, cm2 0.9 [0.8, 1.1] 0.8 [0.7, 1.0]  0.07 
AVA indexed, cm2/m2 0.45 [0.40, 0.57] 0.42 [0.37, 0.51]  0.10 
Dimensionless index 0.25 [0.23, 0.31] 0.24 [0.20, 0.30]  0.26 
Vm, m/s 3.9 [2.5, 3.8] 4.2 [3.7, 4.8]  0.01 
MPG, mmHg 35 [21.0, 42] 38 [29, 50]  0.01 
    - Mild, n (%) 6 (18) 5 (7)  0.09 
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    - Moderate, n (%) 10 (29) 17 (22)  0.43 
    - Severe, n (%) 18 (53) 54 (71)  0.07 
Indexed SV <35mL/m2, n (%) 10 (29) 12 (16)  0.11 
E/A 0.74 [0.65, 1.01] 0.85 [0.69, 1.10]  0.46 
Deceleration Time, ms 211 [160, 256] 214 [178, 247]  0.67 
E/e' 11.6 [9.6, 13.9] 14.2 [11.5, 19.5]  0.001 
LVOT Vm, m/s 0.9 [0.9, 1.1] 1.0 [0.9, 1.1]  0.21 
Bicuspid Aortic Valve n (%) 11 (32) 29 (38)  0.56 
CARDIOVASCULAR MAGNETIC RESONANCE 
Indexed EDV, mL/m2 61 [50, 67] 72 [63, 80]  <0.001 
Indexed ESV, mL/m2 17 [14, 23] 23 [19, 27]  <0.001 
Indexed SV, mL/m2 42±6 48±9  0.001 
Indexed SV <35mL/m2, n (%) 4 (11%) 6 (8%)  0.52 
Ejection fraction, % 70 [64, 74] 67 [63, 72]  0.036 
Longitudinal function, mm 12.3±2.7 11.1±2.8  0.046 
Max Wall Thickness, mm 11 [9, 14] 14 [12, 16]  0.001 
Indexed left ventricular mass, 
g/m2 
79 [73, 86] 
99 [92, 110] 
 
<0.001 
Left ventricular mass/EDV, g/mL 1.28 [1.22, 1.45] 1.41 [1.26, 1.58]  0.017 
Mid-wall Fibrosis, n (%) 6 (18) 40 (53)  <0.001 
Extracellular volume fraction, % 26.4±1.8 28.4±2.9  <0.001 
Indexed Fibrosis volume, mL/m2 20.3 [18.7, 23.2] 27.7 [24.4, 32.1]  <0.001 
BIOMARKERS 
HS-cTnI, ng/L 6.9 [4.7, 11.6] 9.5 [5.0, 18.5]  0.12 
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CAD,coronary artery disease; SBP, systolic blood pressure; MPG, mean pressure 
gradient; LVOT, left ventricular outflow track; EDV, end diastolic volume; ESV, end 
systolic volume; SV, stroke volume; HS-cTnI, high-sensitivity cardiac troponin I; AVR, 




BNP, pg/mL 16.5 [7.9, 37.8] 41.1 [15.0, 81.7]  0.01 
OUTCOMES 






AVR, n (%) 18 (53) 41 (54)  0.92 
AS-related death, n (%) 1 (3) 3 (4)  0.88 
All cause death, n (%) 3 (9) 10 (13)  0.51 
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3.4.3 Echocardiography.  
Using echocardiographic criteria 26 aortic stenosis patients (16%) had normal left 
ventricular structure. Thirty-two (19%) had left ventricular remodelling whilst 108 (65%) 
exhibited left ventricular hypertrophy, of whom 9 (6%) had eccentric hypertrophy. Overall 
echocardiography demonstrated good agreement with magnetic resonance in terms of 




Table 5. Comparison of patient characteristics between subjects with asymmetric wall 
thickening on echocardiography and cardiovascular magnetic resonance imaging.  
   












  (n=29) (n=43) 
BASELINE CHARACTERISTICS  








Males, n (%) 19 (65) 31 (72) 
CAD, n (%) 17 (58) 20 (47) 
Diabetes, n (%) 5 (17) 7 (16) 
Hyperlipidaemia, n (%) 17 (58) 22 (51) 
Hypertension, n (%) 23 (80) 33 (77) 
SBP, mmHg 152±21 153±22 
Six-minute walk, distance. (m) 365±127 358±124 
Symptomatic AS, n (%) 13 (45) 16 (37) 0.52 
ECHOCARDIOGRAPHY 
AVA,.cm2 0.8 [0.6, 1.0] 0.8 [0.7, 1.0] 0.77 
AVA indexed,.cm2/m2 0.45 [0.32, 0.51] 0.43 [0.36, 0.50] 0.91 
Dimensionless index 0.23 [0.19, 0.30] 0.23 [0.19, 0.28] 0.49 
Vm,.m/s 4.4 [4.0, 5.1] 4.2 [3.9, 4.9] 0.60 
MPG, mmHg 45 [35, 60] 41 [35, 50] 0.54 
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    - Mild, n (%) 0 1 (2) NA 
    - Moderate, n (%) 4 (14) 9 (21) 0.43 
    - Severe, n (%) 25 (86) 33 (77) 0.32 
Indexed SV <35mL/m2, n (%) 6 (21) 9 (21) 0.87 
E/A 0.79 [0.61, 1.12] 0.82 [0.63, 1.16] 0.65 
Deceleration Time 223 [200, 247] 217 [196, 247] 0.73 
E/e' 16.8 [12.8, 24.4] 14.2 [11.5, 18.5] 0.27 
LVOT Vm,.m/s 1.0 [0.9, 1.2] 1.0 [0.9, 1.2] 0.60 
Bicuspid Aortic Valve n (%) 7 (24) 14 (33) 0.59 
CARDIOVASCULAR MAGNETIC RESONANCE 











Indexed ESV, mL/m2 22 [18, 25] 22 [18, 26] 
Indexed SV, mL/m2 50±10 48±9 
Indexed SV <35mL/m2, n (%) 2 (7%) 4 (8%) 
Ejection fraction, % 68.[65, 72] 67.[64, 73] 
Longitudinal function, mm 10.9±2.5 11.1±2.6 
Max Wall Thickness, mm 16 [15, 18] 16 [14, 17] 
Indexed left ventricular mass, 
g/m2 
101 [89, 113] 96 [80, 106] 
Left ventricular mass/EDV, g/mL 1.37 [1.24, 1.56] 1.36 [1.21, 1.50] 
Mid-wall Fibrosis, n (%) 13 (44) 21 (48) 
Extracellular volume fraction, % 28.7±2.7 28.1±2.6 0.46 




CAD, coronary artery disease; SBP, systolic blood pressure; MPG, mean pressure 
gradient; LVOT, left ventricular outflow track; EDV, end diastolic volume; ESV, end 
systolic volume; SV, stroke volume; HS-cTnI, high-sensitivity cardiac troponin I; AVR, 





HS-cTnI,.ng/L 13.5 [8.0, 32.5] 13.5 [8.1, 32.8] 0.71 
0.24 BNP,.pg/mL 64.7 [28.1, 130.5] 56.3 [25.5, 112] 
OUTCOMES 
Combined Primary Outcome, n 
(%) 









AS-related death, n (%) 1 (4) 2 (5) 
All cause death, n (%) 3 (10) 6 (14) 
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We were interested whether echocardiography was similarly able to detect asymmetric 
wall thickening. Short-axis images of the left ventricle were either unavailable or non-
interpretable in 31 subjects, in whom analysis was based solely on the parasternal and 
apical long-axis images. Overall 29 of the 166 patients with aortic stenosis exhibited 
asymmetric wall thickening (17%), again it was not observed in the control patients. 
Compared to magnetic resonance (which served as the gold standard in this analysis) 
echocardiography was less sensitive (67%) but showed excellent specificity (100%) in 
detecting patients with asymmetric wall thickening. Half (n=8, 57%) of the patients with 
asymmetric wall thickening on magnetic resonance that were missed by 
echocardiography had non-interpretable short-axis echo images. At the segment level 
echocardiography missed 47 (48%) of the segments with asymmetric thickening detected 
by magnetic resonance, although the distribution of this thickening was similar to 
magnetic resonance: confined to the septum with the exception of 1 patient with anterior 
wall involvement (Figure 10A). Importantly despite the relatively lower sensitivity, patients 
with asymmetric wall thickening on echocardiography again demonstrated troponin and 
BNP concentrations that were more than double the values in patients with concentric 
wall thickening (troponin I 13.5 [8.0,32.5] vs 5.3 [3.6,11.2] ng/L, p=0.001; and BNP 64.7 
[28.1,130.5] vs 24.3 [10.2,52.9] pg/mL, p<0.001) (Tables 6 and 7).  
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  (n=25) (n=37) (n=4) (n=68) (n=25) (n=8)  
BASELINE CHARACTERISTICS          
Age, years 67 [62, 73] 70 [65, 77] 73 [71, 83] 70 [63, 75] 72 [67, 78] 74 [67, 78] 0.18 
Males, n (%) 13 (52) 23 (62) 4 (100) 52 (76) 17 (68) 5 (63) 0.12 
CAD, n (%) 4 (16) 12 (32) 2 (50) 22 (32) 12 (48) 3 (38) 0.07 
Diabetes, n (%) 4 (16) 4 (11) 0 (0) 10 (15) 4 (16) 2 (25) NA 
Hyperlipidaemia, n 
(%) 
8 (32) 16 (43) 4 (100) 




15 (60) 21 (78) 3 (75) 
42 (62) 22 (88) 8 (100) 
0.04 
SBP, mmHg 150±24 151±22 147±19 149±20 154±21 155±24 0.47 
Six minute walk, 
distance (m) 
397±89 375±132 375±45 378±92 373±119 384±71 0.05 
ECHOCARDIOGRAPHY          
Vm, m/s 3.6 [2.9, 4.1] 3.5 [2.8, 3.9] 3.9 [3.4, 4.0] 4.0 [3.3, 4.5] 4.5 [4.0, 4.8] 3.8 [3.1, 4.2] <0.001 
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MPG, mmHg 25 [16, 36] 25 [16, 37] 36 [26, 41] 38 [26, 44] 44 [35, 57] 35 [16, 41] <0.001 






























<35mL/m2, n (%) 

























12.3 [8.7, 19.8] 0.027 
LVOT Vm, m/s 1.0 [0.9, 1.1] 1.0 [0.9,1.1] 1.0 [0.9, 1.1] 0.9 [0.8, 1.1] 0.9 [0.9, 1.2] 0.9 [0.9, 1.1] 0.82 
Bicuspid Aortic 
Valve n (%) 
9 (36) 8 (22) 1 (25) 
28 (41) 8 (32) 3 (37) 0.46 
CARDIOVASCULAR MAGNETIC RESONANCE     
Indexed EDV, 
mL/m2 





21 [18, 25] 22 [17, 25] 21 [14, 24] 25 [21, 29] 22 [19, 28] 26 [24, 40] 0.02 
Indexed SV, mL/m2 45±8 43±7 45±10 50±11 51±9 59±12 0.004 
Indexed SV 
<35mL/m2, n (%) 
2 (8%) 2 (5%) 1 (25%) 5 (7%) 2 (8%) 0 (0%)   NA 
Ejection fraction, % 69 [65, 73] 67 [64, 70] 70 [65, 74] 66 [63, 71] 67 [64, 74] 64 [60, 69] 0.187 
Longitudinal 
function, mm 
13.3±3.4 13.0±2.5 10.9±3.3 12.2±3.0 10.9±2.3 10.8±1.8 0.002 
Max Wall thickness 
(mm) 
8 [6, 9] 10 [9, 12] 15 [14,16] 12 [11, 14] 17 [15, 18] 9 [8, 11] <0.001 
Indexed LV mass, 
g/m2 















Mid-wall Fibrosis, n 
(%) 
3 (12) 9 (33) 1 (25) 27 (40) 16 (64) 3 (38) <0.001 
Extracellular 
volume fraction, % 
27.1±2.5 27.7±2.3 26.6±1.1 27.8±2.7 28.9±2.6 26.7±3.3 0.003 
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CAD, coronary artery disease; SBP, systolic blood pressure; MPG, mean pressure gradient; LVOT, left ventricular outflow track; 

















HS-cTnI, ng/L 3.4 [1.7, 4.9] 4.5 [2.5, 9.1] 6.8 [3.9, 14.5] 7.0 [3.9, 11.4] 14.8 [9.6, 38.3] 6.7 [4.9, 11.0] <0.001 












Outcome, n (%) 
10 (40) 10 (27) 4 (100) 34 (50) 18 (72) 5 (62) 0.001 
AVR, n (%) 9 (15) 8 (22) 4 (100) 30 (44) 15 (60) 5 (62) 0.005 
AS-related death, n 
(%) 
0 1 (3) 0  1 (1) 2 (8) 0  NA 
All-cause death, n 
(%) 
0 2 (5) 0 7 (10) 4 (16) 1 (12) NA 
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Table 7. Comparison of patient characteristics between asymmetric and concentric 
wall thickening diagnosed using echocardiography. Patients with eccentric 
hypertrophy were excluded. 
   







  (n=29) (n=105) P Value 
BASELINE CHARACTERISTICS  
Age, years 73 [69, 81] 70 [63, 74] 0.13 
Males, n (%) 19 (65) 79 (71) 0.58 
CAD, n (%) 17 (58) 37 (33) 0.03 
DM, n (%) 5 (17) 18 (16) 0.89 
Hyperlipidaemia, n (%) 17 (58) 48 (43) 0.16 
Hypertension, n (%) 23 (80) 72 (65) 0.17 
SBP, mmHg 152±21 151±21 0.76 
Six minute walk, distance (m) 365±127 381±100 0.60 
ECHOCARDIOGRAPHY 
AVA, cm2 0.8 [0.6, 1.0] 0.9 [0.7, 1.2] 0.050 
AVA indexed, cm2/m2 0.45 [0.32, 0.51] 0.44 [0.36, 0.56] 0.28 
Dimensionless index 0.23 [0.19, 0.30] 0.26 [0.23, 0.32] 0.049 
Vm, m/s 4.4 [3.9, 5.1] 3.8 [3.2, 4.3] 0.001 
MPG, mmHg 45 [35, 60] 32 [22, 41] 0.003 
Indexed SV <35mL/m2, n (%) 6 (21) 19 (18) 0.75 
E/A 0.79 [0.61, 1.12] 0.87 [0.65, 1.10] 0.68 
Deceleration Time 223 [200, 247] 207 [183, 247] 0.41 
E/e' 16.8 [12.8, 24.4] 12.4 [9.8, 16.6] 0.023 
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CAD, coronary artery disease; SBP, systolic blood pressure; MPG, mean pressure 
gradient; LVOT, left ventricular outflow track; EDV, end diastolic volume; ESV, end 
systolic volume; SV, stroke volume; HS-cTnI, high-sensitivity cardiac troponin I; 
AVR, aortic valve replacement 
 
LVOT Vm, m/s 1.0 [0.9,1.2] 1.0 [0.9, 1.2] 0.21 
Bicuspid Aortic Valve n (%) 7 (24) 38 (35) 0.41 
CARDIOVASCULAR MAGNETIC RESONANCE 
Indexed EDV, mL/m2 71 [64, 80] 68 [61, 79] 0.50 
Indexed ESV, mL/m2 22 [18, 25] 23 [18, 27] 0.89 
Indexed SV, mL/m2 50±10 51±9 0.26 
Indexed SV <35mL/m2, n (%) 2 (7) 10 (9) 0.89 
Ejection fraction, % 68 [65, 72] 67 [63, 71] 0.51 
Longitudinal function, mm 10.9±2.5 12.5±2.9 0.02 
Indexed LV mass, g/m2 101 [89, 113] 96 [85, 107] 0.005 
LV mass/EDV, g/mL 1.37 [1.24, 1.56] 1.23 [1.04, 1.43] 0.003 
Mid-wall Fibrosis, n (%) 13 (44) 36 (32) 0.021 
Extracellular volume fraction, % 28.7±2.7 27.7±2.6 0.13 
Indexed Fibrosis volume, mL/m2 24.9. [20.4, 28.7] 24.4 [20.1, 28.4] 0.48 
BIOMARKERS 
HS-cTnI, ng/L 13.5 [8.0, 32.5] 5.35 [3.6, 11.2] 0.001 
BNP, pg/mL 64.7.7 [28.1, 130.5] 24.3 [10.2, 52.9] <0.001 
OUTCOMES 
Combined Primary Outcome, n (%) 







Cardiac death, n (%) 1 (4) 2 (2) NA 




3.4.4 Clinical outcomes 
Patients were followed up for a median of 28 [22,33] months and 86 events occurred 
(72 aortic valve replacements and 14 patients died). Using the magnetic resonance 
analysis, the primary end-point was higher in patients with asymmetric wall thickening 
(n=35, 81%) compared to both patients with concentric patterns (n=34, 51%) and to 
all patients who did not have asymmetric wall thickening (n=51, 42%). Indeed, 
asymmetric wall thickening was associated with worse outcomes independent of age, 
sex, left ventricular mass index, coronary artery disease and importantly aortic 
stenosis severity assessed with the mean aortic valve gradient (HR=2.15; 95 CI 1.29 
to 3.59; P=0.003, Figure 12). Among patients that underwent aortic valve 
replacement, perioperative complications were also more frequently observed in 
individuals with asymmetric wall thickening than subjects without (55% vs. 13%; 
p=0.004; Figure 12).  
Based upon the echocardiographic assessments, there were 23 outcome events (20 
underwent aortic valve replacement and 3 died) in the 29 patients (79%) with 
asymmetrical wall thickening. This compared with 48 events in the 105 patients (46%) 
with concentric wall thickening. Using our combined primary outcome measure the 
asymmetric group on echo again had worse outcomes independent of age, sex, left 
ventricular mass index, coronary artery disease and the mean aortic valve gradient 
(HR=1.79; 95 CI 1.08 to 3.69; p=0.021). In patients that underwent aortic valve 
replacement, perioperative adverse outcomes were also more frequently reported in 






Table 8. Hazard ratios predicting adverse events (aortic valve replacement or deaths) 
for asymmetric wall thickening on magnetic resonance and echocardiography in 
adjusted and unadjusted analyses. 
 
 
Asymmetric Wall Thickening 
on Magnetic Resonance 
Asymmetric Wall Thickening on 
Echocardiography 
Hazard ratio (95% 
CI) 
p-value Hazard ratio (95% 
CI) 
p-value 
Model 1 2.97 (1.87-4.69) <0.001 2.28 (1.26-3.73) 0.008 
Model 2 2.79 (1.73-4.59) <0.001 2.08 (1.16-3.72) 0.014 
Model 3  2.76 (1.69-4.52) 0.001 2.03 (1.11-3.70) 0.01 
Model 4 2.21 (1.34-3.68) 0.004 1.86 (1.09-3.42) 0.014 
Model 5 2.14 (1.28-3.57) 0.004 1.83 (1.10-3.53) 0.014 
Model 6 2.15 (1.29-3.59) 0.003 1.79 (1.08-3.69) 0.021 
Model 1 – unadjusted; Model 2 – adjusted for age and sex; Model 3 – similar to 
Model 2 additionally adjusted for indexed left ventricular mass; Model 4 – similar to 
Model 2 additionally adjusted for mean aortic valve pressure gradient; Model 5 – 
adjusted for age, sex, indexed left ventricular mass and mean aortic valve pressure 





Table 9. Hazard ratios predicting adverse events (aortic valve replacement or deaths) 
for variables, which were used to construct the models, presented in Table 8 in 
unadjusted analysis. 
 
Variable Hazard ratio (95% CI) p-value 
Age 1.02 (1.00-1.05) 0.043 
Gender 0.83 (0.51-1.33) 0.44 
LV mass 
(indexed)  
1.01 (0.99-1.02) 0.15 
Mean Pressure 
Gradient 
1.49 (1.23-1.82) 0.003 
Coronary Artery 
Disease 















Failure, n (%) 
5 (14) 1 (3) NA 
Atrial Fibrillation, n (%) 6 (17) 2 (5) NA 
Arrhythmia requiring 
Permanent Pacemaker 
Implantation, n (%)  
5 (14) 2 (3) NA 
Perivalvular Leaks, n (%)  2 (6) 0 NA 
Cardiac Tamponade, n 
(%) 
1 (3) 0 NA 





Figure 14. Outcome Data in Aortic Stenosis Patients With and Without Asymmetric 
Wall Thickening. Kaplan-Meier event estimates by adaptation patterns for the 
occurrence of death and AVR in aortic stenosis patients. Asymmetric thickening was 
associated with worse cardiac outcomes both when detected using magnetic 
resonance (A) (HR=2.15 (1.29-3.59); p=0.003) and echocardiography (B) (HR=1.79 
(1.08-3.69); p=0.021). Peri-operative complications in aortic stenosis patients 
undergoing aortic valve replacement. Subjects with asymmetric wall thickening had 
more cardiac complications in the peri-operative period than those without based 
upon both magnetic resonance (C) 55% vs 13% (p=0.004) and echocardiographic 






We here provide a comprehensive multimodality imaging assessment of asymmetric 
wall thickening in 166 patients with aortic stenosis. In a prospective consecutive 
cohort we demonstrate that asymmetric wall thickening is common, affecting a quarter 
(n=43) of patients with mild-to-severe aortic stenosis when assessed using magnetic 
resonance. Echocardiography is less sensitive missing a third of these cases so that 
asymmetric wall thickening was only identified in 17% (n=29). Irrespective of the 
imaging modality used, patients with asymmetric wall thickening had evidence of 
more advanced left ventricular decompensation with elevated myocardial injury and 
increased BNP concentrations compared to those with concentric wall thickening. 
This was despite the two groups having similar co-morbidities, valve narrowing, 
myocardial fibrosis and left ventricular hypertrophy. Moreover, patients with 
asymmetric wall thickening (on both magnetic resonance and echocardiography) 
were found to have an adverse prognosis, with this form of remodelling acting as an 
independent predictor of aortic valve replacement or death after correction for age, 
sex, left ventricular mass index, coronary artery disease and aortic stenosis severity.  
Magnetic resonance has emerged as the gold standard non-invasive assessment of 
left ventricular mass and wall thickness. This is the first study to evaluate the true 
prevalence of asymmetric wall thickening in a cohort of patients with aortic stenosis, 
free from referral bias. This is in contrast to the only previous magnetic resonance 
study examining this question where patients were referred for magnetic resonance 
on clinical grounds. Unusual patterns of remodelling could therefore have potentially 
triggered the referral. Our data have demonstrated that asymmetric wall thickening is 
indeed common amongst patients with aortic stenosis affecting approximately a 
quarter of subjects (40% in those with severe stenosis), and characterised by 




Echocardiography is less well suited to measuring wall thickness and limited by the 
availability of acoustic windows. In this study it missed 14 cases of asymmetric wall 
thickening detected by magnetic resonance. In 8 patients this was because short-axis 
echocardiographic images were not interpretable. Overall our prevalence of 
asymmetric wall thickening on echocardiography is similar to that previously reported 
(B. J. Maron et al., 1977; Panza & Maron, 1988) and to a recent analysis of the 
Intensive Lipid Lowering with Simvastatin and Ezetimibe in AS SEAS trial (Tuseth et 
al., 2010). Importantly patients with asymmetric wall thickening on echocardiography 
demonstrated the same characteristics as those detected by magnetic resonance 
including the increased troponin and BNP levels as well as the adverse prognosis 
(Table 5). This is an important observation because echocardiography, unlike 
magnetic resonance, is performed routinely to assess all patients with aortic stenosis. 
It suggests that the presence of asymmetric wall thickening should therefore be 
actively looked for on echocardiography (not simply ignored and attributed to a 
“sigmoid septum”) and used to help identify patients likely to require aortic valve 
replacement rapidly and who might therefore benefit from more regular clinical follow 
up.  
 
Why do some patients develop asymmetric rather than concentric wall thickening in 
response to increased afterload? The explanation for this observation remains 
unclear. In this comprehensive evaluation we did not observe any clear differences in 
patient demographics, co-morbidity, bicuspid aortic valve prevalence or aortic 
stenosis severity between these two groups. Asymmetric wall thickening did appear 
reversible following surgery suggesting that it represents an adaptive response to an 
increased afterload. One potential theory relates to the bending radius of the septum 
and posterior wall of the left ventricle. It has been suggested that the larger radius of 
the septum leads to greater myocardial tensions during contraction, promoting a more 
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pronounced hypertrophic response (Grossman, Jones, & McLaurin, 1975; Heng, 
Janz, & Jobin, 1985). While this concept explains why asymmetric wall thickening is 
almost universally confined to the septum, it fails to account for inter-individual 
differences in the degree of asymmetric wall thickening. It is possible that patients 
may have a subtle genetic predisposition to regional wall thickening (similar to those 
driving the development of hypertrophic cardiomyopathy) that becomes clinically 
apparent with exposure to an increased left ventricular afterload (Calvin W. L. Chin, 
Anoop S. V. Shah, et al., 2014; Hess et al., 1983b). Unfortunately we do not have 
genetic data in this study to test this hypothesis. The mechanism for the adverse 
event rate in patients with asymmetric wall thickening also remains unclear, although 
it was predominantly driven by increased rates of aortic valve replacement. 
Asymmetric wall thickening was associated with evidence of increased myocardial 
injury (cTnI) and wall stress (BNP) suggesting that it is a marker of more advanced 
decompensation and that patients will be more likely to develop symptoms and 
progress towards aortic valve replacement. The increased wall thickening may 
predispose patients to supply-demand ischemia, increased myocyte injury and 
troponin levels, though this hypothesis requires confirmation. It is interesting that 
patients with asymmetric wall thickening did not have evidence of increased 
myocardial fibrosis, another useful marker of left ventricular decompensation.  
3.5.1 Limitations 
During follow up a total of 14 patients died, limiting our mortality assessments, the 
outcome data is therefore predominantly driven by aortic valve replacement. A large 
multicentre study with longer follow up is desirable. Further attention should also be 
paid to the mechanism underlying asymmetric wall thickening formation, including the 




Chapter 4. Progression and regression of left ventricular 
hypertrophy and myocardial fibrosis in a mouse model of 





We aimed to develop a mouse model to study the development of left ventricular 
hypertrophy and myocardial fibrosis in response to increased afterload and to 
understand how these processes reverse remodel following normalisation of pressure 
loading.  
We performed a longitudinal study with serial cardiac magnetic resonance (CMR) 
every 2 weeks in mice (n=31) subjected to angiotensin II-induced pressure overload 
for 6 weeks and investigated reverse remodelling following normalisation of afterload 
(n=9). Left ventricular volumes, mass, and function as well as myocardial fibrosis 
were measured using cine CMR and indexed extracellular volume (iECV) calculated 
from T1-relaxation times. 
Increased pressure afterload (65.1±12.0 vs 84.7±9.2 mmHg; p<0.001) resulted in 
higher indices of left ventricular hypertrophy (0.091 [0.083, 0.105] vs 0.123 [0.111, 
0.138] g; p<0.001) and myocardial fibrosis (iECV: 0.022 [0.019, 0.024] vs 0.039 
[0.031, 0.043] mL; p<0.001) whilst left ventricular ejection fraction fell (LVEF, 59.3 
[57.6, 59.9] vs 46.9 [38.5, 49.6] %; p<0.001).  
Following normalisation of blood pressure (68.8±5.4 vs baseline 65.1±12.0 mmHg; 
p=0.42), LV mass (0.108 [0.098, 0.116] vs 0.091 [0.083, 0.105] g), iECV (0.034 
[0.032, 0.036] vs 0.022 [0.019, 0.024] mL) and LVEF (51.1 [42.9, 52.8] vs 59.3 [57.6, 
59.9] %) improved but remained impaired compared to baseline (p<0.05 for all). 
There was a strong inverse correlation between LVEF and iECV during both pressure 
overload (r=-0.88, p<0.001) and reverse remodelling (r=-0.74, p=0.001). 
We have developed a mouse model of left ventricular hypertrophy and reverse 
remodelling in response to pressure overload and we demonstrate that changes in 
myocardial fibrosis can be assessed non-invasively by MRI and are closely linked 




Pressure overload heart disease with concomitant myocardial fibrosis is observed in 
multiple common cardiac conditions including hypertension and aortic stenosis 
(Adabag et al., 2008; Assomull et al., 2006; Iles et al., 2008; C.-Y. Liu et al., 2013; 
Puntmann et al., 2013). While there is growing evidence that excessive fibrosis is 
associated with adverse clinical outcomes, longitudinal human data regarding 
changes in left ventricular remodelling and fibrosis over time are sparse. The lack of 
such data is largely due to the natural history of pressure overload heart disease, with 
conditions such as hypertension and aortic stenosis progressing slowly over many 
years and decades and making longitudinal studies challenging. In addition, little is 
known about adverse remodelling reversibility once the trigger is removed (Stuckey 
Daniel et al., 2014). Such insights are of particular interest in aortic stenosis where 
there is growing interest in optimizing the timing of aortic valve replacement (AVR) 
ideally using novel objective biomarkers of LV decompensation (Baumgartner et al., 
2017; Krayenbuehl et al., 1989; Nishimura Rick et al., 2017).    
 
Rodent models of pressure overload cardiomyopathy have been developed and 
potentially allow monitoring of disease progression, from the onset of pressure 
overload out to the advanced stages of heart failure. These models can therefore 
provide longitudinal data that is lacking in humans and can potentially do so using 
advanced imaging techniques that can be directly translated in to humans (Camacho 
et al., 2016; Houser et al., 2012; Ku et al., 2018; Messroghli Daniel et al., 2011).  One 
of most widely used model of pressure overload heart disease is transverse aortic 
constriction. Unfortunately, this approach involves a high dropout rate of animals 
related to surgery and with the band placed distal to the innominate artery causes 
coronary congestion and a disease state more similar to aortic coarctation than aortic 
stenosis (Stuckey Daniel et al., 2014). Furthermore, removal of the band is 
challenging, and results in incomplete relief of the obstruction making the study of 
158 
 
reverse remodelling difficult (Cho et al., 2014). As a consequence only a few studies 
have investigated reverse remodelling upon removal of the pressure overload state 
and these did not include advanced imaging techniques (Bjørnstad et al., 2012; Gao 
et al., 2005; Weinheimer Carla et al., 2018).  
The purpose of this study was to develop a mouse model of reversible pressure 
overload cardiomyopathy and to use state-of-the-art in vivo imaging to interrogate left 
ventricular hypertrophy, myocardial fibrosis, and cardiac function both before and 
after afterload reversal. Ultimately, our aim was to create a model that might help 
develop novel non-invasive biomarkers of left ventricular decompensation in 
response to pressure overload and provide insight in to the optimal timing of aortic 





Thirty-one male C57BL/6J mice (Envigo, UK) were subjected to a continuous 
angiotensin II (Ang II) infusion at 480±34 ng/kg/min. Animals were allocated into one 
of three groups with varying duration of infusion: 2 weeks (n=5), 4 weeks (n=3) and 6 
weeks (n=23). Additionally, a subset (n=9) of the animals receiving a 6-week infusion 
were assessed for an additional 28 days after discontinuation of the infusion to allow 
investigation of reverse remodelling. Finally, a further control cohort of animals 
received a placebo infusion of saline (0.9% NaCl) (n=9, Figure 13). Throughout the 
experiments, animals were on a regular chow diet, housed 5 mice per cage in a 
12h:12h light/dark cycle in animal facilities at the University of Edinburgh. All 
procedures conformed to Home Office guidance on the use of the animals (Scientific 
Procedures) Act of 1986 and were approved by the University of Edinburgh Animal 




4.3.1 Animal model of pressure overload 
To subject animals to pressure overload, subcutaneously implanted osmotic 
minipumps (Alzet, Cupertino, CA) were used (Herrlich, Spieth, Messner, & Zengerle, 
2012). Minipumps were prepared to deliver angiotensin II (Ang-II, Sigma-Aldrich, 
Darmstadt, Germany) at predetermined rates of infusion (Table 11). Implantation was 
performed surgically under anaesthesia. To monitor pressure overload, animals 
underwent serial blood pressure measurements using a Letica LE 5002 Non-Invasive 
Blood Pressure System (Panlab, Cornellá, Spain) which operates on the same basis 
as clinically used sphygmomanometers (tail cuff method). Prior to study 
commencement, mice were trained for tail cuff plethysmography in order to decrease 
animal stress related to measurement acquisition and to improve reproducibility. 
During the experimental period, mice were subjected to plethysmography after each 
imaging session. After 2 preliminary measurements, at least three recordings of 
systolic, diastolic and mean arterial pressure were recorded in each animal.  
 
Table 11. Alzet minipumps specifications. 
Pump Reservoir Volume Infusion Duration Flow rate 
1002 100μl 14 days 0.25μl/hr 
2004 200μl 28 days 0.25μl/hr 






4.3.1.1 Osmotic Minipump Preparation 
To subject animals to pressure overload subcutaneously implanted osmotic 
minipumps (Alzet, Cupertino, CA) were used. These minipumps operate on the basis 
of an osmotic pressure difference between the pump’s osmotic compartment and the 
surrounding tissue environment. They consist of a fluid reservoir (containing the drug) 
which is encapsulated by an osmotic layer covered by a semipermeable membrane. 
The high osmolality of the osmotic layer attracts water from the surrounding 
environment and this influx leads to compression of the reservoir chamber and 
guarantees a continuous delivery of the solution at a predefined rate which is specific 
for each pump model (Herrlich et al., 2012). Minipumps were prepared to deliver 
Angiotensin II (Sigma-Aldrich, Darmstadt, Germany) at the rates and over a time 
which is characteristic for a given pump model (Table 11). The total dose of 
Angiotensin II was calculated considering the pump reservoir size, flow rate and the 
animal weight. All pumps were filled using the provided 25-gauge filling needle (Alzet, 
Cupertino, CA) and a 1mL syringe. Special care was taken to avoid transferring any 
air bubbles into the filling reservoir as these might impede drug delivery. To confirm 
that no substantial air bubbles were present in the solution once filled all pumps were 





4.3.1.2 Surgical Procedures 
Subcutaneous minipump implantation was performed under a sterile technique. To 
anaesthetise the animal, the induction chamber was filled with 3% isoflurane in 
oxygen (flow rate: 1L/min) and the mouse was placed in the box. When induction was 
confirmed (by unresponsiveness to external stimuli and absence of the palpebral 
reflex) the animal was placed on a heated mat (to maintain body temperature at 37°C) 
under a face mask delivering 2-2.5% isoflurane in oxygen (flow rate 1L/min). Hair was 
removed from the interscapular part of the animals’ back using a hair trimmer. 
Afterwards any residual hair was removed diligently with the vetasept chlorhexidine 
surgical disinfectant. A small horizontal incision was made in the interscapular region 
using sharp surgical scissors. Subsequently using blunt, straight dissection forceps a 
pocket under the skin was created for the placement of the Alzet minipump. In the 
next step the minipump was inserted into the newly established subcutaneous pocket 
with the flow moderator of the pump pointing caudally (away from the incision site). 
The wound was closed using Autoclips (Kent Scientific, Torrington, CT) and sterilised 
with Vetasept. The animal was then liberated from the face mask, an analgesic (0.05 
mg/kg buprenorphine/Vetergesic, Alstoe, UK) was administered subcutaneously and 




4.3.1.3 Blood Pressure Measurements 
Blood pressure measurements were carried using the Letica LE 5002 Non-Invasive 
Blood Pressure System (Panlab, Cornellá, Spain). The system operates on the same 
basis as clinically used sphygmomanometers. By inflation of the cuff placed around 
the proximal part of the tail the arterial blood flow is occluded and subsequently during 
controlled deflation a sensor measures both systolic and diastolic BP. 
Prior to the start of the experimental protocol mice were trained to tail cuff 
plethysmography in order to decrease the load of stress related to taking the 
measurements and to improve reproducibility. During the experimental period 
animals were subjected to plethysmography after every imaging session. Mice were 
placed into a restraining chamber while recovering from anaesthesia. The 
plethysmograph cuff which has an inbuilt sensor was positioned at the proximal end 
of the tail. To maintain body temperature during the measurements mice were kept in 
a preheated recovery box (MediHEAT, Vet-Tech solutions, Congleton, UK). After 2 
preliminary measurements, at least three recordings of systolic, diastolic and mean 
arterial pressure per animal were recorded. The time between measurements was 




4.3.1.4 Sacrifice and Tissue Collection 
After the final imaging session animals were kept under anaesthesia and transferred 
to a face mask delivering 3% isoflurane in oxygen (flow 1/L/min). Through a midline 
incision of the abdomen and chest the ribcage and (after cutting the sternum) the 
heart was visualised. Animals were then euthanized by exsanguination via cardiac 
puncture. Blood was collected into heparinized tubes (Multivette 600LH, Sarstedt, 
Nümbrecht, Germany). Death was confirmed by cessation of circulation. The heart 
was then removed and transferred into 10% neutral buffered formalin (Cellstor, 
CellPath, Newton, UK) for fixation for at least 20 hours. Blood was centrifuged at 8000 
rpm for 6 minutes and then the plasma was carefully collected (with special care to 
avoid contamination by erythrocytes, leukocytes or platelets), aliquoted and stored in 




4.3.1.5 Histological Analysis 
After fixation hearts were processed in a tissue processor by immersing in graded 
ethanol washes (70%,95%,100%), Xylene and then finally Paraffin wax. The wax 
infiltrated hearts were then placed in a mould containing molten paraffin which was 
allowed to cool. Samples were embedded in paraffin in a short axis orientation so that 
the sections cut would all show the ventricle lumen. For sectioning heart tissue blocks 
were chilled on ice and then cut on microtome. Prior to histological staining, sections 
were deparaffinized and rehydrated at room temperature according to the following 
protocol. For deparaffinization samples were immersed twice in xylene for 5 minutes. 
In the next step slides were rehydrated by sequentially immersing in graded ethanol 
washes (100%, 95%, 85%,70 and 50%) for 3 minutes each. Subsequently samples 
were washed in 0.85% NaCl for 5 minutes and immersed in phosphate buffered saline 
for 5 minutes. Slides were stained in a 0.1% sirius red solution in saturated picric acid 
(Picrosirius red, Sigma, Dorset, UK) in the dark for 90 minutes. Slides were then 
briefly washed three times in acidified water by quickly dipping 3 times and 
dehydrated by immersing in graded ethanol washes (50%, 70%, 85%, 95% 100%), 
cleared in xylene for 5 minutes and then finally mounted with permanent mounting 
media (Pertex, CellPath,Newtown, UK). All picrosirius red stained slides images were 
acquired on the AxioScan Z1 (Carl Zeiiss, Oberkochen, Germany) using an in-house 
developed protocol for bright field mouse myocardium slides. The .CZI files were then 
converted into tagged image file format (.TIFF) to facilitate image analysis using 
Image-Pro Premiere 9.1 (MediaCybernetics, Rockville, MD, USA). In the first step the 
pixel area occupied by fibrosis was calculated using the counting toll after manual 
protocol adjustment. A pixel intensity threshold of 204-245 on the Mono scale was 
applied. The highlighted area was inspected for any contamination by erythrocytes or 
endo/epicardium and if present these objects were removed before the final output 
was recorded. In a similar fashion the total area of the analysed tissue was calculated 
by considering the area within the threshold of 150-245 on the mono scale with the 
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exceptions outlined above made if necessary. Finally, the area of fibrosis was 





4.3.2 Cardiovascular Magnetic Resonance Imaging 
All animals underwent serial CMR imaging to assess left ventricular structure and 
function as well as myocardial fibrosis. CMR was performed initially at baseline before 
the onset of pressure overload, and then every 2 weeks during angiotensin II infusion. 
In the reverse remodelling subgroup, a final CMR scan was performed 4 weeks after 
the Ang II infusion had been discontinued (Figure 13). At the end of the final imaging 
session, animals were culled by exsanguination under deep anaesthesia with the 
heart stored for further histological analysis.  
 
 
Figure 15. Study outline. Top arrow: study timeframe. Second row: number of 
animals that underwent MRI at a given timepoint in bold. In brackets number of 
animals subjected to Angiotensin infusion and controls. In the bottom row, total 









All MRI scans were performed on a 7-Tesla preclinical horizontal-bore MRI system 
(Agilent Technologies, Yarnton, UK) equipped with a 33-mm inner diameter 
radiofrequency coil for mice (Rapid Biomedical, Rimpar, Germany). Animals were 
anaesthetised using isoflurane (3% isoflurane in 1.0L/min oxygen for induction and 
1.5-2% isoflurane in 0.5 L/min O2/0.5 L/min air for maintenance). Prior to imaging an 
Anicath 26G cannula (Millpledge Veterinary, Clarborough, UK) was placed 
intraperitoneally for administration of the gadolinium-based contrast agent 
(gadobenate dimeglumine 1 μL/g body weight [Multihance]; Bracco Diagnostics, 
Princeton, NJ). Animals were placed in an MRI cradle with electrocardiogram (ECG) 
leads placed subcutaneously. The animals were positioned supine with hearts in the 
centre of the coil, and in the centre of the MRI scanner. A pressure transducer was 
placed under the torso for constant monitoring of respiration (MR-compatible Small 
Animal Monitoring and Gating System, SA Instruments, Stony Brook, NY), and a 
rectal probe was inserted to monitor and maintain body temperature at 37±0.5 °C via 
a feedback-controlled warm air system (MR-compatible Small Animal Heating 
System, SA Instruments, Stony Brook, NY). Throughout the imaging session special 
care was taken to keep the heart rate stable at 530-600 beats/min and to maintain a 
respiratory rate of 45-75 breaths/min.  
 
Scout images were taken to confirm correct positioning and to orientate 1.0-mm short 
axis slices covering the heart. T1 mapping for calculation of regional left ventricular 
myocardial T1 relaxation times was accomplished using a gradient-echo, cardiac-
gated Modified Look-Locker Inversion recovery sequence (MoLLI) during which 30 
images of a single mid-ventricular slice were acquired at unique inversion times 
(dependent on heart rate, ranging from approximately 0.10 to 3.00 s) with the 
recovery time after each inversion pulse > 3×T1 of myocardium. Imaging readout was 
with a cardiac fast gradient echo (repetition time 2.8 ms; echo time 1.4 ms; flip angle 
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10°, matrix 128×128; field of view 30×30 mm2; in-plane resolution=0.23×0.23 mm2; 
trigger delay 0.5×R-R; slice thickness 1.5 mm;). We acquired eight phase-encoding 
echos per segment and 8 signal averages were used to compensate for respiratory 
motion. After acquisition of a baseline T1 map, gadobenate dimeglimine was injected 
via the intraperitoneal cannula, and a second T1-mapping dataset was acquired 20 
minutes post-injection. During the time between the T1-mapping acquisitions, cine 
images were acquired for structural and functional assessment. The short axis, 
vertical and horizontal long axis cardiac images were acquired using an ECG 
triggered and respiratory-gated gradient echo sequence (TR/TE = 5.2/1.3 ms, flip 
angle: 15°) with gradient and radiofrequency spoiling. Eighteen phases were acquired 
with a field of view of 30x30 mm, a 128x128 matrix, and 2 signal averages were used. 
For the left ventricular short axis, nine consecutive 1-mm-thick slices were acquired, 
which encompassed the entire heart from base to apex. Late gadolinium 
enhancement imaging was performed between 12 and 18 minutes after contrast 
administration with a short-axis cardiac-triggered/respiratory-gated T1-weighted 
gradient echo inversion-recovery scan with the following imaging parameters: TR: 
1000ms (depending on respiration rate), TE: 1.45 ms, field of view: 30 x 30 mm, 
number of signal averages: 4, inversion time: 560 ms, flip angle: 90°, nine 1-mm thick 






4.3.3 Image analysis 
Data were analysed using certified software (cvi42, Circle CVI, Calgary, Alberta, 
Canada). The short axis cine images of the LV were used for the assessment of left 
ventricular volumes, mass and ejection fraction. The epicardial and endocardial 
contours were carefully identified and planimetered in end-systole and end-diastole 
for left ventricular volume quantification. The left ventricular mass was calculated from 
the total myocardial volume (excluding trabeculations and papillary muscles) 
multiplied by the density of the myocardium (1.05 g/mL). Maximal wall thickness was 
evaluated in all 17 segments of the LV from cine images of the LV in end-diastole 
(Cerqueira et al., 2002). For LV diffuse fibrosis, we calculated the extracellular volume 
fraction (ECV%) derived from pre- and post-contrast myocardial T1 values corrected 
for blood-pool T1. The ECV% was calculated according to: ECV% = partition 
coefficient x [1-hematocrit]; where partition coefficient = [∆R1myocardium/∆R1blood-
pool] and ∆R1 = (1/post-contrast T1-1/pre-contrast T1). In order to evaluate the total 
amount of interstitial fibrosis in each animal, we calculated the indexed ECV (iECV) 
in each animal using the following equation: ECV% x left ventricular myocardial 
volume, where left ventricular myocardium volume = left ventricular mass divided by 
the density of myocardium (1.05 g/mL) (7). To avoid blood-pool contamination and 
partial volume effects, we used a mid-myocardial region of interest for the T1-mapping 
analysis. A two-pixel wide myocardium and ventricular boundary zone was excluded 
from all applicable slices. Late gadolinium enhancement was used for detection of 
focal replacement fibrosis. Where present, it was quantified as an area of myocardium 
with a signal intensity exceeding the threshold of two standard deviations above the 
mean value of normal myocardium. All areas of inversion artefact or myocardial 








Histological validation was performed for each CMR technique used to measure 
myocardial fibrosis. After the final imaging session, animals were kept under 
anaesthesia and euthanized. The heart was removed and transferred into 10% 
neutral buffered formalin (Cellstor, CellPath, Newton, UK) for fixation for at least 20 
hours. After fixation hearts were processed and embedded in paraffin in a short axis 
orientation so that the cut sections would all show the ventricle lumen. Slides were 
stained in a 0.1% sirius red solution in saturated picric acid (Picrosirius red, Sigma, 
Dorset, UK). All picrosirius red stained slides images were acquired on the AxioScan 
Z1 (Carl Zeiss, Oberkochen, Germany) and analysed using Image-Pro Premiere 9.1 
(MediaCybernetics, Rockville, MD, USA) using tissue specific threshold. The area of 
fibrosis was expressed as a percentage of the total myocardial area (supplemental 
data). The total burden of myocardial fibrosis assessed by histology was calculated 





4.3.5 Statistical Analysis 
 
Continuous variables were tested for distribution with the Shapiro-Wilk test. Data are 
presented as mean±SD, median [interquartile range] or percentages where 
appropriate. Differences between groups were assessed with the use of a 2-sided 
Student t-test, paired Student t-test, ANOVA for continuous variables, Wilcoxon rank-
sum test for ordinal variables and the χ2 test or Fisher’s exact test for categorical 
data. The relationship between 2 continuous variables was assessed using Pearson’s 





4.4.1 Left ventricular remodelling under pressure overload 
Mean arterial pressure (MAP) was elevated after 2 weeks of Ang II infusion compared 
to baseline (84.2±13.6 vs 65.1±12.0 mmHg, p<0.001) and remained stable for the 
remainder of the infusion phase (p>0.50; Table 11). Both maximum wall thickness 
and LV mass increased during angiotensin II infusion (0.73 [0.71,0.76] vs 0.84 [0.81, 
0.86] mm, p=0.001 and 0.091 [0.083, 0.105] vs 0.108 [0.101, 0.121] g, p<0.001 
respectively). Wall thickness and LV mass were elevated after 2 weeks and further 
increased up to the 4-week time point (0.84 [0.81, 0.86] vs 0.88 [0.80, 0.95] mm, 
p<0.001 and 0.108 [0.101, 0.121] vs 0.121 [0.111, 0.136] g, p<0.001) after which both 




Table 12. Left ventricular remodelling under pressure overload and after load 
normalization. 
  




MAP, mm Hg 65.1±12.0 84.2±13.6 86.5±7.1 84.7±9.2 68.8±5.4 <0.001 






















































ECV, % 24.03±3.39 29.53±4.25 29.99±2.65 29.98±1.84 27.10±1.64 0.001 












































4.4.2 Histological assessment of myocardial fibrosis  
Hearts from 28 animals were available for histological analysis and validation of the 
CMR fibrosis measurements (n=13 culled during increased pressure overload, n=9 
culled after reverse remodelling and six control animals) (Figure 14A). An increase in 
myocardial fibrosis was observed in animals exposed to the angiotensin II infusions 
compared to control animals (4.4, [3.5, 5.8] vs 10.1 [8.7, 12.9] %, p<0.001). There 
was a strong correlation between the histological assessment of myocardial fibrosis 
(% myocardium comprised of fibrosis) and the ECV% as measured by CMR (r=0.89, 
p=0.001; Figure 14B). Similar correlations were observed between histological 
fibrosis and native T1 (r=0.80, p<0.001), post contrast T1 (r=-0.75, p<0.001) and iECV 
(r=0.82, p<0.001). Finally, a close correlation was observed between the total volume 
of myocardial fibrosis in the left ventricle on histology (%myocardium comprised of 
fibrosis multiplied by the volume of the left ventricular myocardium) and the equivalent 




Figure 16. Fibrosis on histology and T1-mapping data. Examples of diffuse fibrosis 
on histology - picrosirius red staining (A). The relationship between fibrosis on 
histology and the native T1-values (B), post contrast T1-values (C), extracellular 
volume (D) and indexed ECV(E) 
A. 
 
B.      C. 
 
 






4.4.3 LV fibrosis and function under pressure overload 
While there was no change in native T1 relaxation times during exposure to pressure 
overload (p=0.10), both ECV% and iECV demonstrated progressive increases. This 
increase in ECV% demonstrated a similar pattern of change as the blood pressure 
with an initial increase (24.28±3.35 vs 29.53±4.25 %, p=0.004) followed by a plateau 
phase after 4 weeks (p>0.40). By contrast iECV increased during the first 2 weeks 
(0.033 [0.029, 0.035] vs 0.022 [0.019, 0.024] mL, p<0.001), and then kept on 
expanding at 4 and 6 weeks (0.036 [0.035, 0.040] and 0.039 [0.031, 0.043] mL, 
p=0.041 and p=0.07 respectively) following a similar pattern to that demonstrated by 
EF, which also demonstrated an ongoing gradual reduction with time spent on the 
Ang II infusion (LVEF 59.3 [57.6, 59.9] % at baseline, 52.4 [47.7, 53.9] % at 2 weeks, 
49.5 [41.2, 51.7] % at 4 weeks and 46.9 [38.5, 49.6] % at 6 weeks; p<0.001 for trend) 





Figure 17. Cardiovascular magnetic resonance imaging of mice subjected to 
pressure overload. Modified Look-Locker Inversion Recovery T1-mapping (A). T1 
relaxation times for the myocardium and bloodpool are generated from images shown 
in the upper row. The calculated T1 relaxation times can be used to generate native 
(blue) and postcontrast (orange) T1 maps. End-diastolic and end-systolic LV short 




Figure 18. Adverse remodelling under pressure overload. Mean arterial pressure (A), 
Left ventricular mass (B) Extracellular volume fraction (C), iECV (D), LV ejection 
fraction (E), LV end diastolic volume  
A.       B. 
 
C.       D. 
 






4.4.4 Reverse remodelling  
Four weeks after the end of the Ang II infusion, reversal of the pressure overload state 
was observed with mean arterial blood pressure values returning to baseline (p=0.42 
for difference, Figure 16A). In response LV mass, ECV% and iECV all regressed 
(p<0.01; Table 12). However, this reverse remodelling was only partial with none of 
these parameters returning to their baseline values (Figure 16). Indeed, ECV% only 
partially resolved, with values reducing from 30.0±1.8% during the infusion to 
27.1±1.6% (p=0.001) 4 weeks following its discontinuation compared to baseline 
values of 24.0±3.4% (p=0.06). Similarly, iECV was lower than during angiotensin II 
infusion (0.030 [0.028, 0.036] vs. 0.039 [0.031, 0.043] mL, p=0.002) but remained 
higher than at baseline (0.022 [0.019, 0.024] vs. 0.034 [0.032, 0.036] mL, p=0.001; 
Table 1). Importantly the LV ejection fraction again demonstrated a similar pattern to 
iECV, showing a trend towards recovery (46.9 [38.5, 49.6] vs 51.1 [42.9, 52.8] %, 
p=0.10) yet remaining lower at 4 weeks than at baseline (59.3 [57.6, 59.9] vs 51.1 
[42.9, 52.8] %, p=0.029; Table 1).  The LV end-diastolic volume remained elevated: 






4.4.5 ECV% is associated with systolic function  
There was a strong inverse correlation between LVEF and iECV values during 
pressure loading (r=-0.88, p<0.001 at 6 weeks; Figure 17A). Whilst ECV% was also 
associated with LVEF at this timepoint, the observed correlation was only moderate 
(r=-0.54, p<0.001). Following reversal of pressure overload again a strong 
association was observed between iECV and ejection fraction (r=-0.74, p=0.001). On 
multivariable linear regression analysis, ECV%, and iECV were independently 
associated with LVEF independent of MAP and LV mass. Interestingly the model 
incorporating iECV had a higher R-Square (0.78) than the one with ECV% (0.54, 
Table 13). 
We found a strong correlation between the increases in ECV% observed in the first 
two weeks of pressure overload (from baseline to week 2) and the reduced ejection 




Table 13. Univariable and multivariable linear regression analysis to examine 
association of variables with LV ejection fraction after 6 weeks of pressure overload.  
Variable
s  
































































































































Figure 19. Diffuse fibrosis and systolic function. Indexed ECV is associated with 
ejection fraction under pressure overload (A). Early changes in ECV% predict later 








In this study we have established reversible angiotensin II infusion as an animal 
model of left ventricular hypertrophy and reverse remodelling. This model has allowed 
us to assess how the hypertrophic response and myocardial fibrosis develop in 
response to an increased afterload and then reverse remodels once that stimulus is 
removed. We believe our model will allow improved understanding of the processes 
underlying LV decompensation in patients with aortic stenosis and hypertension that 
may ultimately help to optimise patient treatment including the timing of AVR. In this 
study we have demonstrated that myocardial fibrosis appears to be the primary 
determinant of LV dysfunction both before and after reversal of pressure overload. 
Further studies should investigate the optimum time to reverse pressure overload in 
order to ensure more complete recovery in left ventricular function.  
 
Our preclinical model offers several important advantages, using state-of-the-art in 
vivo CMR imaging it enables longitudinal collection of data on remodelling in the same 
subject within a timespan of months rather than years or decades as observed in 
humans. Further it provides an almost unlimited amount of myocardium for 
histological evaluation, enabling validation of our CMR markers of fibrosis, including 
iECV confirmed for the first time as a biomarker of the total burden of left ventricular 
fibrosis. Finally, to the best of our knowledge, we have developed the first preclinical 
model to provide insight into both the hypertrophic response and reverse remodelling 
using state-of-the-art longitudinal imaging assessments. While several studies have 
utilized transverse aortic constriction as a model of aortic stenosis this model has 
several limitations. The surgical technique is associated with a 25% drop-out of 
animals in the peri-procedural period (Stuckey Daniel et al., 2014). With the aortic 
band placed between the origin of the innominate and left common carotid arteries 
the model recreates proximal aortic coarctation leading to significant hemodynamic 
consequences. These include elevated pressure in the innominate, right common 
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carotid, coronary and right subclavian arteries as opposed to a the left subclavian and 
carotids. In severe constriction perfusion of organs distal to the band can be 
maintained through the Willis circle yet this again is not typical for aortic valve 
stenosis.   
 
Continuous infusion of Ang II leads to systemic hypertension and holds major promise 
in improving our understanding of LV decompensation in aortic stenosis and in the 
development of novel biomarkers and treatment strategies. Indeed, in this study we 
have demonstrated that reductions in ejection fraction in pressure overload conditions 
are more closely associated with the total burden of myocardial fibrosis (as measured 
with iECV) than the degree of pressure afterload. Moreover, we observed that reverse 
remodelling 1 month after load normalization is incomplete with residual fibrosis again 
closely associated with residual systolic impairment. Our findings are in line with the 
hypothesis that fibrosis is a principal driver of left ventricular decompensation in 
pressure overload (C. W. L. Chin et al., 2017), a key determinant of LV systolic 
function and an important potential therapeutic target. This is a particularly appealing 
target given that several drug therapies have already demonstrated their ability to 
reduce myocardial fibrosis in other contexts (Díez et al., 2002; Dweck et al., 2011). 
Indeed, our model could potentially be used to assess the efficacy of existing or novel 
anti-fibrotic therapies before proceeding to expensive clinical trials.  
 
This model might also prove of value in determining the optimal timing of aortic valve 
replacement. The data presented here suggests that if pressure overload continues 
for too long then irreversible fibrosis will develop in the ventricle, leading to long term 
impairment of systolic function. Further studies should investigate whether reversing 
pressure overload earlier might potentially lead to complete recovery in left ventricular 
function and whether the optimal timing can be identified using imaging or other 
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biomarkers. This strategy could ultimately then be applied to aortic stenosis, thereby 




We acknowledge that our study has limitations. While our model recreates the 
myocardial response to increased afterload observed in patients with hypertension 
and aortic stenosis it is not a pure model for either. For T1-mapping we only acquired 
data from the mid-ventricle short axis slice potentially introducing a sampling error. In 
patients with aortic stenosis, data are usually obtained from 3 slices so that the basal, 
mid and apical segments are all interrogated. Since our model of pressure overload 
affects the entire left ventricle and due to animals’ welfare, we chose to shorten the 
image acquisition by focusing on the mid-ventricle slice. We performed blood 
pressure measurements immediately after the imaging sessions at the time animals 
were recovering from anaesthesia. We found such an approach to be less stressful 




Chapter 5. Sex-Related Differences in the Extent of 
























Previous studies reported sex-related differences in the left ventricular remodeling 
response to pressure overload in aortic stenosis. However, there are very few data 
regarding the effect of sex on myocardial fibrosis, a key marker of left ventricular 
decompensation and adverse cardiac events in aortic stenosis. The aim of this study 
was to assess the effect of sex on myocardial fibrosis as assessed by cardiac 
magnetic resonance in aortic stenosis. 
Two hundred forty-nine patients (66±13 years, 30% women) with at least mild aortic 
stenosis were recruited from two prospective observational cohort studies and 
underwent comprehensive Doppler echocardiography and magnetic resonance 
exams. On cardiovascular magnetic resonance, T1 mapping was used to quantify 
extracellular volume fraction as a marker of diffuse fibrosis, and late gadolinium 
enhancement was used to assess focal fibrosis. 
There was no difference in age between women and men (66±15 vs 66±12 years, 
p=0.78). However, women presented a better cardiovascular risk profile than men 
with less hypertension, dyslipidemia, diabetes, and coronary artery disease (all 
p≤0.10). As expected, left ventricular mass index measured by cardiovascular 
magnetic resonance was smaller in women than in men (p<0.0001). Despite less 
comorbidities, women presented larger extracellular volume fraction [29.0 (27.4-30.6) 
vs. 26.8 (25.1-28.7) %, p<0.0001] and similar late gadolinium enhancement [4.5 (2.3-
7.0) vs. 2.8 (0.6-6.8) %, p=0.20] than men. In multivariable analysis, female sex 
remained an independent determinant of higher extracellular volume fraction and late 
gadolinium enhancement (all, p≤0.05).  
Women have greater diffuse and focal myocardial fibrosis independent of the degree 
of aortic stenosis severity. These findings further emphasize the sex-related 




Calcific aortic stenosis (AS) is the most prevalent valvular heart disease in high 
income countries (Brian R. Lindman et al., 2016). In patients with AS, the 
development of symptoms and subsequent adverse cardiovascular events are 
essentially related to the increased left ventricular (LV) global hemodynamic load 
(Blase A. Carabello, 2013; Marc R. Dweck et al., 2012; Brian R. Lindman et al., 2016). 
In response to chronic pressure overload, LV remodeling and hypertrophy maintain 
normal LV wall stress and systolic function. However, this LV hypertrophic response 
is often maladaptive and leads to myocardial oxygen supply-demand mismatch, 
repetitive ischemia, and initiates a cascade of signalling pathways associated with 
inflammation, increased extracellular matrix remodeling, myocyte apoptosis or 
necrosis, and the development of myocardial fibrosis (Burchfield, Xie, & Hill, 2013; 
Hein et al., 2003; K. T. Weber, Sun, Bhattacharya, Ahokas, & Gerling, 2013; 
Westermann et al., 2011). To this regard, myocardial fibrosis by histopathology has 
been documented in patients with AS and has been associated with increased 
morbidity and mortality (Azevedo et al., 2010; Weidemann et al., 2009).  
Cardiac magnetic resonance (CMR) imaging offers a non-invasive, accurate and 
reproducible assessment of LV architecture and function. CMR detects the presence 
of replacement myocardial fibrosis using late gadolinium enhancement (LGE), and 
diffuse reactive myocardial fibrosis using extracellular volume (ECV) fraction 
calculated from T1 mapping (Barone-Rochette et al., 2014; Dweck et al., 2011; 
Fontana et al., 2012; Singh et al., 2015; Taylor, Salerno, Dharmakumar, & Jerosch-
Herold, 2016). Both LGE and ECV correlate strongly with collagen content as 
measured by histology, suggesting that they are both surrogate markers of 
myocardial fibrosis (Bull et al., 2013; Andrew S. Flett et al., 2011). Recent studies 
have reported an association between LGE and ECV with worse outcomes in patients 
with AS (C. W. L. Chin et al., 2017; Heesun Lee et al., 2018; S.-P. Lee et al., 2015). 
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Several factors, and in particular age and sex, may also have an effect on the 
expansion of diffuse myocardial fibrosis, a key marker of LV decompensation in AS 
(C. W. L. Chin et al., 2017; Treibel, Lopez, et al., 2018). The objectives of this study 
were thus to assess the determinants of diffuse (ECV) and focal (LGE) myocardial 
fibrosis in patients with AS, and in particular, to assess the effect of sex on these 2 






5.3.1 Patient Population 
Patients were prospectively recruited in 2 centers: Quebec Heart and Lung Institute 
the (PROGRESSA study: Metabolic Determinants of the Progression of Aortic 
Stenosis [NCT01679431]), and Edinburgh Heart Centre (NCT01755936) (Romain 
Capoulade et al., 2015; C. W. L. Chin et al., 2017). The study inclusion criteria for the 
PROGRESSA study are age >21 years old and peak aortic jet velocity (Vpeak) >2.0 
m/s. The exclusion criteria were symptomatic AS, significant (> mild) aortic 
regurgitation or mitral valve disease (mitral stenosis or regurgitation), LV ejection 
fraction (LVEF) <50% and if they are pregnant or lactating women (Romain 
Capoulade et al., 2015)(1). In Edinburgh, all stable patients with at least mild AS 
(Vpeak >2.0 m/s) were invited to participate in a prospective observational cohort 
study. The exclusion criteria were other forms of valvular heart disease (≥moderate 
severity), significant comorbidities with limited life expectancy, contraindications to 
gadolinium-enhanced cardiac magnetic resonance (CMR), acquired or inherited non-
ischemic cardiomyopathies (C. W. L. Chin et al., 2017)(2). The present study included 





Figure 20. Study Flow Chart 
Description of the inclusion of the study population. CMR = cardiac magnetic 





5.3.2 Clinical Data 
The clinical data included age, sex, weight, height, body surface area (BSA), body-
mass index (BMI), documented diagnoses of hypertension, dyslipidemia, diabetes 
mellitus, coronary artery disease, and renal function (plasma level of creatinine). 
Symptomatic status was assessed using the New York Heart Association (NYHA) 
functional classification. 
5.3.3 Doppler Echocardiography  
The aortic valve phenotype (i.e. bicuspid vs. tricuspid) was recorded. The Doppler-
echocardiographic indices of AS severity included Vpeak, mean transvalvular 
pressure gradient (MG), and aortic valve area (AVA) calculated by the standard 
continuity equation and indexed to body surface area (AVAi). Stroke volume was 
calculated by multiplying the LV outflow tract area by the flow velocity-time integral 
and was indexed to BSA (SVi). LV mass was calculated with the corrected formula of 
the American Society of Echocardiography and European Association of 
Cardiovascular Imaging guidelines and was indexed to body surface area (3). Left 
ventricular hypertrophy (LVH) was defined as LV mass index >95 g/m² in women and 
>115 g/m² in men. Relative wall thickness (RWT) was calculated (i.e. RWT = 
[PWT+IVST]/LVID) and, as previously recommended, RWT >0.42 was used to define 
concentric remodeling (Lang et al., 2015). By taking into account both values of LV 
mass index and RWT, patients were classified into four different patterns using the 
following criteria: i) normal pattern: absence of LVH and RWT ≤0.42; ii) concentric 
remodeling: absence of LVH and RWT >0.42; iii) concentric hypertrophy: presence of 
LVH and RWT >0.42; iv) eccentric hypertrophy: presence of LVH and RWT ratio 
≤0.42 (3). 
Mitral annulus velocity was assessed using Doppler tissue imaging and diastolic 
function was classified according to guidelines (Lang et al., 2015).  
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As a measure of global LV hemodynamic load, we calculated the valvulo-arterial 
impedance: Zva = (SBP + MG)/SVi, where SBP is the systolic blood pressure. 
5.3.4 Cardiac Magnetic Resonance  
5.3.4.1 Acquisition 
Magnetic resonance imaging was performed with 1.5 and 3 Tesla scanners (Quebec: 
Philips Achieva or Philips Ingenia, Philips Healthcare, Best, The Netherlands; 
Edinburgh: Magnetom Verio, Siemens AG, Erlangen, Germany). Short-axis cine 
images extending from the mitral valve to the left ventricular apex were obtained using 
a balanced steady-state free precession sequence (Quebec: 8-mm parallel slices with 
no gap; Edinburgh: 8-mm parallel slices with 2-mm spacing with temporal resolution 
≤45 ms). Typical parameters at 1.5T were TR/TE 3.2/1.6ms, flip angle 60º. Equivalent 
acquisition parameters at 3T were TR/TE 2.8/1.3ms, flip angle 45º. 
Focal replacement and diffuse interstitial myocardial fibrosis was assessed in all 
patients using late gadolinium enhancement (LGE) and myocardial T1 mapping, 
respectively. Late gadolinium enhancement was performed 15 min following 
gadobutrol (Gadovist, Bayer Pharma AG, Germany, 0.2 mmol/kg [Quebec], 0.1 
mmol/kg [Edinburgh]) using an inversion-recovery fast gradient-echo sequence 
performed in two phase-encoding directions to differentiate true late enhancement 
from artefact (Larose et al., 2010). The inversion time was optimized to achieve 
satisfactory nulling of the myocardium. 
Diffuse myocardial fibrosis was assessed using Modified Look-Locker Inversion-
recovery (MOLLI) with built-in motion correction. The heart beat acquisition scheme 
was 5(3)-3 in Quebec (with a post-contrast acquisition scheme of 4(1)3(1)2 used in 
patients scanned at 3T) (Kellman et al., 2014), whilst the acquisition scheme was 
3(3)-3(3)-5 in Edinburgh (flip angle 35 ; minimum TI 100 ms; TI increment of 80 ms; 
time delay of 150 ms) (D. R. Messroghli et al., 2007; Daniel R. Messroghli et al., 2004; 
195 
 
Moon et al., 2013). A gradient echo field map and associated shim were performed 
to minimize off-frequency artefact. 
5.3.4.2 Image analysis 
Image analysis was performed offline in a core laboratory using a standardized 
approach (cmr42 version 3.4.1, Circle Vascular Imaging, Canada). In Quebec, 
images were quantified by trained operators supervised by an experienced 
cardiologist (Quebec: E.L.; Edinburgh: M.D.) (Cerqueira et al., 2002; Schulz-Menger 
et al., 2013). Left ventricular volume, mass and function measurements were 
performed using the contiguous short-axis multi-slice acquisition with delineation of 
atria/ventricles confirmed in matched long-axis planes. Papillary muscles and 
trabeculations were included when measuring mass (equivalent to weighting the LV) 
and excluded when measuring volumes (equivalent to blood pool techniques) in line 
with recommendations (Cerqueira et al., 2002). 
LV hypertrophy was defined as LV mass indexed to BSA >95th centile using age- and 
sex-specific reference ranges (Kawel-Boehm et al., 2015). LV remodeling was 
determined as the ratio of LV mass index to LV end-diastolic volume index. By taking 
into account the presence of LV hypertrophy (LVH) and increased LV mass-volume 
ratio (i.e., ratio ≥1.15) (Kawel-Boehm et al., 2015; Treibel, Kozor, et al., 2018), four 
patterns of LV remodeling were defined: i) normal pattern: no LVH and LV mass-
volume ratio <1.15; ii) concentric remodeling: no LVH and LV mass-volume ratio 
≥1.15; iii) concentric hypertrophy: LVH and LV mass-volume ratio ≥1.15; iv) eccentric 
hypertrophy: LVH and LV mass-volume ratio <1.15. 
Focal replacement fibrosis and extracellular volume (ECV) fraction were assessed 
using late gadolinium enhancement (LGE). LGE was performed 15 min following 
administration of gadobutrol (Gadovist, Bayer Pharma AG, Germany; 0.2 mmol/kg 
[Quebec], 0.1 mmol/kg [Edinburgh]). In Quebec, quantitative assessment of LGE was 
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performed on short-axis inversion recovery images by semi-automated signal 
intensity analysis, using the full width at half-maximum technique on the 17-segment 
model (4,9). In Edinburgh, a pattern of mid-wall fibrosis was determined qualitatively 
(2). LGE was quantified in a semi-automated manner using a signal intensity 
threshold of >3 standard deviations above the mean value in a region of normal 
myocardium. Areas of inversion artefact, infarct pattern LGE or signal contamination 
by epicardial fat or blood pool were manually excluded. Sub-endocardial LGE was 
also identified and quantified using the same analysis technique. 
T1 mapping was performed using the Modified Look-Locker Inversion Recovery 
(Figure 19) (2). The regions of the endocardium and epicardium on the native motion-
corrected T1 maps were manually contoured to avoid partial-volume or cardiac-
motion-related blurring of the myocardium-blood boundary, where blood signal may 
contaminate myocardial data (Everett et al., 2018). These contours were then copied 
onto the corresponding post-contrast maps (Quebec: 15-min post-contrast maps; 
Edinburgh: 20-min post-contrast maps) with minor adjustments made to avoid partial 
volume effects. Regions of interest (ROIs) were then drawn in the blood, avoiding 
myocardium and papillary muscles. The extracellular volume (ECV) fraction was 
calculated according to: ECV fraction = partition coefficient x [1-hematocrit], where 
partition coefficient = [∆R1myocardium/∆R1blood-pool] and ∆R1 = (1/post-contrast 
T1-1/native T1). Hematocrit was measured as per protocol before cardiovascular 




Figure 21. Assessment of T1 Mapping and Late Gadolinium Enhancement. 
Myocardial fibrosis assessment in a 70-year-old female with severe AS. The native 
(A) and post contrast (B) T1 relaxation time maps were used to calculate the 
extracellular volume (ECV) fraction. On late gadolinium enhancement (LGE) imaging, 
there was evidence of mid-wall enhancement in the basal inferolateral wall (C) which 







5.3.5 Statistical Analysis 
Continuous data were expressed as mean ± SD or median (interquartile range), and 
were tested for normality of distribution and homogeneity of variances with the 
Shapiro-Wilk and Levene tests, respectively. Continuous data were compared 
between women and men using Student t test, Wilcoxon-Mann-Whitney test, one-
way analysis of variance followed by Tukey post-hoc, or Kruskal-Wallis test followed 
by Dunn’s post-hoc as appropriate. Categorical data were compared with the Chi-
square test or Fisher’s exact test as appropriate. Analysis of covariance (ANCOVA) 
was performed to assess the effect of sex on ECV fraction taking into account 
hemodynamic AS severity and LV mass index respectively. Univariable and 
multivariable linear regression analyses were performed to determine the predictors 
of diffuse myocardial fibrosis. Results were presented as standardized regression 
coefficients ± standard error (βeta coeff. ± SE). Traditional risk factors and/or clinically 
relevant variables and those with a p-value <0.10 in univariable analysis were 
included in the multivariable models. The explanatory variables entered in the 
multivariable models were age, sex, hypertension, diabetes, coronary artery disease, 
hemodynamic AS severity (i.e. Vpeak), Zva, and LV mass index measured by CMR. 
A frequency-matched analysis where patients were matched for age, cardiovascular 
risk factors, hemodynamic severity of AS, and prevalence of LVH was also performed 
to further compare the distribution of ECV and LGE between women and men. 
Statistical analyses were performed with STATA (V.14.2). A p value <0.05 was 





5.4.1 Population Characteristics 
The study population had a mean age of 66±13 years and 30% were women (Table 
14). Participants had a BMI of 28±5 kg/m², systolic blood pressure of 143±22 mmHg 
and 86% were in NYHA class I-II. The mean Vpeak was 3.4±1.0 m/s, 38% of patients 
had mild (Vpeak<3.0 m/s), 28% moderate (Vpeak 3.0-3.9 m/s), and 34% severe 
(Vpeak ≥4.0 m/s) AS.  
Age was similar in women versus men (women: 66±15 vs. men: 66±12 years, p=0.78) 
but women presented with overall better clinical risk profile, particularly, lower 
prevalence of dyslipidemia (41% vs. 59%, p=0.004), diabetes (8% vs. 18%, p=0.04), 
and coronary artery disease (15% vs. 41%, p<0.0001; Table 14). Despite similar 
systolic (women: 146±25 vs. men: 142±21 mmHg, p=0.25) and diastolic (women: 
81±12 vs. men: 81±11 mmHg, p=0.93) blood pressures, there was a trend toward 
less documented diagnosis of hypertension in women (59% vs. 70%, p=0.10) (Table 
14). There was a trand for lesser use of anti-hypertensive medications (58% vs. 66%, 
p=0.26), and in particular of antagonists of the renin-angiotensin system (36% vs. 
48%, p=0.10) in women versus men (Table 14). 
The echocardiographic measures, and in particular AS severity (Vpeak: 3.3±1.0 vs. 
3.5±0.9 m/s, p=0.32), were similar between women and men, (Table 14). However, 
women had a higher ratio of mitral E-wave and e’ velocities (15.6±8.7 vs. 12.1±5.4, 
p=0.0002; Table 14).  
As expected, the LV size and volumes quantified by CMR were smaller in women 
than in men (all, p≤0.04) but LV mass/volume ratio was lower in women compared 
with men [0.98 (0.80-1.20) vs. 1.12 (0.88-1.34), p=0.01] (Table 14). Despite lower LV 
mass index in women versus men [63 (56-80) vs. 82 (65-96) g/m², p<0.0001; Table 
14 and Figure 20A), the prevalence of LVH was not different between sexes (27% vs. 
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36%, p=0.17; Table 14). However, there was a trend toward more LV concentric 
remodeling and concentric hypertrophy in men compared with women (Table 14). The 
systolic function as measured by LV ejection fraction was not different between sexes 




TABLE 14. Characteristics of the Study Population according to Sex 
 
All Patients 
(n = 249) 
Men 
(n = 175, 70%) 
Women 




Clinical   
Age, years 66 ± 13  66 ± 12 66 ± 15 0.78  
Body surface area, m2 1.87 ± 0.19 1.94 ± 0.17 1.72 ± 0.15 <0.0001  
Body mass index, kg/m2 28 ± 5 29 ± 4 28 ± 6 0.43  
Systolic blood pressure, mmHg 143 ± 22 142 ± 21 146 ± 25 0.26  
Diastolic blood pressure, mmHg 81 ± 11 81 ± 11 81 ± 12 0.93  
Hypertension, % 67 70 59 0.10  
Dyslipidemia, % 53 59 41 0.004  
Diabetes, % 15 18 8 0.04  
Coronary artery disease, % 33 41 15 <0.0001  
Creatinine, µmol/l 79 ± 18 84 ± 18 68 ± 12 <0.0001  
Creatinine clairance, ml/min 87 ± 19 89 ± 20 84 ± 18 0.06  
Hematocrit 0.41 ± 0.04 0.42 ± 0.04 0.38 ± 0.03 <0.0001  
NYHA functional class, %  
I 51 54 46 
0.61 
 
II 35 33 41  
III 12 11 12  
IV 2 2 1  
Medication  
ACEIs/ARBs, % 45 48 36 0.10  
Beta-blockers, % 30 31 27 0.55  
Diuretics, % 28 25 35 0.11  
Statins, % 52 58 39 0.007  
Doppler-echocardiographic data   
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Bicuspid aortic valve, % 26 26 27 0.85  
Peak aortic jet velocity, m/s 3.4 ± 1.0 3.5 ± 0.9 3.3 ± 1.0 0.32  
Mean transvalvular gradient, mmHg 28 ± 18 29 ± 17 27 ± 18 0.34  
Aortic valve area, cm2 1.05 ± 0.37 1.08 ± 0.39 0.96 ± 0.31 0.02  
Indexed aortic valve area, cm²/m2 0.56 ± 0.19 0.56 ± 0.20 0.56 ± 0.18 0.99  
AS severity, %   
Mild 38 34 46 
0.22 
 
Moderate 28 30 24  
Severe 34 36 30  
Valvulo-arterial impedance, mmHg/mL/m2 4.2 ± 1.1 4.2 ± 1.1 4.2 ± 1.1 0.81  
Mean e’, cm/s 7.0 ± 2.2 7.1 ± 2.1 6.7 ± 2.5 0.18  
Mean E/e’ ratio 13.2 ± 6.7 12.1 ± 5.4 15.6 ± 8.7 0.0002  
LV mass index, g/m2 112 (93 - 132) 117 (97 - 135) 98 (83 - 119) <0.0001  
Relative wall thickness ratio 0.57 (0.48 - 0.66) 
0.57 (0.48 - 
0.66) 
0.56 (0.44 - 
0.67) 
0.83  
LV hypertrophy, % 53 53 54 0.97  
LV remodeling patterns, %  
Normal pattern 11 9 14 
0.43 
 
Concentric remodeling 36 38 32  
Concentric hypertrophy 52 52 51  
Eccentric hypertrophy 2 1 3  
Cardiac magnetic resonance data  
End-diastolic volume index, ml/m2 71 (62 - 82) 73 (64 - 85) 69 (61 - 78) 0.01  
End-systolic volume index, ml/m2 24 (19 - 28) 24 (21 - 29) 22 (17 - 27) 0.005  
Stroke volume index, ml/m2 47 (42 - 55) 49 (42 - 56) 46 (40 - 53) 0.04  
LV ejection fraction, % 67 (63 - 71) 66 (62 - 70) 68 (63 - 72) 0.16  
LV mass index, g/m2 75 (61 - 93) 82 (65 - 96) 63 (56 - 80) <0.0001  
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LV mass/volume ratio 1.06 (0.84 - 1.32) 
1.12 (0.88 - 
1.34) 
0.98 (0.80 - 
1.20) 
0.01  
LV hypertrophy, % 33 36 27 0.17  
LV remodeling patterns, %  
Normal pattern 52 47 65 
 
 
Concentric remodeling 15 17 8  
Concentric hypertrophy 27 29 23  
Eccentric hypertrophy 6 7 4  
Presence of LGE, % 38 42 30 0.08  
LGE, % 3.2 (0.7 - 7.0) 2.8 (0.6 - 6.8) 4.5 (2.3 - 7.0) 0.20  
Presence of non-infarct LGE, % 34 37 27 0.12  
Non-infarct LGE, % 2.8 (0.7 - 6.8) 2.1 (0.6 - 6.8) 4.5 (2.0 - 6.3) 0.22  
Extracellular volume fraction  
Mean, % 27.8 ± 3.2 27.2 ± 3.0 29.2 ± 3.2 <0.0001  
Median, % 27.6 (25.3 - 29.7) 
26.8 (25.1 - 
28.7) 




Value are mean±SD, % or median [25th – 75th percentiles]. 
ACEIs = angiotensin-converting-enzyme inhibitors; ARBs = angiotensin receptor blockers; AS = aortic valve 









Figure 22. Comparison of Extracellular Volume Fraction and Left Ventricular Mass 
Index According to Sex. Comparison of left ventricular (LV) mass index (A) and ECV 
fraction (B) in women (n = 74) versus men (n = 175). The box shows the 25th to 75th 
percentiles, the median line on the box shows the median value, and the error bars 
the 95th range; circles are outliers; the numbers of the top of the graph are median 





5.4.2 Association between Sex and Expansion of Late Gadolinium 
Enhancement. 
In the study population, LGE was present in 95 (38%) patients and non-infarct LGE 
was present in 85 (34%) patients (Table 14). There was a trend towards higher 
proportion of patients with detectable LGE in men compared to women (42% vs. 30%, 
p=0.08), although the absolute value of LGE expressed in percentage was similar 
between sexes (2.8 [0.6-6.8] vs. 4.5 [2.3-7.0] %, p=0.20) (Table 14). Moreover, there 
was no significant difference in the proportion of LGE between sexes according to AS 
severity (p=0.58) but a trend according to tertiles of LV mass index defined using sex-
specific thresholds (p=0.08) (Figure 21 A and B). Excluding the patients with areas of 
infarction provided similar results for the proportion of detectable LGE (Table 14), as 
well as the distribution of LGE according to AS severity (Figure 21C). However, there 
were significant differences between sexes according to tertiles of LV mass index 





Figure 23. Comparison of Late Gadolinium Enhancement between Women and Men 
According to Hemodynamic Severity of Aortic Valve Stenosis and Left Ventricular 
Mass Index. Caption: Comparison of LGE between women and men in each class of 
severity of AS (mild AS, Vpeak<3.0 m/s; moderate AS, Vpeak 3.0-3.9 m/s; Vpeak 
≥4.0 m/s) (A) and in each tertile of LV mass index (B), and in the subset of patients 
with non-infarct LGE (C and D). The tertiles of LV mass index were designed 
according to sex: i) women: bottom tertile ≤58 g/m², mid tertile 59 g/m² - 73 g/m², top 
tertile >73 g/m²; ii) men: bottom tertile <70 g/m², mid tertile 70 g/m² - 92 g/m², top 





Univariable linear regression analysis in the whole study population showed that 
Vpeak and LV mass index were associated with higher LGE (both p<0.0001), while 
there was only a trend toward association between coronary artery disease and LGE 
(p=0.07; Table 15). On multivariable analysis, only female sex and LV mass index 
were associated with higher LGE (both p≤0.001; Table 15). In women, univariable 
analysis demonstrated that age (p=0.05), coronary artery disease (p=0.02), and LV 
mass index (p=0.007) were associated with higher LGE (Table 15). After multivariable 
adjustment, age and LV mass index continued to be associated with higher LGE (all 
p≤0.03), but there was only a trend towards an association with coronary artery 
disease (p=0.07; Table 15). Univariable analysis in men demonstrated that Vpeak 
(p<0.0001) and LV mass index (p<0.0001) were associated with higher LGE (Table 
2). On multivariable analysis, only LV mass index remained associated with higher 
LGE (p<0.0001), with a trend toward an association with Vpeak (p=0.09; Table 15). 
Including Zva instead of Vpeak showed an association for Zva and LV mass index 
(both p≤0.009) with higher LGE. The frequency-matched analysis showed that 
women with similar age, comorbidities as well as hemodynamic AS severity had 
similar amount of LGE [4.5 (2.5-7.6) vs. 3.2 (1.7-7.5) %, p=0.46] and non-infarct LGE 
[4.5 (2.3-7.6) vs. 3.0 (1.7-6.7) %, p=0.52] compared with men, despite higher LV mass 
index in men (Online Table 16). Results were similar when analyzed separately in 




Table 15. Univariable and Multivariable Analyses of the Predictors of Higher Late Gadolinium Enhancement. 
 
All Patients 
(n = 249) 
 
Men 
(n = 175) 
 
Women 
















 βeta ±SE p Value βeta ±SE p Value  βeta ±SE p Value βeta ±SE p Value  βeta ±SE p Value βeta ±SE p Value 





0.91 0.21±0.54 0.001  - - - -  - - - - 
Hypertension 0.02±0.53 0.71 -0.02±0.54 0.76  0.03±0.63 0.73 0.08±0.62 0.32  0.02±0.99 0.89 -0.24±1.09 0.07 
Diabetes -0.08±0.69 0.22 -0.06±0.62 0.31  -0.06±0.74 0.40 -0.02±0.66 0.77  -0.13±1.77 0.27 -0.18±1.58 0.08 
Coronary artery disease 0.12±0.52 0.07 0.10±0.52 0.11  0.07±0.58 0.36 0.04±0.57 0.58  0.27±1.32 0.02 0.20±1.24 0.07 
Vpeak, m/s 0.25±0.21 <0.0001 0.05±0.31 0.49  0.34±0.29 <0.0001 0.16±0.37 0.09  0.08±0.48 0.49 -0.18±0.56 0.19 
LV mass index, g/ m2 0.39±0.01 <0.0001 0.61±0.01 <0.0001  0.45±0.01 <0.0001 0.56±0.02 <0.0001  0.31±0.03 0.007 0.59±0.03 <0.0001 
βeta are standardized regression coefficient ± SE.  




Figure 24. Comparison of Late Gadolinium Enhancement between Women and Men 
According to Centre. Comparison of late gadolinium enhancement (LGE) between 
women and men (A) and non-infarct LGE (B) in the Quebec Centre, and non-infarct LGE 
in the Edinburgh Centre (C). 
 
 





5.4.3 Association between Sex and Expansion of Extracellular Volume Fraction 
As expected, LGE was associated with ECV fraction in the whole cohort as in each sex 
subset (whole cohort: r=0.35, p<0.0001; women: r=0.41, p=0.0003; men: r=0.35, 
p<0.0001). Compared with men, women presented higher ECV fraction in the whole 
cohort [29.0 (27.4-30.6) vs. 26.8 (25.1-28.7) %, p<0.0001] (Figure 20B) as well as in each 
hemodynamic AS severity stage (mild AS: [29.5 (26.8-32.5) vs. 26.4 (25.3-28.5) %, 
p=0.0004]; moderate AS: [28.7 (27.7-30.0) vs. 26.8 (25.0-29.1) %, p=0.002]; severe AS: 
[29.0 (27.7-30.1) vs. 26.8 (25.0-29.0)%, p=0.01]; Figure 24A). Furthermore, there was a 
significant effect of sex on the relationship between AS severity and ECV fraction 
(pancova<0.0001), suggesting a more pronounced impact of the AS-related pressure 
overload on LV fibrosis in women compared to men.  
When ECV fraction was analyzed according to the tertiles of LV mass index, defined by 
sex-specific thresholds, women presented significantly higher ECV fraction than men in 
the lower and upper tertiles (lower tertile: [30.3 (28.1-32.5) vs. 26.0 (24.7-28.2) %, 
p<0.0001]); mid tertile: ([28.0 (26.4-28.7) vs. 26.8 (25.0-28.4)%, p=0.11); and upper 
tertile ([29.6 (28.3-30.2) vs. 28.0 (25.6-30.3)%, p=0.01]) (Figure 24B). There was also an 




Figure 25. Comparison of Extracellular Volume Fraction between Women and Men 
According to Hemodynamic Severity of Aortic Valve Stenosis and Left Ventricular Mass 
Index. Comparison of ECV fraction between women and men in each class of severity of 
AS (A) and in each tertile of LV mass index (B). The figure shows that ECV fraction 
remains significantly higher in women as compared to men in each class of AS severity. 





Interestingly, after frequency-matching of men and women for age, comorbidities and 
hemodynamic AS severity, women still had higher ECV fraction [28.9 (27.3-30.3) vs. 27.2 
(25.0-29.2) %, p=0.002], but also higher ratio of mitral E-wave and e’ velocities (16.2±9.3 
vs. 12.6±7.1, p=0.02; Table 17).  
The analyses of ECV fraction according to sex within each center provided similar results 





Table 16. Frequency-Matched Characteristics of the Study Population according to Sex 
 All Patients 
(n = 112) 
Men 
(n = 56, 50%) 
Women 




Clinical   
Age, years 68 ± 12  68 ± 12 68 ± 12 0.98  
Body surface area, m2 1.83 ± 0.19 1.94 ± 0.17 1.73 ± 0.16 <0.0001  
Body mass index, kg/m2 28 ± 5 28 ± 4 28 ± 6 0.89  
Systolic blood pressure, mmHg 145 ± 23 145 ± 22 145 ± 24 0.89  
Diastolic blood pressure, mmHg 82 ± 12 83 ± 12 81 ± 13 0.58  
Hypertension, % 62 61 63 0.85  
Dyslipidemia, % 45 45 45 1.00  
Diabetes, % 9 9 9 1.00  
Coronary artery disease, % 20 20 20 1.00  
Creatinine, µmol/l 76 ± 15 83 ± 15 69 ± 12 <0.0001  
Hematocrit 0.40 ± 0.04 0.42 ± 0.04 0.38 ± 0.03 <0.0001  
NYHA functional class, %  
I 57 64 50 
0.19 
 
II 30 29 32  
III 11 5 16  
IV 2 2 2  
Medication  
ACEIs/ARBs, % 32 29 36 0.42  
Beta-blockers, % 29 29 29 1.00  
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Diuretics, % 28 36 20 0.06  
Statins, % 46 45 48 0.71  
Doppler-echocardiographic data  
Bicuspid aortic valve, % 25 27 23 0.63  
Peak aortic jet velocity, m/s 3.4 ± 0.9 3.3 ± 0.8 3.4 ± 1.0 0.77  
Mean transvalvular gradient, mmHg 27 ± 15 27 ± 13 27 ± 16 0.82  
Aortic valve area, cm2 1.01 ± 0.31 1.07 ± 0.31 0.96 ± 0.31 0.07  
Indexed aortic valve area, cm²/m2 0.55 ± 0.17 0.55 ± 0.15 0.55 ± 0.18 0.98  
AS severity, % 
 
 
Mild 45 43 46 
0.78 
 
Moderate 21 23 18  
Severe 35 34 36  
Valvulo-arterial impedance, 
mmHg/mL/m2 
4.3 ± 1.2 4.4 ± 1.2 4.2 ± 1.2 0.53  
Mean e’, cm/s 6.7 ± 2.1 7.1 ± 2.0 6.3 ± 2.1 0.06  
Mean E/e’ ratio 14.4 ± 8.4 12.6 ± 7.1 16.2 ± 9.3 0.02  
LV mass index, g/m2 108 (91 - 125) 115 (98 - 127) 101 (85 - 122) 0.06  
Relative wall thickness ratio 
0.57 (0.48 - 
0.67) 
0.55 (0.48 - 
0.65) 
0.57 (0.48 - 
0.67) 
0.98  
LV hypertrophy, % 54 51 57 0.56  
LV remodeling patterns, %  
Normal pattern 11 8 11 
0.43 
 
Concentric remodeling 36 42 32  
Concentric hypertrophy 52 51 53  
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Eccentric hypertrophy 2 0 4  
Cardiac magnetic resonance data  
End-diastolic volume index, ml/m2 69 (62 - 79) 73 (64 - 82) 68 (60 - 76) 0.05  
End-systolic volume index, ml/m2 22 (18 - 27) 23 (20 - 27) 22 (18 - 26) 0.09  
Stroke volume index, ml/m2 47 (41 - 54) 48 (42 - 56) 45 (40 - 52) 0.09  
LV ejection fraction, % 67 (63 - 71) 67 (64 - 70) 68 (62 - 72) 0.84  
LV mass index, g/m2 70 (59 - 86) 74 (62 - 92) 63 (56 - 80) 0.004  
LV mass/volume ratio 
0.99 (0.80 - 
1.31) 
0.98 (0.80 - 
1.41) 
1.01 (0.81 - 
1.25) 
0.34  
LV hypertrophy, % 29 29 29 1.00  
LV remodeling patterns, %  
Normal pattern 60 57 63 
0.80 
 
Concentric remodeling 12 14 9  
Concentric hypertrophy 24 25 23  
Eccentric hypertrophy 4 4 5  
Presence of LGE, % 34 38 30 0.43  
LGE, % 4.0 (1.9 - 7.6) 3.2 (1.7 - 7.5) 4.5 (2.5 - 7.6) 0.46  
Presence of non-infarct LGE, % 31 36 27 0.31  
Non-infarct LGE, % 3.4 (1.7 - 7.5) 3.0 (1.7 - 6.7) 4.5 (2.3 - 7.6) 0.52  
Extracellular volume fraction  
Mean, % 28.1 ± 2.9 27.2 ± 2.9 29.0 ± 2.9 0.002  
Median, % 
28.4 (25.6 - 
29.8) 
27.2 (25.0 - 
29.2) 





Value are mean±SD, % or median [25th – 75th percentiles]. 
ACEIs = angiotensin-converting-enzyme inhibitors; ARBs = angiotensin receptor blockers; LGE = late 





Figure 26. Comparison of Extracellular Volume Fraction between Women and Men 
According to Centre. Comparison of extracellular volume fraction between women and 





5.4.4 Factors Associated with Higher Extracellular Volume Fraction 
In the whole cohort, age (p=0.03), female sex (p<0.0001), and hematocrit (p<0.0001) 
were significantly associated with ECV fraction (Table 18). After multivariable adjustment, 
female sex (p<0.0001), hematocrit (p<0.0001), and LV mass index (p<0.0001) were 
significantly associated with ECV fraction (Table 18). There was a trend toward 
significant association for age (p=0.07) (Table 18). In women, the univariable and 
multivariable analyses revealed no significant association between the explanatory 
variables and higher ECV fraction (Table 18), whereas in men, univariable analysis 
demonstrated that age, hematocrit, Vpeak, and LV mass index were associated with ECV 
fraction (all p≤0.02; Table 18). On multivariable analysis, age, hematocrit and LV mass 













Table 17. Univariable and Multivariable Analyses of the Predictors of Higher Extracellular Volume Fraction 
 
All Patients 
(n = 249) 
 
Men 
(n = 175) 
 
Women 
















 βeta ±SE p Value βeta ±SE p Value  βeta ±SE p Value βeta ±SE p Value  βeta ±SE p Value βeta ±SE p Value 
Age, years 0.14±0.02 0.03 0.13±0.02 0.07  0.21±0.02 0.006 0.19±0.02 0.03  0.06±0.03 0.63 0.16±0.04 0.38 
Female sex 0.29±0.43 <0.001 0.30±0.49 <0.001  - - - -  - - - - 
Hypertension -0.03±0.43 0.65 -0.10±0.45 0.12  0.05±0.50 0.51 -0.03±0.51 0.69  -0.10±0.77 0.40 -0.19±1.01 0.20 
Diabetes 0.04±0.57 0.48 0.05±0.52 0.41  0.11±0.60 0.16 0.09±0.55 0.21  0.03±1.39 0.82 -0.04±1.45 0.77 




0.92  0.03±1.06 0.80 0.04±1.11 0.76 
Creatinine clairance -0.12±0.01 0.06 -0.07±0.01 0.24  -0.10±0.01 0.18 -0.07±0.01 0.31  -0.07±0.02 0.57 -0.08±0.03 0.61 
Hematocrit -0.39±4.67 <0.001 -0.29±5.07 <0.001  -0.37±5.43 <0.001 -0.27±5.51 <0.001  -0.18±12.2 0.12 -0.19±12.8 0.12 
Vpeak, m/s 0.05±0.21 0.48 -0.08±0.25 0.29  0.17±0.24 0.02 -0.03±0.30 0.78  -0.15±0.37 0.21 -0.12±0.53 0.47 
LV mass index, g/ m2 0.11±0.01 0.08 0.42±0.01 <0.001  0.31±0.01 <0.001 0.47±0.01 <0.001  -0.03±0.02 0.78 0.28±0.03 0.10 
βeta are standardized regression coefficient ± SE. Abbreviations as in Table 14 and 15. 
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Further analyses including correlates of ECV fraction are presented in Table 18. There 
was significant association between higher ECV fraction and E/e’ ratio (p=0.004) and 
NYHA class (p=0.04) in univariable analysis (Table 18). However, in multivariable 
analysis E/e’ ratio was not significantly (p=0.61) associated with ECV%, whereas there 




Table 18. Correlates of Extracellular Volume Fraction. 
 Univariable Analysis  Multivariable Analysis  
 βeta Coeff. ± SE p value  βeta Coeff. ± SE p value  
Age, years 0.14±0.02 0.03  0.14±0.02 0.05  
Female sex 0.29±0.43 <0.0001  0.31±0.51 <0.0001  
Hypertension -0.03±0.43 0.65  -0.10±0.45 0.12  
Diabetes 0.04±57 0.48  0.05±0.53 0.41  
Coronary artery disease -0.03±0.43 0.64  0.03±0.43 0.68  
Creatinine clairance -0.12±0.01 0.06  -0.06±0.01 0.37  
Hematocrit -0.39±4.67 <0.0001  -0.28±5.19 <0.0001  
NYHA functional class 0.13±0.27 0.04  0.09±0.28 0.14  
Peak aortic jet velocity, m/s 0.05±0.21 0.48  -0.11±0.27 0.16  
E/e’ ratio 0.18 ±0.03 0.004  -0.03 ±0.03 0.61  
LV mass index, g/m² 0.11 ±0.009 0.08  0.45 ±0.01 <0.0001  
 
βeta coeff. are standardized regression coefficient.  





5.5 Discussion  
In this bicenter CMR prospective study of patients with AS, we have demonstrated that 
despite having smaller LV mass index, women have similar amounts of LGE but a larger 
ECV fraction across the range of disease severities. Moreover, this expansion of 
myocardial fibrosis appeared to be less dependent on LV mass than occurs in men. 
5.5.1 Noninvasive Assessment of Myocardial Fibrosis in AS 
Several studies have reported an association between expansion of ECV, a surrogate 
marker of diffuse myocardial fibrosis, and adverse cardiac events in patients with AS (C. 
W. L. Chin et al., 2017; Wong et al., 2012). As opposed to ECV, LGE is a marker of the 
expansion of dense focal extracellular matrix deposition and has been primarily related 
to ischemic heart disease (Ambale-Venkatesh & Lima, 2014). However, recent findings 
showed that a non-ischemic pattern of focal fibrosis is also detected using LGE and this 
pattern is mainly related to chronic pressure overload conditions such as AS or systemic 
arterial hypertension (Calvin W. L. Chin et al., 2016). We previously reported that mid-
wall fibrosis pattern is present in 38% of patients with moderate to severe AS and is 
independently associated with increased risk of mortality (Dweck et al., 2011). However, 
few studies have examined the respective determinants of ECV and LGE fractions in 




5.5.2 Factors associated with myocardial fibrosis in AS 
Our analysis showed that LV mass index was the strongest determinant for both higher 
ECV fraction and higher amount of LGE. This is consistent with previous studies that 
have demonstrated an association between an advanced hypertrophic response and 
myocardial fibrosis as assessed by CMR (Shah et al., 2014). Moreover, histological 
investigations have demonstrated that fibrosis is a key pathological characteristic of the 
LV hypertrophic response to AS  and an important driver to its decompensation and the 
transition to heart failure (Bull et al., 2013; Treibel, Lopez, et al., 2018). In the present 
study, traditional cardiovascular risk factors such as hypertension and coronary artery 
disease were not independently associated with diffuse or focal myocardial fibrosis. The 
lack of association between hypertension and the surrogate CMR markers of fibrosis 
could be related to the fact that the vast majority of patients with diagnosis of 
hypertension were treated with anti-hypertensive medications. In this study, few patients 
presented infarct-pattern of fibrosis and such pattern was also excluded from the analysis 
of LGE in one center, which could explain why coronary artery disease was not 
independently associated with higher ECV fraction or presence of LGE. Consistent with 
a previous study, we reported no association between hemodynamic severity of AS and 
both patterns of myocardial fibrosis (C. W. L. Chin et al., 2017). This suggests that the 
ability of the LV to adapt to AS-related pressure overload may vary from patient to patient, 
and is not solely determined by AS severity. An association was also observed between 
older age and higher ECV fraction, but not with LGE. The association between age and 
ECV fraction has been reported in previous studies (C.-Y. Liu et al., 2013; Ugander et 
al., 2012). This association could reflect age-dependent mechanisms of myocyte loss 
and increased proliferation of extracellular matrix and collagen (i.e. cardiac fibroblasts) 
(Keller & Howlett, 2016). The present study also reported a trend for association between 
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diabetes and higher ECV fraction. Increased ECV fraction has been previously reported 
in patients with diabetes (Wong et al., 2014). Indeed, the metabolic ‘milieu’ of diabetic 
patients may predispose to the expansion of extracellular matrix through the stimulation 




5.5.3 Sex Differences in LV Remodeling and Extent of Myocardial Fibrosis 
Several studies have reported sex-related differences in the LV response to pressure 
overload (R. Capoulade et al., 2017; Dana Cramariuc et al., 2008; Dobson et al., 2016; 
Pamela S. Douglas et al., 1998; Petrov et al., 2014) . The present study provides further 
evidence to support the fundamental difference in LV remodeling between women and 
men with AS. Indeed, despite similar AS severity and LV global hemodynamic load as 
well as more favourable cardiovascular risk profile, women presented lower indexed LV 
mass but paradoxically a larger extent of diffuse myocardial fibrosis (ECV) and a similar 
amount of replacement myocardial fibrosis (LGE). Moreover, after comprehensive 
multivariable analyses, female sex remained an important independent determinant of 
higher ECV fraction and LGE. Noteworthy, the greater expansion of ECV fraction 
observed in women was also accompanied by higher estimated LV filling pressure (E/e’ 
ratio), which may be related to reduced LV compliance and more advanced LV diastolic 
dysfunction in women (Dunlay, Roger, Weston, Jiang, & Redfield, 2012). A previous 
analysis of the Multi-Ethnic Study of Atherosclerosis also reported higher ECV fraction in 
women compared with men (31). In a recent study including 100 patients with severe AS 
undergoing AVR, women had smaller LV mass but similar amount of replacement 
myocardial fibrosis as assessed by LGE (Dobson et al., 2016)(38). Nevertheless, our 
findings differ from those of previous studies suggesting a greater propensity of men to 
develop myocardial fibrosis (Montalvo et al., 2012; Weinberg et al., 1999). In addition, a 
recent study including 168 patients with severe symptomatic AS reported higher LGE 
fraction as well as ECV fraction indexed to LV end diastolic volume in men, but similar 
extent of ECV fraction between sexes (Treibel, Kozor, et al., 2018). However, this 
previous study included only patients with severe AS planned for AVR in which men 
harbored a high proportion (>70%) of LVH. This could explain, at least in part, the larger 
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fibrotic burden observed in men versus women in this previous study. Similarly, in a 
recent study by Singh et al including patients with mainly severe AS, men presented 
larger LGE and indexed ECV fraction compared to women (Singh et al., 2017). However, 
despite the larger fibrotic burden reported in men, women presented higher incidence of 
symptoms.  The main added value of our study is that we compared the expansion of 
LGE and ECV in men versus women subsets having similar cardiovascular risk profile 
and similar distribution of age, AS severity, and degree of LV hypertrophy/remodeling. 
The susceptibility to fibrosis has been mostly attributed to sex hormones such as 
estrogen, which could exert a cardioprotective effect in the female hearts (Patten et al., 
2004; Pedram, Razandi, Narayanan, & Levin, 2016; Satoh et al., 2007). However, most 
patients with AS are >60 years old and the effect of sex hormones on profibrotic process 
in post-menopausal women remains unknown. On the other hand, chronic activation of 
the renin-angiotensin-aldosterone system is thought to play a key role in the cardiac 
remodeling as well as profibrotic processs (Keller & Howlett, 2016). Some evidence 
suggests that these processes may predominantly affect the female hearts and thus may 
explain, at least in part, the sex differences observed in the LV remodeling and expansion 
of diffuse myocardial fibrosis (Greiten, Holditch, Arunachalam, & Miller, 2014). Further 
studies are needed to determine the underlying mechanisms for the sex differences in 
the magnitude of myocardial fibrosis in patients with AS. 
This study is the first to perform separate analyses of explanatory variables for increased 
diffuse and replacement fibrosis in women and men. In women, there were no variables 
associated with higher ECV fraction, but interestingly older age, presence of coronary 
artery disease and LV mass index were associated with higher LGE. The latter findings 
could reflect the presence of impaired coronary microcirculation related to the LV 
hypertrophic response and increased LV transmural pressures associated with AS. 
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Some studies reported that among patients with AS, the coronary microcirculation is 
more frequently impaired in women (Reis et al., 2001). Hence, in older women with AS, 
repetitive myocardial ischemia related to chronic reduction of the coronary 
microcirculation could lead to apoptosis of myocyte cells and ultimately to the 
development of replacement fibrosis. In men, older age and higher LV mass index were 
associated with higher ECV fraction; whilst LV mass index was the strongest variable 
associated with higher LGE. Therefore, in men, the LV hypertrophic response due to 
chronic pressure overload appears to be the main factor for the adverse LV remodeling 
and subsequent fibrosis. This is consistent with a previous study that demonstrated a 
maladaptive LV remodeling associated with the activation of profibrotic markers 
predominantly in men with AS (Kararigas et al., 2014). The association of older age with 
higher ECV fraction in men has been previously reported (31). This is also supported by 
histological evidence suggesting that the ageing process associated with myocyte cell 
loss affects the myocardium of men but not women (Olivetti et al., 1995). All together 
these findings strongly support the existence of sex differences in the LV remodeling as 





5.5.4 Clinical implications 
The noninvasive assessment of the expansion and pattern of myocardial fibrosis by CMR 
could help to determine the optimal timing of AVR in asymptomatic patients with severe 
AS. Future studies are needed to determine whether an earlier intervention based on the 
extent of diffuse fibrosis may be associated with better outcomes in these patients. 
However, the results of the present study suggest that women may develop greater 
extent of diffuse fibrosis than men independently of the degree of stenosis severity. 
Further studies are still needed to determine whether women larger expansion of diffuse 
myocardial fibrosis as measured by CMR could be a potential trigger for early valve 
replacement in women with severe AS.  
These findings also suggest that adjuvant pharmacotherapy targeting pro-fibrotic 
pathways, such as inhibitors of renin-angiotensin system might help to improve outcomes 





5.5.5 Study limitations 
The present study is a cross-sectional analysis and thus have inherent limitations related 
to this type of design. In particular, the sex-related differences in LV remodeling and 
expansion of fibrosis reported in this study need to be confirmed by further studies with 
a longitudinal design. In addition, this study was not a prespecified analysis from our two 
prospective studies. The rationale for this study is, however, supported by recent 
evidences suggesting substantial sex-related differences in the pathophysiology of AS 
(Clavel et al., 2013; Hervault & Clavel, 2018; Simard et al., 2017). The CMR exams were 
performed with scanners from different vendors and there were some minor differences 
in the acquisition protocols. Moreover, the areas of infarction were excluded from LGE 
analysis by one center and included by the other. However, these limitations did not affect 
the main findings of this study. Furthermore, an analysis stratified according to the centre 
revealed that the results with respect to the sex-differences in LV remodeling and fibrosis 
were similar in the two centres, which indirectly supports the generalizability of the results 
of this study.  
ECV fraction is not specific to fibrosis, thus it is possible that larger ECV fraction in women 
could be related to many other factors including the intravascular compartment rather 
than interstitial expansion due to diffuse myocardial fibrosis (Mahmod et al., 2014). 
However, multiple histological studies have demonstrated that T1 mapping parameters 
are closely correlated to myocardial fibrosis as quantified by biopsy, suggesting that ECV 
fraction is a non-invasive surrogate marker of fibrosis. Whereas, similar histological 








Chapter 6. Feasibility of coronary 18F-sodium fluoride PET 
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We assessed the feasibility of utilizing previously acquired computed tomography 
angiography (CTA) with a subsequent PET-only scan for the quantitative evaluation of 
18F-NaF PET coronary uptake. 
Forty-five patients (age 67.1±6.9 years, 76% males) underwent CTA (CTA1) and 
combined 18F-NaF PET/CTA (CTA2) imaging within 14[10,21] days. We fused CTA1 from 
visit one with 18F-NaF PET from the second visit (PET) and compared visual pattern of 
activity, maximal standard uptake values (SUVmax) and target to background (TBR) 
measurements on (PET/CTA1) fused versus hybrid (PET/CTA2) data. 
On PET/CTA2, 226 coronary plaques were identified. Fifty-eight coronary segments from 
28(62%) patients had high 18F-NaF uptake (TBR>1.25), whilst 168 segments had lesions 
with 18F-NaF TBR ≤1.25. Uptake in all lesions was categorized identically on co-
registered PET/CTA1. There was no significant difference in 18F-NaF uptake values 
between PET/CTA1 and PET/CTA2 (SUVmax: 1.16±0.40 vs. 1.15±0.39,p=0.53; 
TBR:1.10±0.45 vs. 1.09±0.46,p=0.55). The intraclass correlation coefficient for SUVmax 
and TBR was 0.987 (95%CI 0.983 to 0.991) and 0.986 (95%CI 0.981 to 0.992). There 
was no fixed or proportional bias between PET/CTA1 and PET/CTA2 for SUVmax and 
TBR. Cardiac motion correction of PET scans improved reproducibility with tighter 95% 
limits of agreement (±0.14 for SUVmax and ±0.15 for TBR vs. ±0.20 and ±0.20 on 
diastolic imaging;p<0.001). 
Coronary CTA/PET protocol with CTA first followed by PET-only allows for reliable and 
reproducible quantification of 18F-NaF coronary uptake. This approach may facilitate 
selection of high-risk patients for PET-only imaging based on results from prior CTA, 




Coronary computed tomography angiography (CTA) has emerged as powerful method 
for accurately assessing coronary artery stenosis and characterizing coronary 
atherosclerosis, providing a wealth of diagnostic and prognostic information. These 
anatomic measurements, however, do not provide insight into the activity of the disease 
and fail to depict the biological processes implicated in plaque rupture (Dweck, Williams, 
Moss, Newby, & Fayad, 2016). Assessment of plaque activity may improve the patient 
risk prediction provided by CTA. Recently, it was shown that 18F-sodium fluoride (18F-
NaF) PET imaging, providing an assessment of developing microcalcification within 
coronary plaque, might provide such an assessment (M. R. Dweck, M. W. L. Chow, et 
al., 2012). 18F-NaF PET imaging, however, requires co-registered CTA images for 
precise anatomical localization of 18F-NaF within coronary plaques (Joshi et al., 2014; 
Kitagawa et al., 2017; Thomas & Haraszti, 2014).  Increased 18F-NaF uptake has been 
observed with hybrid PET/CTA to localize in regions of recent plaque rupture in patients 
with acute myocardial infarction as well as in coronary plaques with high-risk features on 
intravascular ultrasound in patients with stable coronary artery disease (Joshi et al., 
2014). Other PET tracers targeting different aspects of coronary plaque activity are 
increasingly becoming available (Tarkin et al., 2017).   
The standard approach used to date for coronary 18F-NaF PET/CT has several limitations 
which hamper its practical implementation into a meaningful clinical workflow (Thomas & 
Haraszti, 2014). Studies to date have utilized CTA acquired using hybrid PET/CTA 
scanner during the same imaging session (Joshi et al., 2014; Oliveira-Santos et al., 2017; 
T. A. Pawade et al., 2016; Vesey et al., 2017). This approach, however, does not lend 
itself to patient selection for imaging based on prior CTA findings. If the 18F-NaF imaging 
becomes part of a clinical assessment strategy, it is likely that patients would be selected 
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for 18F-NaF PET based on the findings of a CTA performed for clinical purposes 
(Motoyama et al., 2015; Nerlekar et al., 2018). Another key limitation of the single-session 
hybrid PET/CTA protocol is that it may not allow for the use of optimal CT equipment for 
CTA which may only be available on standalone CT scanners. Finally, the use of hybrid 
PET/CTA requires multi-faceted staff expertise in both PET and coronary CTA during a 
single session. To address these limitations, we assessed the feasibility of utilizing a 
previously acquired CTA with a subsequent PET-only coronary scan for the evaluation 





6.3.1 Study Population 
We analyzed scans of patients with stable coronary artery disease who first underwent 
CTA (CTA1) followed by a hybrid 18F-NaF PET of the coronary arteries with second CTA 
(CTA2). We analyzed data from two cohorts of patients. Cohort 1 consisted of 20 subjects 
who underwent CTA 1 and hybrid PET/CTA on the same scanner within 14 days. Cohort 
2 consisted of 25 patients whose initial CTA acquisition was performed on a standalone 
CT and had hybrid PET/CTA in a median of 17 days [14-37] after CTA 1. All subjects had 
angiographically proven multivessel coronary artery disease (defined as at least two 
major epicardial vessels with any combination of either >50% luminal stenosis, or 
previous revascularization (percutaneous coronary intervention or coronary artery 
bypass graft surgery). Exclusion criteria included an acute coronary syndrome within the 
previous 12 months, renal dysfunction (eGFR ≤30 mL/min/1.73 m2) and contraindication 
to iodinated contrast agents. The study was approved by the investigational review 
board, and written informed consent was obtained from all subjects. Study data can be 




6.3.2 Image acquisition and reconstruction 
6.3.2.1 Initial Coronary CTA 
Cohort 1 had the CTA1 scan performed on the 128-slice Biograph mCT scanner 
(Siemens Medical Systems, Erlangen, Germany) using the following settings: 330 ms 
rotation time, 100 or 120kV (depending on body mass index), 160-245 mAs. Cohort 2 
underwent CTA1 on a dual source CT scanner (Definition; Siemens Medical Systems, 
Erlangen, Germany). The scan parameters were as follows: 330 ms gantry rotation time, 
reference tube current of 400 mAs per rotation, and a peak tube voltage of 120 kV. 
Patients in both cohorts received beta blockers (orally or intravenously) to achieve a 
target heart rate <60beats/min and sublingual nitrates. A bolus of 60-100 mL of contrast 
(300-400 mgI/mL; Iomeron) was power injected intravenously at 6 mL/s, after 
determining the appropriate trigger delay with a test bolus of 20 mL contrast. Transverse 
images were reconstructed with 0.75/0.6 mm slice thickness, 0.4 mm increment and a 




6.3.3.2 18F-NaF PET /CTA 
Prior to the PET imaging, 250 MBq of 18F-sodium fluoride was injected intravenously and 
patients rested in a quiet environment for 60 minutes. Because emission scanning was 
followed by CTA during that hour subjects were administered with beta-blockers. Imaging 
was performed on 2 different PET/CTA scanners 128-slice Biograph mCT, Siemens 
Medical Systems (Cohort 1) and 128-slice Discovery 710 (GE Healthcare, Milwaukee, 
WI, USA (Cohort 2). In both cohorts low-dose CT attenuation correction scan (120 kV, 
50 mAs, 3 mm slice thickness), a 30-min single bed position PET acquisition with ECG-
gating in list mode was performed.  Image corrections were applied for attenuation, dead 
time, scatter, and random coincidences. In Cohort 1 PET data were reconstructed using 
a Siemens implementation of iterative reconstruction algorithm (Ultra-HD; with Point 
Spread function correction and time of flight reconstruction, matrix 256, Gaussian filter of 
5 mm and 2 iterations and 21 subsets). In Cohort 2 data were reconstructed with GE 
implementation of iterative reconstruction algorithm (Sharp IR with Point Spread function 
correction and time of flight reconstruction, matrix 256, Gaussian filter of 5 mm and 4 
iterations and 24 subsets)(Mhairi K. Doris et al., 2018). 
In both cohorts, a second CTA (CTA2) was obtained on the hybrid scanner with patient 
remaining on the table in the same position as during emission scanning. In Cohort 1 
(Siemens Biograph mCT) imaging was performed on the same scanner and according 
to the same protocol as CTA1. In Cohort 2 (GE Discovery 710) CTA2 was acquired with 
rotation time 350ms, tube voltage 120 kV, tube current 150-250 mAs) and reconstructed 




6.3.4 Image analysis 
6.3.4.1 Cardiac motion correction 
In addition to assessing diastolic PET data, we also analyzed cardiac motion corrected 
18F-NaF PET images. This technique compensates for coronary artery motion by aligning 
all cardiac gates to the reference gate (the one which is used for PET and CTA co-
registration - see below). This approach was shown to reduce image noise and improve 
target to background ratios(Rubeaux, Joshi, Dweck, Fletcher, Motwani, Thomson, 
Germano, Dey, Li, et al., 2016). To perform cardiac motion correction in the first step 
coronary artery centerlines were extracted from coronary CTA by applying a vessel 
tracking algorithm based on Bayesian maximal paths using dedicated software 
(Autoplaque version 2.0, Cedars Sinai Medical Center). Secondly, a diffeomorphic mass-
preserving image registration algorithm was used to align the gates of PET data to the 
end-diastolic (reference) gate. As a result, all gates were summed back together 





6.3.4.2 Image registration 
Image registration was performed using FusionQuant Software (Cedars Sinai Medical 
Center, Los Angeles). PET and CTA reconstructions were reoriented, fused and carefully 
co-registered in all 3 planes (a X-Y-Z translation was performed) as described previously 
(T. A. Pawade et al., 2016; Vesey et al., 2017). Key points of reference were the sternum, 
vertebrae, blood pool in the left and right ventricle (based upon high 18F-fluoride activity 
in the blood pool in comparison to the surrounding myocardium) and the great vessels. 
We fused CTA1 from the first visit with PET and also separately fused CTA2 with PET.  
Although CTA2 was obtained at the same imaging session as PET on the hybrid scanner, 
co-registration was performed to account for any possible patient motion between PET 
and CTA2. Both CTA1 and CTA2 were co-registered to PET in an identical fashion 
(Figure 25). This way, we could compare directly a clinical protocol using a CTA scan 
acquired up to 4 weeks before a PET-only 18NaF scan, with a standard hybrid 18NaF-CTA 
protocol in individual patients. To assess interobserver reproducibility of the CTA and 
PET registration both datasets of cohort 1 patients were fused and reoriented by 2 




6.3.4.3 18F-NaF PET quantification   
After registration of CTA1 and CTA2 to the PET, plaque activity was measured by 
defining 3-dimensional volumes of interest (spheres with a 5mm radius) around coronary 
plaques on both the fused PET/CTA2 and PET/CTA1 images. The maximum standard 
uptake value (SUVmax) was recorded from each coronary segment that had a diameter 
of at least 2 mm and included coronary atheroma with a >25% stenosis on CTA and had 
not been stented previously. Background blood pool activity was measured by delimiting 
a spherical volume of interest (radius 10-15 mm depending on atrium size) in the middle 
of the left atrium. Target to background ratios (TBRs) were calculated by dividing 
SUVmax by averaged background blood pool activity. To categorize lesions according 
to PET tracer uptake, we utilized the previously validated methodology (M. R. Dweck, M. 
W. L. Chow, et al., 2012; Joshi et al., 2014). In brief, plaques were considered to have 
high uptake if they presented with focal tracer uptake which followed the course of the 
vessel over more than one slice and their TBR on diastolic imaging was >1.25. Image 
noise was defined as the mean standard deviation of the blood pool activity. Signal to 
noise ratio was defined as the plaque SUVmax divided by image noise. To assess 
interobserver reproducibility of the uptake measurements on the PET/CTA1 datasets 
coronary 18F-NaF activity of cohort 1 patients was assessed by 2 experienced observers 




6.3.4.4 Reproducibility analysis 
Image analysis of PET/CTA1 and PET/CTA2 was carried out on diastolic and motion 
corrected images. To limit the potential for recall bias between PET/CTA1 and 
PET/CTA2, PET/CTA1 was anonymized against PET/CTA2 and there was at least a 
three-week interval between reading PET/CTA1 and PET/CTA2 images. For each scan, 
PET registration and regions of interest were saved using the reference CTA and the 
same registration position so that the same regions of interest could be measured in the 
diastolic and motion corrected images. Reproducibility was defined as the difference in 





Figure 27. Utilization of prior coronary CT angiography for the assessment 18F-NaF PET 
coronary uptake. We fused (orange arrow) the CTA from the first visit (CTA1) with an 18F-
NaF PET from the second visit (PET). The PET/CTA imaging session comprised the 
acquisition of a low-dose attenuation correction scan (AC) followed by a 30min long PET 





6.3.5 Statistical Analysis 
Data was tested for normality using Shapiro Wilks test. Continuous variables were 
expressed as mean ±SD or median [interquartile range] and compared with paired 
Student t or Wilcoxon signed-rank test where appropriate. We presented all categorical 
variables as percentages and used the chi-square test for comparison. We used Bland-
Altman plots to visualize reproducibility of measurements. The 95% normal range for 
differences between sets of SUV and TBR measurements (the limits of agreement) were 
estimated by multiplying the SD of the mean difference by 1.96 (W. A. Weber et al., 
1999). Intra-class correlation coefficients with 95% confidence intervals (CIs) were 
calculated for PET/CTA1 vs. PET/CTA2 scan variation. The Pitman-Morgan test was 
used to compare the homogeneity of variance between uptake measurements derived 
from diastolic gate and motion corrected datasets. In our per lesion analysis we assumed 
independence of lesions within patients. A 2-sided p value <0.05 was regarded as 
statistically significant. Statistical analysis was performed with SPSS software (version 





A total of 45 patients (age 67.1±6.9 years, 76% males) underwent CTA1 and a 
subsequent PET/CT with CTA2 at a median of 14 [10,21] days. All patients had 




Table 19. Patients baseline clinical characteristics 
 Cohort 1, n=20 Cohort 2, n=25 Study population, 
n=45 
Demographics  
Age (years) 69.5±7.3 65.0±6.1 67.1±6.9 
Gender (male) 17 (85%) 17 (68%) 34 (76%) 
Height (cm) 173.0±9.4 168.0±6.4 170.3±8.7 
Weight (kg) 82.9±17.1 73.9±14.8 78.1±16.2 
Cardiovascular risk factors  
Diabetes  2 (10%) 5 (20%) 7 (16%) 
Hyperlipidemia 20 (100%) 8 (32%) 28 (62%) 
Hypertension 14 (70%) 15 (60%) 29 (64%) 
Tobacco use 14 (70%) 7 (28%) 21 (47%) 
Family history of 
coronary heart disease 
12 (60%) 4 (16%) 16 (36%) 
Peripheral vascular 
disease 
1 (5%) 1 (4%) 2 (4%) 





6.4.1 Image registration 
Compared to PET/CTA2 registration, PET/CTA1 registration required larger spatial 
adjustments in all three axes (0.5 [0.0, 1.5] vs 12.6 [2.5, 21.8] mm, p<0.001; 1.4 [0.0, 2.9] 
vs 6.3 [1.5, 14.1] mm, p=0.007; 3.2 [0.6, 5.9] vs 15.9 [5.1, 30.3] mm, p= 0.001; for the x, 
y, z axis respectively) (Figure 26A). The intraclass correlation coefficient for spatial 
adjustments between two observers was 0.92 (95% CI 0.87 to 0.95) for PET/CTA2 and 
0.99 (95% CI 0.993 to 0.997) for PET/CTA1 (Figure 26D). There was no fixed or 
proportional bias between observers with limits of agreement of ±4.5mm for both the 
hybrid and the prior CTA dataset (Figure 26). Despite the need for larger adjustments of 
PET/CTA1 there was no significant difference in the reproducibility of adjustments 
between both datasets (p=0.76). 
 
Figure 28. Co-registration of 18F-NaF PET and CTA data. Boxplots presenting the 
translational adjustments in 3 axes (X,Y,Z) made to the PET images to align the two 
datasets for CTA (coronary CT angiography) acquired during hybrid PET/CTA session 
(Hybrid) and for  prior-CTA fused with PET-only 18F-NaF scan (Prior CTA). The prior CTA 
(PET/CTA1) dataset required bigger adjustments than the hybrid – single imaging 
session (PET/CTA2) dataset (all p<0.01) (A). Bland Altman plots presenting the 
interobserver variability of the co-registration adjustments of the hybrid (B) and prior CTA 
(C) datasets. There was no significant difference in the reproducibility of adjustments for 
hybrid vs prior datasets (p=0.76). Scatter plot presenting the co-registration adjustments 






6.4.2 18F-NaF PET quantification 
Twenty-eight (62%) patients had high 18F-NaF coronary uptake on PET/CTA2. Fifty-eight 
coronary segments showed high 18F-NaF uptake (TBR>1.25). The remaining 168 
segments with at least a 25% CTA stenosis, had PET TBR measurements ≤ 1.25. On 
PET/CTA1, all interrogated segments were classified identically as on PET/CTA2 





Figure 29. The assessment of coronary 18F-NaF uptake on hybrid (PET/CTA2) and prior 
CTA (PET/CTA1). Both datasets were motion corrected after registration of CTA to PET. 
For the hybrid acquisition the required adjustments were 0.5, 2.5 and 0mm in the x,y and 
z axis respectively. For prior CTA dataset PET had to be moved by 2.5, 3 and 5mm in 
the corresponding axes. Lesions with increased tracer uptake were identified in the left 
main, lesion TBR 1.56 and 1.55 (A and A’) and proximal right coronary artery, lesion TBR 






6.4.3 Diastolic imaging 
There was no significant difference in SUVmax measurements across all identified 
lesions (n=226) on PET/CTA2 compared to PET/CTA1 (1.16±0.40 vs 1.15±0.39, 
p=0.53). Importantly, no significant difference was found when the TBR>1.25 and 
TBR<1.25 lesions were compared separately (1.71±0.44 vs 1.72±0.45, p=0.47 and 
1.03±0.17 vs 1.05±0.18, p=0.48). In a similar fashion, there were no significant 
differences in measurements of coronary TBR (1.10±0.45 vs 1.09±0.46, p=0.55) or the 
signal to noise ratio (25.7±12.6 vs. 25.2±11.9, p=0.49).  
6.4.4 Motion correction 
After applying motion correction, the signal to noise ratio improved when compared to 
diastolic imaging (25.2±11.9 vs 30.8±17.2, p=0.01). On motion corrected images, 
SUVmax and TBR showed no significant difference between PET/CTA1 and PET/CTA2 
(all p>0.40;). The intraclass correlation coefficient for uptake measurements in cohort 1 
patients between two independent observers was 0.987 (95% CI 0.96 to 0.99) for 





Figure 30. Interobserver variability of uptake measurements on prior CTA (PET/CTA1). 
Scatter plots and Bland Altman plots of prior CTA (PET/CTA1) SUVmax (a, c) and TBR 
(b, d) measurements of lesion with (red) and without (blue) increased tracer uptake. 





6.4.5 Reproducibility of measurements  
On diastolic imaging the intraclass correlation coefficient for SUVmax and TBR between 
PET/CTA1 and PET/CTA2 measurements was 0.987 (95% CI 0.983 to 0.991) and 0.986 
(95% CI 0.981 to 0.991). There was no fixed or proportional bias between PET/CTA1 
and PET/CTA2 with limits of agreement of ±0.20 for SUVmax and ±0.20 for TBR 
measurements. On motion corrected images the intraclass correlation coefficients for 
SUVmax and TBR values on PET/CTA1 and PET/CTA2 was 0.991 (95% CI 0.988 to 
0.994) and 0.992 (95% CI 0.989 to 0.994). Motion correction improved the reproducibility 
of measurements between PET/CTA1 and PET/CTA2. Compared to diastolic imaging, 
the limits of agreement decreased from ±0.20 to ±0.14 for SUVmax and from ±0.20 to 





Figure 31. SUVmax measurements. Scatter plots and Bland Altman plots of prior CTA 
(PET/CTA1) and hybrid (PET/CTA2) SUVmax values for diastolic gate (a, c) and motion 
corrected (b, d) data. SUVmax measurements of lesion with (red) and without (blue) 
increased tracer uptake are shown. Motion corrected analysis resulted in lower variation 
of the of SUVmax measurements, as compared to the diastolic gate analysis (p<0.001). 






Figure 32. TBR measurements. Scatter plots and Bland Altman of prior CTA (PET/CTA1) 
and hybrid (PET/CTA2) TBR values for diastolic gate (a, c) and motion corrected (b, d) 
data. TBR measurements of lesion with (red) and without (blue) increased tracer uptake 
are shown. Motion corrected analysis resulted in reduced variation of TBR 
measurements compared to the diastolic gate imaging (p<0.001). TBR= target to 






Figure 33. Examples of coronary 18F-NaF uptake on hybrid (PET/CTA2) data (left 





In this multivendor and multicenter study, we report how utilizing a previously acquired 
CTA with a subsequent standalone PET-only coronary scan can be used for the 
evaluation of coronary 18F-NaF PET uptake. On a population comprised of patients who 
underwent repeat CTA studies on the same PET/CT scanner (cohort 1) and a separate 
subset that had the initial CTA acquired on a solely CT machine (cohort 2) we show that 
a prior CTA and subsequent PET-only approach enables equivalent categorization of 
plaques with increased 18F-NaF activity and accurate quantification of PET uptake. We 
demonstrate that staged coronary PET and CTA protocols can reliably and reproducibly 
generate quantitative 18F-NaF PET coronary images, that are enhanced by motion 
correction.  
These findings have important implications for future research and clinical coronary 18F-
NaF imaging. The prior CTA and subsequent PET-only acquisition protocol lends itself 
to a practical clinical workflow, with the initial CTA providing a basis for selection of patient 
for the coronary PET study. CTA is growing rapidly in a wide variety of clinical settings. 
Therefore, CTA will likely be the most common basis for selection of patients who might 
benefit from assessment of disease activity with coronary PET imaging. In this scenario, 
the requirement for a second CTA obtained at the time of coronary PET imaging would 
not be practical or economically feasible, and incurs unnecessary additional radiation 
exposure.  In carefully selected populations at exceptionally high risk of adverse events, 
18F-NaF PET could provide insight into the biology of atherosclerosis and may prove to 
be of importance in patient management (Adamson, Vesey, Joshi, Newby, & Dweck, 
2015; Raggi, Pontone, & Andreini, 2018). It has been shown that the presence of 
vulnerable plaque features predicts acute coronary syndromes and in the absence of 
significant stenosis and coronary calcification, the likelihood of adverse events is very 
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low (Greenland, LaBree, Azen, Doherty, & Detrano, 2004; Oliveira-Santos et al., 2017). 
Therefore, the CTA-first approach could limit unwarranted 18F-NaF PET scans in low risk 
populations.  On the other hand, a follow-up standalone 18F-NaF PET scan could be 
warranted in individuals who present with a very high atherosclerotic plaque burden to 
differentiate active from burnt out stable disease, or in patients with high risk plaque 
features such as those with positive remodeling, low attenuation components and the 
napkin-ring sign on CTA (Kitagawa et al., 2017).    
Importantly, CTA scans acquired on hybrid PET/CT are often of suboptimal quality due 
to limited CT performance in this configuration.  In many PET laboratories, either the PET 
scanner does not have performance characteristics required for coronary CTA, or a 
standalone CT scanner with better imaging characteristics for coronary CTA is available. 
Since coronary CTA is strongly dependent on image quality, the most advanced CT 
scanners should be used for this application.  While the current hybrid PET/CT scanners 
are at best 128-slice systems, the dedicated CTA equipment can be a 320-slice or dual 
source (196 slices) setup which can cover the entire heart in one gantry rotation (Einstein 
et al., 2010). Further, the scanning protocol for hybrid PET/CTA requires technical staff 
with expertise in both PET and coronary CTA to be present during a single session. In 
many centers that offer both PET and CTA scans, the imaging team performing PET 
studies does not have extensive experience in CTA. Thus, separate technologists with 
CTA expertise might be required to perform the CTA portion of the PET/CT examination, 
raising the cost and complexity of the procedure. With the utilization of CTA obtained 
prior to the 18F-NaF PET, such inconvenience would no longer occur. A prior CTA 
approach to 18F-NaF PET would also shorten the duration of image acquisition 
substantially and overall patient radiation exposure by avoiding repetition of the CTA 
scan.   
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As expected, we observed that larger registration adjustments were needed to achieve 
perfect alignment of CT acquired during a different imaging session from the PET 
compared to hybrid PET/CTA acquisition. However, with the image registration approach 
utilized, all images could be successfully registered and analyzed. Moreover, it is 
important to realize that even the hybrid PET/CTA approach requires substantial 
modification of image alignment for adequate co-registration (Figure 26). This is largely 
due to gross patient motion which occurs during the pause between PET and CTA 
acquisitions and differences in respiratory patterns. Indeed, no hybrid PET/CTA scan in 
this study was perfectly co-registered at baseline with each requiring such spatial 
adjustments.   
In patients with multiple foci of increased 18F-NaF activity achieving perfect registration 
of all lesions can be challenging. In our study, in such cases we observed a maximal 
misalignment of 5mm (from the center of vessel on CTA to the center of the hot spot on 
PET. Importantly misalignment was similarly common on both single visit acquisitions 
and when using prior CTA data. To offset for such issues, for the SUVmax measurements 
we used a spherical volume of interest (radius 5 mm) which encompasses the plaque in 
question (as seen on the CTA) and its immediate surroundings. As a result, in our study 
misregistration of 2-4 mm which can easily occur (Figure 26BC) had no adverse impact 
on the accuracy of the uptake measurement as shown on the scatterplots with 
interobserver variability of SUVmax and TBR measurements (Figure 28AB). 
The sensitivity of SUVmax measurements on the accuracy of the registration varies from 
patient to patient and depends on the anatomy. In an ideal scenario (that is when uptake 
is only present within coronary arteries) since the volumes of interest utilized have a 
radius of 5 mm misregistration of up to ~5mm will not have an enormous impact. 
However, in patients with multiple non-coronary uptake foci within that distance from the 
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actual coronary lesions, such misregistration will potentially lead to false positive findings. 
For instance, when assessing 18F-NaF activity in the left main or mid left anterior 
descending artery, special care should be taken to avoid assigning uptake originating 
from the ascending aorta and main pulmonary artery to the coronaries. Likewise, extra-
coronary foci of uptake (in patients who suffered from pericardial, aortic or mitral disease 
which resulted in calcification outside of coronary arteries) need to be distinguished. 
Without anatomical reference provided by CTA accurate quantification of uptake is 
impossible as increased tracer activity of non-coronary microcalcifications can be 





Figure 34. Case example of coronary and non-coronary 18F-NaF uptake. A 67-year-old-
male with uptake in the distal RCA (yellow arrow) and non-coronary uptake in the 
inferomedial papillary muscle (red arrow) (A). The uptake in the papillary muscle is more 
pronounced than in the coronary plaque (B). In the transverse plane the extra coronary 
foci of uptake can be easily seen (red arrows) (C) and have higher activity than the RCA 
plaques (yellow arrows) (D).  
Taking advantage of the CTA, which was used for anatomical reference, careful 
inspection of the dataset revealed an area of low attenuation within the inferior LV wall 
and the postero-medial papillary muscle (red arrow) as compared to the LV anteroseptum 
(blue arrow) (E&F). Such low attenuation can be seen in infarcted myocardium – which 
might, in the process of healing, develop foci of microcalcification (which attract 18F-NaF). 
Without the reference of a CTA the foci of pronounced 18F-NaF uptake could potentially 
be erroneously attributed to plaques in the posterior descending artery (PDA) or the 
posterior left ventricular (PLV) artery. Due to the findings on the PET study the patient 
underwent cardiac magnetic resonance imaging which revealed scarring of the inferior 
wall and postero-medial papillary muscle (area of delayed enhancement [white] as 
opposed to the remote myocardium [black]) (G). 
While uptake situated within the myocardium is a rare finding, the same patient showed 
non-coronary 18F-NaF activity in the aorta – which without anatomical reference could be 
easily attributed to one of the left coronary proximal plaques (H). Yellow arrows indicate 
coronary plaque uptake (in the distal RCA and proximal LAD). The red arrow highlights 
the infarcted postero-medial papillary muscle. The purple arrow indicates increased PET 
tracer activity in the ascending aorta and the blue arrow highlights uptake immediately 






Finally, we have demonstrated that by applying correction for coronary artery motion, the 
reproducibility of such PET-only measurements with prior CTA are significantly improved. 
In fact, our limits of agreement between PET/CTA1 and PET/CTA2 are comparable to 
the inter-observer repeatability for uptake measurements in the same scan as shown by 
Dweck et al (M. R. Dweck, M. W. L. Chow, et al., 2012)(2).  The improved PET/CTA2- 
PET/CTA1 reproducibility with motion correction is likely due to the higher signal to noise 
in the motion corrected PET images.  
6.5.1 Study Limitations 
There are several limitations of our work. Our motion correction method compensated 
only for cardiac motion; nevertheless, we have been able to demonstrate the utility of this 
technique in reducing the variation of 18F-NaF PET quantification with prior CTA. In this 
study we have not performed any quality control to identify any gross patient motion 
during the 30-minute-long emission scan. While the significance of such motion during 
acquisition has not been explored for coronary PET imaging it is likely that it has a 
detrimental effect on image quality and hence should be addressed in future studies.  It 
might be speculated that gross patient motion correction would make the co-registration 
of PET and CTA more straightforward as borders between high and low update areas 
could be better defined.  Currently the PET-CT co-registration was performed manually 
with translations made in the X,Y and Z axis and no rotations between datasets. It is likely 
that automatization of this process could decrease the time and expertise required for 
image analysis and translate into rapid dissemination of coronary 18F-NaF PET imaging 
beyond highly experienced academic centers. Nevertheless, in this study, despite the 
manual registration of CTA, we were already able to demonstrate excellent reproducibility 
of quantification 18F-NaF PET with separately obtained CTA. 
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Chapter 7. Three-hour delayed imaging improves assessment 
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Coronary 18F-sodium fluoride (18F-NaF) PET imaging identifies ruptured plaques in 
patients with recent myocardial infarction and localizes to atherosclerotic lesions with 
active calcification. Most studies to date performed the PET acquisition 1-hour (1h) post-
injection. Although qualitative and semi-quantitative analysis is feasible with 1h images, 
often residual blood pool activity makes it difficult to discriminate plaques with 18F-NaF 
uptake from noise. We aimed to assess whether delayed 3-hour (3h) post-injection PET 
scan improves image quality and uptake measurements.  
Twenty patients (67±7years old, 55% male) with stable coronary artery disease 
underwent coronary CT angiography and PET/CT both 1 h and 3 h after the injection of 
266.2±13.3 MBq of 18F-NaF. We compared the visual pattern of coronary uptake, 
maximal background (blood pool) activity, noise, standard uptake values (SUVmax), 
corrected SUV (cSUVmax) and target to background (TBR) measurements in lesions 
defined by CTA on 1h vs 3h post injection 18F-NaF PET.    
On 1h PET 26 CTA lesions with 18F-NaF PET uptake were identified in 12 (60%) patients.  
On 3h PET we detected 18F-NaF PET uptake in 7 lesions which were not identified on 
the 1h PET. The median cSUVmax and TBR values of these lesions were 0.48 
[interquartile range (IQR) 0.44-0.51] and 1.45 [IQR, 1.39-1.52] compared to -0.01 [IQR, 
-0.03-0.001] and 0.95 [IQR, 0.90-0.98] on 1h PET, both p<0.001. Across the entire cohort 
3h PET SUVmax values were similar to 1h PET measurements 1.63 [IQR, 1.37-1.98] vs. 
1.55 [IQR, 1.43-1.89], p=0.30 and the background activity was lower 0.71 [IQR, 0.65-
0.81] vs. 1.24 [IQR, 1.05-1.31], p<0.001. On 3h PET, the TBR values, cSUVmax and the 
noise were significantly higher (2.30 [IQR, 1.70-2.68] vs 1.28 [IQR, 0.98-1.56], p<0.001; 
0.38 [IQR, 0.27-0.70] vs 0.90 [IQR, 0.64-1.17], p<0.001 and 0.10 [IQR, 0.09-0.12] vs. 
265 
 
0.07 [IQR, 0.06-0.09], p=0.02). The median cSUVmax and TBR values increased by 92% 
(range: 33-225%) and 80% (range: 20-177%). 
Blood-pool activity decreases on delayed imaging facilitating the assessment of 18F-NaF 
uptake in coronary plaques. The median target to background ratios increase by 80% 
leading to the detection of more plaques with significant uptake compared to the standard 
1h protocol. A greater than a 1h delay may improve the detection of 18F-NaF uptake in 











Coronary 18F-sodium fluoride (18F-NaF) PET imaging depicts biological processes 
involved in plaque formation and rupture in patients with coronary artery disease (M. R. 
Dweck, M. W. L. Chow, et al., 2012). Increased 18F-NaF uptake has been observed with 
hybrid PET (positron emission tomography)/coronary CT angiography (CTA) to localize 
in regions of recent plaque rupture in patients with acute myocardial infarction as well as 
in coronary plaques with high-risk features on intravascular ultrasound in patients with 
stable coronary artery disease (CAD) (Joshi et al., 2014). As this promising imaging 
approach is still in its infancy, several technical aspects regarding 18F-NaF coronary PET 
imaging remain to be addressed (Adamson et al., 2015; Thomas & Haraszti, 2014).   
In the 1970s when 18F-NaF was first used for bone scanning, Blau et al suggested that 
the optimal scanning time for 18F-NaF is 2-4 hours post injection (Monte Blau et al., 1972; 
M. Blau et al., 1962). Nevertheless, whole-body 18F-NaF PET is nowadays most often 
performed with imaging commencing 60 minutes after injection (Czernin et al., 2010; 
Grant et al., 2008; Hawkins et al., 1992; Segall et al., 2010). In cardiovascular PET, in 
most studies to date assessing 18F-NaF uptake in atherosclerotic plaques, acquisition 
was performed 1-hour (1h) after tracer administration (Derlin et al., 2010; Derlin, Toth, et 
al., 2011; Derlin, Wisotzki, et al., 2011). Although semi-quantitative analysis is feasible 
with 1h images, it can be difficult to discriminate plaques with 18F-NaF uptake from noise. 
Recently, it has been speculated that the optimal time for atherosclerotic plaque imaging 
with 18F-sodium fluoride might differ from the 1h post injection time-point used for bone 
imaging (Derlin, Wisotzki, et al., 2011). Up to date only one study looked at the optimal 
timing for cardiovascular 18F-NaF imaging, but performed the ungated low-count PET 
acquisition measuring overall uptake in the entire heart rather than in coronary plaques 
(Björn A. Blomberg et al., 2014).  In this study, we aimed to quantitatively assess whether 
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delayed 3-hour (3h) post-injection state-of-the-art PET scanning improves image quality 

















We analyzed scans of 20 patients with stable coronary artery disease who underwent 
coronary CTA and PET/CT imaging both 1h and 3h after a single injection of 18F-NaF at 
Severance Cardiovascular Hospital.  All study participants had angiographically proven 
CAD (defined as at least one >50% luminal stenosis). Exclusion criteria included, renal 
dysfunction (eGFR ≤30 mL/min/1.73 m2), contraindication to iodinated contrast agents, 
significant ventricular or atrial arrhythmia (which could compromise image quality), class 
III congestive heart failure and ejection fraction <35%. The study was approved by the 





7.3.2 Imaging acquisition and reconstruction 
7.3.2.1 PET 
All patients underwent 18F-NaF PET/CT on a hybrid PET-CT scanner (Discovery 710, GE 
Healthcare, Milwaukee, WI, USA). Prior to imaging, subjects were administered with a 
target dose of 250 MBq of 18F-NaF and rested in a quiet environment for 60 minutes. 
After the acquisition of a non-contrast attenuation correction scan, PET data was 
acquired in list mode for 30 minutes. The list mode dataset was reconstructed using a 
standard ordered expectation maximization algorithm with resolution recovery (SharpIR). 
Corrections were applied for attenuation, dead time, scatter and random coincidences. 
Utilizing 10 cardiac gates, the data were reconstructed on a 256x256 matrix (20x20cm 
field of view) using 24 subsets and applying 4 iterations along with 5mm Gaussian 
smoothing(Mhairi K. Doris et al., 2018). For standard uptake value (SUV) assessment, 
all analyzed values were decay-corrected to the injection time. 
7.3.2.2 CT angiography 
After the 1h PET acquisition, contrast-enhanced coronary CTA was performed with 
prospective ECG-triggering if the heart rate was <60 beats/min and regular or with ECG 
gated helical acquisition if the heart rate >60 beats/min or irregular. All patients received 
beta blockers and sublingual nitrates. For contrast-enhanced imaging iodinated contrast 
(65-130ml) was power injected at 5-6 ml/sec, followed by a saline flush. Transverse 
images were reconstructed using filtered back projection with 0.65-mm slice thickness, 




7.3.2.3 Delayed PET 
A second low-dose CT for attenuation correction and PET was performed 3h after tracer 
administration using the same protocol for imaging and the same reconstruction of PET 
datasets as used in the 1h study.  
7.3.2.4 PET Motion correction 
Cardiac motion correction was performed on the 1h and 3h 18F-NaF PET/CT data. This 
technique compensates for coronary artery motion by aligning all gates to the end-
diastolic position and has demonstrated its ability to reduce image noise and improve 
target to background ratio (TBR) (Rubeaux, Joshi, Dweck, Fletcher, Motwani, Thomson, 
Germano, Dey, Li, et al., 2016). First, anatomic coronary artery data was extracted from 
diastolic coronary CTA by applying a vessel tracking algorithm based on Bayesian 
maximal paths using dedicated software (Autoplaque version 2.0, Cedars-Sinai Medical 
Center). Second, a diffeomorphic mass-preserving image registration algorithm was 
used to align the 10 gates of PET data to the end-diastolic gate (gate 7 or 8 dependent 
on the timing of the CTA acquisition). After motion correction, the 10 gates were summed 




7.3.3 Image analysis 
7.3.3.1 Coronary CTA 
Evaluation of coronary artery plaques was conducted in accordance with the Society of 
Cardiovascular Computed Tomography guidelines (Leipsic et al., 2014). The extent of 
disease was characterized by lesion maximal stenosis (Autoplaque version 2.0, Cedars-
Sinai Medical Center), plaque composition (non-calcified/partially calcified/totally 
calcified), the segment involvement score (SIS) and coronary calcium scoring (Agatston 
et al., 1990; Min et al., 2007). 
7.3.3.2 Positron emission tomography 
Coronary 18F-NaF image analysis was performed on axial images using FusionQuant 
Software (Cedars Sinai Medical Center, Los Angeles). PET and CTA reconstructions 
were reoriented, fused and systematically co-registered in all 3 planes. Key points of 
reference were the sternum, vertebrae, blood pool in the ventricles and the great vessels. 
For each scan, plaque activity was measured by delimiting 3-dimensional volumes of 
interest on lesions. All segments with coronary plaque (at least a grade 2 stenosis 
[>25%]) and a lumen diameter ≥2 mm, as defined by CTA were interrogated. The 
maximum standard uptake value (SUVmax) was recorded from all these segments by 
delimiting a spherical volume of interest (radius=5mm). Background blood pool activity 
(SUVmean) was measured by delimiting a cylindrical volume of interest (radius=10mm, 
thickness = 5mm) in the right atrium on the level of the right coronary artery orifice (T. A. 
Pawade et al., 2016). TBRs were calculated by dividing SUVmax by averaged 
background blood pool activity. Corrected maximum standard uptake values (cSUVmax) 
were calculated by subtracting the blood-pool activity from SUVmax. Image noise was 
defined as the coefficient of variance of the blood pool activity. Coronary plaques were 
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considered clearly positive for 18F-NaF uptake if they presented with focal tracer uptake 
arising from the coronary plaque which followed the course of the vessel in three 
dimensions over more than one slice and had a TBR>1.25 (Joshi et al., 2014). In addition 
to reporting decay corrected uptake values we also evaluated the raw counts. The PET 
acquisitions were analyzed independently with at least a 21-day interval between the 
reading of the 1h and the 3h after injection scan.  
 
7.3.4 Statistical Analysis 
Continuous data are expressed as mean (standard deviation) or median [interquartile 
range (IQR)] as appropriate. Parametric data were compared using student’s T-test and 
paired student’s T-test, non-parametric data were compared using Wilcoxon rank sum 
and Wilcoxon signed-rank test where appropriate. Categorical variables are presented 
as absolute numbers (percentage) and were compared using a Chi-squared test or 
Fisher’s exact test where appropriate. A two-sided p value <0.05 was considered 












Twenty patients (67±7 years old, 55% male) were recruited into the study. Patient 
baseline characteristics are shown in Table 20. On CTA, the median segment 
involvement and coronary calcium scores were 6 [IQR, 3-8] and 413 [IQR, 50-770] 




Table 20. Patients’ baseline clinical characteristics.  
 Study cohort 
(n=20) 
SD, IQR, % 
Baseline Characteristics 
Age, years 67 ±7 
Males, n (%) 11 (55%) 
Diabetes, n (%) 4 (20%) 
Hyperlipidemia, n (%) 5 (25%) 
Hypertension, n (%) 12 (60%) 
Tobacco use, n (%) 6 (30%) 
Family history of CAD, n (%) 3 (15%) 
Serum Biomarkers 
Total Cholesterol 162 [135-189] 
HDL 43 [38-46] 
LDL 93 [71-107] 
Triglyceride 121 [86-140] 




Aspirin, n (%) 13 (65%) 
Statin, n (%) 6 (30%) 
ACEI/ARB, n (%) 6 (30%) 
Beta Blocker, n (%) 7 (35%) 
Leading clinical indication for CTA 
Chest pain, n (%) 15 (75%) 
Dyspnea, n (%) 3 (15%) 
Risk assessment (asymptomatic 
patient), n (%) 
2 (10%) 
Coronary Computed Tomography Angiography  
Segment involvement score 6 [3-8] 
Multivessel disease, n (%) 6 (30%) 
Coronary calcium score 312 [50-770] 
CAD: coronary artery disease; CTA: coronary computed tomography angiography; HDL 
– high density lipoprotein; LDL – low density lipoprotein; ACEI – angiotensin converting 







7.4.1 1h post injection imaging 
On 1h PET (acquisition 66.5 [IQR, 64.5-71.8] min post injection), coronary uptake 
exceeding the TBR=1.25 threshold was observed in 12 (60%) patients. Twenty-six CTA 
segments were considered positive for 18F-NaF uptake. Eleven (41%) were in the left 
anterior descending, 6 (23%) in the left circumflex, 4 (16%) in the left main and 5 (20%) 
in the right coronary artery. The association between patients’ baseline characteristics, 




Table 21.  Univariate and multivariate linear regression analysis to examine association 
of variables with maximum per patient 1h post injection target to background uptake 
measurements. Both multivariate models with: LDL levels, segment involvement scores, 
presence of multivessel disease, coronary calcium scores and quantitative stenosis. 
Model 1 additionally includes lipid lowering treatment; Model 2 includes partially calcified 
plaques.  
Variables Univariate  Multivariable – Model 1 
(included: lipid lowering 
treatment) 
Multivariable – Model 2 
(included: plaque 





P value Relative 
change in TBR 
(95% CI) 
P value Relative 
change in TBR 
(95% CI) 
P value 
























































0.030  0.56 (0.1-1.0) 0.020 
CI: confidence interval, LDL: low density lipoprotein, TBR: maximum target to 
background ratios.  
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Table 22.  Univariate and multivariate linear regression analysis to examine association 
of variables with maximum per patient 3h post injection target to background uptake 
measurements. Both multivariate models with: LDL levels, segment involvement scores, 
presence of multivessel disease, coronary calcium scores and quantitative stenosis. 
Model 1 additionally includes lipid lowering treatment; Model 2 includes partially calcified 
plaques. 
Variables Univariate  Multivariable – Model 1 
(included: lipid lowering 
treatment) 
Multivariable – Model 2 
(included: plaque 





P value Relative 
change in TBR 
(95% CI) 
P value Relative 
change in TBR 
(95% CI) 
P value 






















































0.005  1.3 (0.7-1.9) <0.001 






7.4.2 3h post injection imaging 
On delayed PET imaging (acquisition 180.5 [IQR, 177.3-193.0] min post injection), by 
visual inspection background 18F-NaF activity was markedly reduced, and coronary 
lesions were more conspicuous. We identified all segments which were detected on 1h 
post injection imaging (Figure 33). In addition, 7 new segments (median stenosis 48.6% 
[IQR, 35.7-60.2]) which were previously negative for 18F-NaF uptake demonstrated focal 
uptake with TBR>1.25 (Figure 34). These lesions were found in 2 patients who had 
uptake elsewhere in the coronary vasculature and in 3 patients classified as negative for 
18F-NaF coronary uptake on 1h post injection imaging. While the SUVmax of these 7 new 
positive lesions was similar on 3h vs 1h PET (1.51 [IQR, 1.42-1.60] vs. 1.48 [IQR, 1.40-
1.55], p=0.68), the cSUVmax and TBR values were higher on delayed imaging (0.48 
[IQR, 0.44-0.51] vs. -0.01 [IQR, -0.03-0.001] and 1.45 [IQR, 1.39-1.52] vs. 0.95 [IQR, 





Figure 35. Assessment of 18F-NaF coronary uptake on 1h and 3h delayed PET.  
Four patients with significant (TBR>1.25) on 1h post injection (left column) coronary 
uptake in the left anterior descending artery. Uptake can be difficult to differentiate in this 
region from blood pool in the adjacent pulmonary artery. On 3h PET (right column) the 
TBR increased significantly, and blood pool activity reduced improving image quality. 
  
18F-NaF: 18F-sodium fluoride; PET: positron emission tomography; TBR: target to 




Figure 36. Examples of coronary plaques with significant uptake on 3h PET and low 
tracer activity of 1h post injection imaging.  
Short axis images of proximal left anterior descending, proximal circumflex (A) and distal 
right coronary artery (B) plaques which had a TBR<1.0 on 1h PET (left column) and 
showed uptake exceeding the 1.25 TBR threshold at 3h
 





Across the entire cohort on 3h PET compared to 1h PET, the SUVmax of the detected 
lesions remained similar (1.63 [IQR, 1.37-1.98] vs. 1.55 [IQR, 1.43-1.89], p=0.30). 
However, the background activity decreased to 0.71 [IQR, 0.65-0.81] vs. 1.24 [IQR, 1.05-
1.31], p<0.001 with a median decrease of 42% (range 18-48%).  Consequently, the TBR 
values were higher (2.30 [IQR, 1.70-2.68] vs 1.28 [IQR, 0.98-1.56], p<0.001), with a 
median TBR increase of 80% (range: 20-177%, Figures: 35 and 36). A similar change 
was observed in the cSUVmax 0.38 [IQR, 0.27-0.70] vs 0.90 [IQR, 0.64-1.17], p<0.001; 
median cSUVmax increased by 92% (range: 33-225%, Figures 35 and 36). In 
accordance with the Poisson’s distribution, we observed a 49.0±3.8% decrease in counts 
on delayed imaging compared to 1h PET. As expected due to fewer counts on 3h PET, 




Table 23.  Comparison of 18F-NaF motion corrected measurements on 1h and 3h post 
injection PET imaging. 
 1-hour post 
injection PET 
3-hour post injection 
PET 
P Value 
SUVmax 1.55 [1.43-1.89] 1.63 [1.37-1.98] 0.30 
TBR 1.28 [0.98-1.56] 2.30 [1.70-2.68] <0.001 
Corrected SUVmax 0.38 [0.27-0.70] 0.90 [0.64-1.17] <0.001 
Background (blood pool) 1.24 [1.05-1.31] 0.71 [0.65-0.81] <0.001 
Noise 0.07 [0.06-0.09] 0.10 [0.09-0.12] 0.02 
Segments with TBR>1.25, n (%) 26 (8%) 33 (10%) 0.01 
Patients with TBR>1.25, n (%) 12 (60%) 15 (75%) 0.004 
18F-NaF: 18F-sodium fluoride; PET: positron emission tomography; SUVmax: maximum 




Figure 37. 18F-NaF coronary uptake measures on 1h and 3h delayed PET.  
Maximum standard uptake values (SUVmax) values were comparable on both scans (A). 
The corrected SUVmax and target to background (TBR) values were higher on 3h post 
injection PET (B,C). The background (right atrium blood pool SUVmean) was lower on 
3h imaging (D). 
 
 




Figure 38. Line-plots of 18F-NaF coronary uptake measurements on 1h and 3h delayed 
PET. 
Maximum standard uptake values (SUVmax) values were comparable on both scans (A). 
The corrected SUVmax and target to background (TBR) values were higher on 3h post 
injection PET (B,C). The background (right atrium blood pool SUVmean) was lower on 
3h imaging (D). 
 





This is the first study which utilized a 30min acquisition cardiac-gated coronary PET 
protocol and compared the image quality and quantitative measures of 18F-NaF coronary 
uptake on 1h vs 3h post injection PET images. We hereby show that prolonging the time 
from tracer injection to PET acquisition can facilitate image analysis and provide lower 
background activity, higher TBR and cSUV values compared to the currently utilized 
protocol. We demonstrate that by delaying image acquisition to 3h new lesions, 
categorized as false-negative on the 1h PET, were now readily identified.  
By utilizing currently used imaging protocols with PET acquisition (1h post injection), the 
reader is often challenged to distinguish true coronary uptake from overspill from the 
surrounding structures. A large proportion of 18F-NaF positive plaques present with 
uptake which is at or only slightly higher than the background activity. Visualization of 
these lesion is usually possible because of below blood-pool activity in the adjacent 
myocardium. However, analysis can often be difficult particularly in the proximal and mid-
LAD which lies close to blood pool in the pulmonary artery (Figure 33) and in the proximal 
circumflex that lies adjacent to the left atrial appendage. Techniques to improve the 
detection of such lesions are therefore required. To some extent blurring of the tracer 
uptake which occurs due to cardiorespiratory and patient motion can be mitigated with 
end-diastolic imaging, improving the conspicuousness of lesions (M. R. Dweck, M. W. L. 
Chow, et al., 2012). Recently developed cardiac motion correction techniques further 
improve image quality by co-registration of all cardiac gates to the reference one and 
allowing all PET data rather than that from a single diastolic gate to be utilized (Rubeaux, 
Joshi, Dweck, Fletcher, Motwani, Thomson, Germano, Dey, Li, et al., 2016). In this study, 
we show that delaying 18F-NaF coronary image acquisition further facilitates assessment 
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of coronary uptake, predominantly as a result of a decrease in the background blood pool 
activity.  
Improved visual identification of the lesions on the delayed 18F-NaF PET acquisition is 
accompanied by significant improvements in TBR and corrected SUVmax 
measurements. While the coronary SUVmax remained unchanged on 3h PET imaging, 
the TBR values improved significantly. We observed an increase in the noise on delayed 
imaging (as expected due to a lower count statistic), however given the favorable 
decrease in the background (blood pool) activity, the noise level on 3h PET does not 
impede image analysis. 
The benefit of delayed PET acquisition for the detection of disease is widely appreciated 
in oncological applications with 18F-fluorodeoxyglucose (FDG)(Caoduro et al., 2013; 
Kubota et al., 2004; W. Y. Lin et al., 2005; Nishiyama et al., 2005). There is good 
agreement that because background activity decreases on delayed imaging, the image 
quality improves. The lower background activity is a critical feature and advantage of 
delayed imaging, because it increases target to background ratios ((Cheng et al., 2013; 
Houshmand et al., 2016). It has been shown that a longer time window from injection to 
acquisition translates to higher signal to noise and therefore facilitates visual analysis 
providing higher diagnostic accuracy (Kubota et al., 2001). For coronary PET imaging, it 
was suggested that the optimal timing for acquisition with FDG is 2.5-3h after tracer 
administration (Bucerius et al., 2014; Rudd et al., 2002).  
In case of 18F-NaF PET bone imaging, since it has faster blood clearance and higher 
bone uptake compared to 99mTc-methylene diphosphonate, the SNM practice guideline 
recommends emission scanning for the axial skeleton as soon as 30-45 minutes after 
injection in patients with normal renal function (Segall et al., 2010) to decrease the overall 
time of the study. However, a longer waiting time of 90-120 minutes was recommended 
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to acquire high-quality images of the extremities. Compared to uptake in the bony 
skeleton, 18F-NaF uptake due to active microcalcification formation in coronary plaque is 
very small in amount. Therefore, it is not surprising that a higher TBR in coronary plaques 
is observed with a longer waiting time from injection to acquisition. Longer delays for 
cardiovascular 18F-NaF PET imaging were evaluated by only one study to date (Björn A. 
Blomberg et al., 2014). Blomberg et al. concluded that delayed 18F-NaF PET imaging 
does not improve quantification of vascular calcification. However, the authors measured 
only overall heart 18F-NaF activity (including blood pool) by placing regions of interest 
around the cardiac silhouette on ungated PET/CT images (excluding 18F-NaF activity 
originating from bones and cardiac valves), and averaged the SUV values derived from 
all slices. As a result, identifying additional foci of uptake on delayed imaging was not 
feasible. Moreover, that study was performed without cardiac gating and motion 
correction. Further, with 2.5-minute scan time and a 2.2 MBq dose of 18F-NaF per 
kilogram of body weight the authors had approximately 16 times less counts compared 
to our coronary scans (~3.4MBq dose per kg and 30-min long acquisition).  
The utilization of coronary CT angiography in our study enabled measuring 18F-NaF 
uptake in individual coronary plaques. It also provided an opportunity to evaluate 
potential predictors of uptake by means of regression modelling (supplemental Tables 
21 and 22). While our study is slightly underpowered such analysis revealed that TBR is 
positively associated with partially calcified plaque and inversely with lipid lowering drugs 
(statins). These findings are in line with previously published data showing that active 
calcification, macrophage infiltration and partially calcified plaques are associated with 
18F-NaF uptake (Joshi et al., 2014; Kitagawa et al., 2017). On the contrary in our study 
completely calcified plaques did not attract the PET tracer which is in accordance with 
prior studies and supports the view that 18F-NaF is a marker active calcification including 
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the stage before the development of advanced atherosclerotic lesions rather than 
established disease (McKenney-Drake et al., 2016; Oliveira-Santos et al., 2017). 
Interestingly, as shown by the explanatory uni- and multivariate analysis the associations 
with clinical and imaging data are stronger when 3h PET measures rather 1h post 
injection PET values are utilized (Tables 21 and 22).  
Our findings have important clinical implications. Given the challenges that 18F-NaF 
imaging faces, which include, but are not limited to small target lesion size, cardiac, 
respiratory and gross patient motion which collectively compromise image quality, a 
delayed acquisition protocol is an important step in mitigating the modest TBR reported 
in studies utilizing the 1h post injection protocol. By decreasing the background (blood 
pool) signal, not only do the TBR values improve, but also lesions which were difficult to 
detect 1h post injection can be easily identified. Additionally, by utilizing the 3 hours’ post 
injection approach coronary uptake can be more readily assessed by less experienced 
readers. In our view, such a protocol can facilitate dissemination of this imaging 
techniques beyond academic institutions.  
7.5.1 Limitations 
We acknowledge that our study was based on a modest number of patients with stable 
CAD. Importantly, despite this limitation our findings are supported by statistically 
significant data. The normal limits applied to define an increase in TBR values in our 
population were based on those derived from 1h data; thus, it is likely that reference 
values for relevant uptake on 3h 18F-NaF coronary PET will need to be derived for optimal 
use of delayed imaging (Joshi et al., 2014). The utilization of TBR as a measure of tracer 
uptake remains to some degree controversial (Chen & Dilsizian, 2015); however, we also 
evaluated corrected SUVmax measurements which have been suggested to be more 
robust for coronary imaging. The low TBR values in our study can be attributed to partial 
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volume effects as adjacent myocardium presents on average with 60% of the blood-pool 
uptake (Trivieri et al., 2016). We acknowledge that a 3h post injection PET protocol may 
lead to reorganizing the workflow within the nuclear medicine imaging facility and will 
prolong the time patients spend in the imaging facility. Nevertheless, the benefits of 
delayed PET acquisition for the assessment of 18F-NaF coronary uptake undoubtedly 












8.1 Summary of findings 
Aortic stenosis is a disease of the valve and the myocardium. In the past years advanced 
cardiovascular imaging has greatly improved our understanding of the processes driving 
disease progression and enabled monitoring how the valve and the myocardium 
deteriorate over time. Both cardiovascular magnetic resonance and 18F-sodium fluoride 
PET imaging showed promise in refining patients’ diagnosis and providing early markers 
of disease progression. In this thesis I have demonstrated that in aortic stenosis 
asymmetric wall thickening is associated with adverse prognosis, I have shown that there 
are significant differences in the fibrosis burden between male and female patients and 
that the adverse remodeling of the ventricle can be reproduced in a simple animal model 
of pressure overload. Further I have demonstrated that utilizing a CT angiography 
acquired before the PET acquisition enables adequate 18F-NaF uptake quantification and 




8.1.1 Adverse Prognosis Associated with Asymmetric Myocardial Thickening in 
Aortic Stenosis. 
Asymmetric wall thickening is most commonly associated with hypertrophic 
cardiomyopathy. However, this form of remodelling has recently been described in 
patients with increased afterload such as hypertension and aortic stenosis. An initial 
magnetic resonance study suggested that asymmetric wall thickening could be observed 
in around a quarter of aortic stenosis patients. In my multimodality imaging assessment 
of asymmetric wall thickening in 166 patients with aortic stenosis, I have demonstrated 
this pattern of remodeling is common, affecting a quarter of patients with mild-to-severe 
aortic stenosis when assessed using magnetic resonance. Echocardiography is less 
sensitive missing a third of these cases. Irrespective of the imaging modality used, 
patients with asymmetric wall thickening have evidence of more advanced left ventricular 
decompensation with elevated myocardial injury and increased BNP concentrations 
compared to those with concentric wall thickening. This is despite the two groups having 
similar co-morbidities, valve narrowing, myocardial fibrosis and left ventricular 
hypertrophy. Moreover, patients with asymmetric wall thickening (on both magnetic 
resonance and echocardiography) have an adverse prognosis, with this form of 
remodelling acting as an independent predictor of aortic valve replacement or death after 
correction for age, sex, left ventricular mass index, coronary artery disease and aortic 
stenosis severity. In the future further attention should be paid to the mechanism 
underlying asymmetric wall thickening formation, including the underlying genetics and 




8.1.2 Progression and regression of left ventricular hypertrophy and myocardial 
fibrosis in a mouse model of pressure overload cardiomyopathy. 
Rodent models of pressure overload cardiomyopathy have been developed and 
potentially allow monitoring of disease progression, from the onset of pressure overload 
out to the advanced stages of heart failure. These models can therefore provide 
longitudinal data that are lacking in humans and can potentially do so using advanced 
imaging techniques that can be directly translated in to humans. In a longitudinal 
preclinical study with serial cardiac magnetic resonance performed every 2 weeks in mice 
subjected to pressure overload and followed after cessation of the increased afterload I 
established an animal model of angiotensin II-induced left ventricular hypertrophy and 
subsequent reverse remodelling. This model allows to assess how the hypertrophic 
response and myocardial fibrosis develop in response to an increased afterload and then 
reverse remodels once that stimulus is removed. Using state-of-the-art in vivo CMR 
imaging, I have been able to obtain longitudinal data on myocardial remodelling within a 
timespan of months rather than years or decades as observed in humans. Importantly, 
the proposed model facilitates histological correlation with imaging findings, enabling 
validation of our CMR markers of fibrosis, including iECV, as biomarkers of left ventricular 
fibrosis. This model will allow improved understanding of the processes underlying LV 
decompensation in patients with aortic stenosis and hypertension. In this study I have 
demonstrated that myocardial fibrosis appears to be the primary determinant of LV 
dysfunction both before and after reversal of pressure overload. Further studies should 
investigate the optimum time to reverse pressure overload in order to ensure long-term 




8.1.3 Sex-Related Differences in the Extent of Myocardial Fibrosis in Patients with 
Aortic Valve Stenosis. 
Cardiac magnetic resonance imaging detects the presence of replacement myocardial 
fibrosis using late gadolinium enhancement and diffuse reactive myocardial fibrosis using 
extracellular volume fraction calculated from T1 mapping. Both these surrogate 
measures of fibrosis correlate strongly with collagen content measured by histology. 
Recent studies have reported an association between LGE and ECV with worse 
outcomes in patients with aortic stenosis. In a multicenter prospective observational 
study of two hundred forty-nine patients with at least mild aortic stenosis I demonstrated 
that despite similar AS severity and LV global hemodynamic load as well as more 
favorable cardiovascular risk profile, women presented lower indexed LV mass but 
paradoxically a larger extent of diffuse myocardial fibrosis. While LV mass index was the 
strongest determinant for both higher ECV fraction and higher amount of LGE, in the 
present study, traditional cardiovascular risk factors such as hypertension and coronary 
artery disease were not independently associated with diffuse or focal myocardial 
fibrosis. This lack of association between hypertension and the surrogate CMR markers 
of fibrosis could be related to the fact that the vast majority of patients in the study with 
diagnosis of hypertension were treated with anti-hypertensive medications.  After 
comprehensive multivariable analyses, female sex remained an important independent 
determinant of higher ECV fraction and LGE. Noteworthy, the greater expansion of ECV 
fraction observed in women was also accompanied by higher estimated LV filling 
pressure (E/e’ ratio), which may be related to reduced LV compliance and more 
advanced LV diastolic dysfunction in women. Future studies should elucidate the 




8.1.4 Feasibility of coronary 18F-sodium fluoride PET assessment with the 
utilization of previously acquired CT angiography. 
18F-NaF PET imaging has shown hope as a tool for predicting valve calcifications. For 
precise anatomical localization of 18F-NaF uptake within the heart, this imaging modality 
requires co-registered CT angiography images. To date studies utilized CT angiography 
acquired using hybrid PET/CT scanners during the same imaging session. This approach 
has several limitations which hamper its practical implementation into a meaningful 
clinical workflow. For instance, an important limitation of the single-session hybrid 
PET/CT is that it may not allow for the use of optimal CT equipment for CT angiography 
which may only be available on standalone CT scanners. In a multivendor and 
multicenter study of 45 patients I report how utilizing a previously acquired CTA with a 
subsequent standalone PET-only scan can be used for the evaluation of 18F-NaF PET 
uptake. On a population comprised of patients who underwent repeat CT angiography 
studies on the same PET/CT scanner and a separate subset that had the initial CTA 
acquired on a solely CT machine, I showed that a prior CT angiography and subsequent 
PET-only approach enables accurate quantification of 18F-NaF PET uptake. This prior 
CT angiography and subsequent PET-only acquisition protocol lends itself to a practical 
clinical workflow, with the initial CT angiography providing a basis for selection of patient 
for the PET study. CT angiography is growing rapidly in a wide variety of clinical settings. 
It will likely be the most common basis for selection of patients who might benefit from 
assessment of disease activity with PET imaging. In this scenario, the requirement for a 
second CT angiography obtained at the time of PET imaging would not be practical or 
economically feasible and would incur unnecessary additional radiation exposure. 
Additionally, CT angiography scans acquired on hybrid PET/CT are often of suboptimal 
quality due to limited CT performance in this configuration.  In many PET laboratories, 
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either the PET scanner does not have performance characteristics required for CT 
angiography, or a standalone CT scanner with better imaging characteristics for CT 
angiography is available. Further, the scanning protocol for hybrid PET/CT requires 
technical staff with expertise in both PET and CT angiography to be present during a 
single session. In many centers that offer both PET and CT angiography scans, the 
imaging team performing PET studies does not have extensive experience in CT 
angiography. Thus, separate technologists with CT angiography expertise might be 
required to perform the CT angiography portion of the PET/CT examination, raising the 
cost and complexity of the procedure. With the utilization of CT angiography obtained 




8.1.5 Three-hour delayed imaging improves assessment of coronary 18F-sodium 
fluoride PET. 
As 18F-sodium fluoride imaging is still in its infancy, several technical aspects remain to 
be addressed. One of these is the optimal timing for emission scanning. In the 1970s 
when 18F-NaF was first used for bone scanning, it was suggested that the optimal 
scanning time for 18F-NaF is 2-4 hours post injection. Nevertheless, whole-body 18F-NaF 
PET is nowadays performed with imaging commencing 60 minutes after injection. In 
cardiovascular PET, in most studies to date assessing 18F-NaF uptake in the 
cardiovascular system, acquisition was performed 1-hour (1h) after tracer administration. 
Up to date only one study looked at the optimal timing for cardiovascular 18F-NaF 
imaging, but performed the ungated low-count PET acquisition measuring overall uptake 
in the entire heart rather than uptake localized to single foci of microcalfication. On a 
cohort of twenty patients with stable coronary artery disease who underwent PET/CT 
imaging both 1 h and 3 h after the injection of 18F-NaF I demonstrate that prolonging the 
time from tracer injection to PET acquisition can facilitate image analysis. In the study, I 
show that delaying 18F-NaF coronary image acquisition further facilitates assessment of 
coronary uptake, predominantly as a result of a decrease in the background blood pool 
activity. The improved visual identification of the lesions on the delayed 18F-NaF PET 
acquisitions is accompanied by significant improvements in TBR and corrected SUVmax 
measurements. While I observed an increase in the noise on delayed imaging (as 
expected due to a lower count statistic), because of the favorable decrease in the 





8.2 Future Directions 
Cardiovascular magnetic resonance imaging has provided a wealth of information 
regarding left ventricular reverse remodeling in aortic stenosis. The observations 
regarding the impact of fibrosis on disease progression and asymmetric wall thickening 
on outcome can potentially enable personalized decision making in this most common 
form of valve disease. However, before the non-invasive markers of left ventricular 
decompensation can be incorporated into clinical practice they should be formally 
validated in the context of multicenter randomized clinical trials. The currently ongoing 
Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic 
Patients With Severe AS (EVoLVeD, NCT03094143) study shall address this need. It will 
challenge the current clinical guidelines suggesting that aortic valve replacement should 
be performed only when symptoms develop or the heart presents with an impaired 
systolic function on echocardiography. Using cardiovascular magnetic resonance 
imaging the investigators shall actively search for early markers of decompensation 
including replacement fibrosis. Patients with such form of myocardial scarring will be 
randomised to routine clinical care, or referral for valve replacement surgery. The 
overarching hypothesis of the study is that early surgery will lead to fewer complications 
and reduced risk of death compared to standard care. The evolved trial aims to recruit 
1000 participants and shall therefore provide a unique dataset for assessing gender 
differences in aortic stenosis. It will enable determining whether the larger expansion of 
diffuse myocardial fibrosis in women as measured by cardiovascular magnetic resonance 
could be a potential trigger for early valve replacement in women with severe aortic 
stenosis. 
While in this thesis I provided a CT followed by PET workflow which enables maximizing 
the benefits of CT imaging and showed that delayed imaging is beneficial in terms of 
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image quality, several aspects regarding cardiovascular 18F-NaF PET remain to be 
addressed. Cardiorespiratory and patient body motion create serious limitations to 
imaging cardiovascular microcalcifications with PET. Natural tidal breathing can cause 
the heart to move over 1 cm, normal heart systolic function can lead to motion up to 26 
mm depending on the location. Additionally, typical gross patient motion (repositioning 
during emission scanning) can also result in a loss in the contrast to noise ratio. These 
joint motion effects need to be compensated for and to date only cardiac contractility has 
been addressed. Future research should aim to develop techniques correcting for tidal 
breathing and patient repositioning. Another aspect of 18F-NaF cardiovascular PET which 
requires refinement is CT and PET co-registration which is essential for image analysis 
but requires a certain level of expertise and is time consuming. Automatization of this 
process would facilitate dissemination of this imaging modality. While in my thesis I have 
shown that 3-hour delayed emission scanning is beneficial the optimal timing for imaging 
remains to be comprehensively assessed. At the moment it is unclear whether a 2-hour 
delay would be equally robust. Likewise, potentially a longer interval between tracer 
injection and imaging could further facilitate uptake assessment.  
In aortic stenosis 18F-NaF has already been shown to predict disease progression in 
native and surgical bioprosthetic valves. Given the successful application of 18F-NaF PET 
for early diagnosis of structural valve degeneration in patients post-surgical valve 
replacement translating this approach for TAVR imaging appears as the ultimate frontier 
for 18F-NaF cardiovascular PET imaging. While a combined CT angiography and 18F-NaF 
PET appear to be ideally suited for this purpose, imaging TAVR presents unique 
challenges. After TAVR deployment, leaflets of the native valve are displaced against the 
aortic wall making it difficult to discern PET tracer uptake within the implanted 
bioprosthesis from the native valve. Similarly, distinguishing TAVR calcifications from 
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stent struts and native valve calcium with non-contrast CT is impossible and requires 
high quality CT angiography. 
 
Future studies should aim to further optimize 18F-NaF imaging specifically for TAVR 
imaging. Two areas appear particularly relevant in this regard. Firstly, for anatomical 
reference and detection of overt prosthesis degeneration high quality CT angiography is 
required. While (according to the conventional protocol) 18F-NaF and CT angiography 
are acquired during a single imaging session on a hybrid PET/CT scanner such an 
approach has several limitations. It may not allow for the use of optimal CT equipment 
(which may only be available on standalone CT scanners) and requires multi-faceted 
staff expertise in both PET and cardiac CT during a single session. As shown in chapter 
6 of this thesis utilization of a previously acquired CT with a subsequent PET-only cardiac 
18F-NaF acquisition enables adequate categorization of coronary plaques with respect to 
the presence of increased tracer activity and accurate quantification of PET uptake 
(Kwiecinski et al., 2018). This CT first approach could be an important protocol 
refinement for 18F-NaF TAVR imaging. Secondly, for precise evaluation of 18F-NaF 
uptake a high contrast to noise ratio is of critical importance. For coronary imaging I have 
recently shown (chapter 7) that a greater interval between tracer injection and image 
acquisition facilitates images analysis (Kwiecinski et al., 2019). Delayed imaging leads 
to a decrease in the background bloodpool activity and therefore enables distinction of 
subtle 18F-NaF uptake which on conventional 1-h post injection imaging can be difficult 
to discern from background signal. Given the proximity of the native valve to the 
bioprothesis and the overall only subtle PET tracer activity in the leaflets (as reported for 





8.3 Clinical perspectives 
The cardiovascular magnetic resonance based stratification of risk in severe aortic 
stenosis holds hope in offering timely aortic valve replacement. If the hypotheses of this 
thesis are successfully tested in the context of the Evolved trial ultimately important 
modifications in managing aortic valve stenosis would be mandated. A fibrosis burden 
guided referral for valve replacement as well as a gender specific approach in aortic 
stenosis could be an important step on the path to individualized medicine. 
Whether 18F-sodium fluoride PET becomes the holy grail of coronary artery disease and 
aortic stenosis remains to be assessed. With several ongoing trials utilizing this promising 
imaging approach in the following years we shall learn its true potential. The PREFFIR 
(Prediction of Recurrent Events With 18F-Fluoride) and DIAMOND (Dual Antiplatelet 
Therapy to Reduce Myocardial Injury) trials will provide key insights in the field of 
coronary artery disease. The SALTIRE-2 (Study Investigating the Effect of Drugs Used 
to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis) and FAABULOUS 
(18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome) shall elucidate 
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